CAPITAL UNIVERSITY OF SCIENCE AND TECHNOLOGY, ISLAMABAD

Association of Factor V Leiden and Prothrombin Gene Mutation in Male and Placental Mediated Pregnancy Complications in Female with their Risk Factors

by

Tamoor Akhtar

A thesis submitted in partial fulfillment for the degree of Master of Science

in the

Faculty of Health and Life Sciences
Department of Bioinformatics and Biosciences

2021

I dedicate this thesis to all the great people came in my life specially my beloved Mother and my Supervisor who taught me to stand out in this world with dignity and fearlessly. After that I dedicate it to my lovely sisters that supported me like a solid rock after that to all haters in my life that encouraged me to step ahead without any fear.

CERTIFICATE OF APPROVAL

Association of Factor V Leiden and Prothrombin Gene Mutation in Male and Placental-Mediated Pregnancy Complications in Female with their Risk Factors

by

Tamoor Akhtar

(MBS181009)

THESIS EXAMINING COMMITTEE

S. No.	Examiner	Name	Organization
(a)	External Examiner	Dr. Jawad Hassan	NUMS, Rawalpindi
(b)	Internal Examiner	Dr. Syeda Mariam Bakhtiar	CUST, Islamabad
(c)	Supervisor	Dr. Arshia Amin Butt	CUST, Islamabad

Dr. Arshia Amin Butt
Thesis Supervisor
May, 2021

Dr. Sahar Fazal
Head
Dept. of Bioinformatics and Biosciences
May, 2021

Dr. Muhammad Abdul Qadir
Dean
Faculty of Health and Life Sciences
May, 2021

Author's Declaration

I, **Tamoor Akhtar** hereby state that my MS thesis titled "**Association of Factor V Leiden and Prothrombin Gene Mutation in Male and Placental-Mediated Pregnancy Complications in Female with their Risk Factors**" is my own work and has not been submitted previously by me for taking any degree from Capital University of Science and Technology, Islamabad or anywhere else in the country/abroad.

At any time if my statement is found to be incorrect even after my graduation, the University has the right to withdraw my MS Degree.

(Tamoor Akhtar)
Registration No: MBS181009

Plagiarism Undertaking

I solemnly declare that research work presented in this thesis titled "**Association of Factor V Leiden and Prothrombin Gene Mutation in Male and Placental-Mediated Pregnancy Complications in Female with their Risk Factors**" is solely my research work with no significant contribution from any other person. Small contribution/help wherever taken has been duly acknowledged and that complete thesis has been written by me.

I understand the zero tolerance policy of the HEC and Capital University of Science and Technology towards plagiarism. Therefore, I as an author of the above titled thesis declare that no portion of my thesis has been plagiarized and any material used as reference is properly referred/cited.

I undertake that if I am found guilty of any formal plagiarism in the above titled thesis even after award of MS Degree, the University reserves the right to withdraw/revoke my MS degree and that HEC and the University have the right to publish my name on the HEC/University website on which names of students are placed who submitted plagiarized work.

(Tamoor Akhtar)
Registration No: MBS181009

Acknowledgement

My first word of thanks to the one who taught words to Adam, Who blessed man with knowledge, who is the sublime without whose "Kun" nothing is possible.

Secondly my humblest thanks from the core of my heart, to our beloved Prophet Hazrat Mohammad (S.A.W.W) who is the eternal fountain of knowledge and guidance for the whole mankind.

Then i would like to pay my deepest gratitude to my admirable teacher and supervisor Dr. Arshia Amin Butt, Department of Bioinformatics and Biosciences, Capital University of science and Technology Islamabad. I am grateful to her for approving research topic, her disciplinarian attitude, and strictness in punctuality and working in organized manner makes possible to complete this work. I am really grateful to Dr. Sahar Fazal and Dr. Syeda Marriam Bakhtiar for their guidance and support throughout my research.

Not to be forgotten, my friend Zaki-ul-Hassan, Mudasir Ahmed and Samra Bibi who helped me morally for accomplishment of this goal. They always encouraged me during my research.

I now turn to those who were and are first on my mind but are mentioned last, my Father,Mother and all teachers of my career. I believe their most sincere and innocent prayers which were a constant source of strengthen and inspiration to me that resulted in the completion of this work. I dedicate this work to my beloved parents at the end. I pray to God Almighty to give me the strength and resources to serve them to the best of my efforts best and wisdom not to neglect them in future; Ameen

(Tamoor Akhtar)

Abstract

Factor V Leiden is the most common inherited form of inherited thrombophilia, accounting for 40 –50% of cases. The prevalence varies by population Factor V Leiden (FVL) and prothrombin gene mutation (PGM) are common inherited thrombophilias. Retrospective studies variably suggest a link between maternal FVL and placenta-mediated pregnancy complications Factor V Leiden is associated with a 2- to 3-fold increased relative risk for pregnancy loss and possibly other complications such as preeclampsia, intrauterine growth restriction and placental abruption. Prothrombin gene mutation increases the risk of venous thrombosis .This was a prospective case–control study evaluating 111 of total samples of women and men. We investigated mutations including FV Leiden and factor II prothrombin G20210A along with heterogenous and homozygous carriers. The principle findings of our research resulted out to be 4.50% and also homozygous of Factor V mutation and Factor II was in 0.90% and also of Heterozygous which has been found in the Factor II mutation

Contents

Author's Declaration iv

Plagiarism Undertaking v

Acknowledgement vi

Abstract vii

List of Figures xi

Abbreviations xii

1 Introduction 1
- 1.1 Prevalence . . . 2
- 1.2 Risk for a first VTE . . . 3
- 1.3 Aims and Objectives . . . 7

2 Literature Review 8
- 2.1 High Prothrombin Activity Association with G20210a Mutation Carriers . . . 8
- 2.2 Devastating Effect of Mutation in Pregnancy . . . 9
- 2.3 Effect of Mutation in Preeclampsia and HELLP Syndrome . . . 11
- 2.4 Genetic Susceptibility to to Venous Thromboembolism in Pregnancy . . . 12
- 2.5 Severe Preeclampsia and High Frequency of Genetic Thrombophilic Mutations . . . 13
- 2.6 Association between the Factor V Leiden Mutation and also Pregnancy Outcomes of Mother and Baby . . . 13
- 2.7 Some of the Risk Elements for Preeclampsia . . . 14
  - 2.7.1 Age . . . 15
  - 2.7.2 Body Habitus . . . 15
  - 2.7.3 Working During Pregnancy . . . 16
  - 2.7.4 Cigarette Smoking and Alcohol Consumption . . . 17
- 2.8 Recurrent VTE . . . 18
- 2.9 Complication in Pregnancy . . . 19

2.10 Clinical Expression of Factor V Leiden . . . 22
2.10.1 Existing Thrombophilic Disorders . . . 22
2.10.2 Risk Elements for Certain Situations . . . 23
2.10.3 Intermediate Toxic Catheters . . . 23
2.10.4 Pregnancy . . . 24
2.10.5 Oral Contraceptives . . . 24
2.10.6 Hormone Replacement Therapy . . . 26
2.10.7 Selective Estrogen Receptor Modulators . . . 26
2.11 Thrombosis not Convincingly Related with Elements V Leiden . . . 28
2.11.1 Thrombosis Arterial . . . 28
2.11.2 Myocardial Infarction . . . 29
2.12 Stroke . . . 30
2.13 Genotype-Phenotype Correlations . . . 31
2.13.1 HR2 Haplotype . . . 31
2.13.2 Genetically Related (Allelic) Disorders . . . 32
2.14 Pen-etrance . . . 33
2.15 Difference Tests . . . 34
2.15.1 Inheritance Disorder . . . 34
2.15.2 Disruption Detected . . . 35
2.16 Management . . . 36
2.17 Genetic Directing . . . 39
2.17.1 Proband Heterozygous for Element V Leiden . . . 39
2.17.2 Proband Homozygous for Element V Leiden . . . 40
2.17.3 Examination of High-Rate Family Members . . . 40
2.18 Risk of Intermittent Venous Thromboembolism among Heterozygous Carriers of Element V Leiden or Prothrombin G20210A Mutation . . . 41
2.18.1 Heterozygous Flow of FVL and Risk of VTE Recurrence . . . 42
2.18.2 Heterozygous Carriage of PTM and Danger of VTE Repeat 43
2.19 Maternal Morbidity . . . 44
2.20 Pathophysiology . . . 47
2.21 Clinical Conditions . . . 48
2.21.1 VTE Danger with Prothrombin G20210A Mutation . . . 48
2.21.2 VTE Danger when Prothrombin 20210A Cosegregates with Different Types of Thrombophilia . . . 49
2.22 Reproductive Complications due to Prothrombin G20210A Mutation . . . 50
2.23 Prothrombin 20210A as a Potential Danger Elements for Blood Vessel Thrombotic Illness . . . 51
2.24 Risk of Venous Thrombosis and Pregnancy Misfortune in Carriers . 51
2.25 Factor V Leiden, PTH G20210A and MTHFR C677T Polymorphisms . . . 55

3 Material and Methods **57**
3.1 Determination . . . 58
3.1.1 Testing . . . 58
3.2 Characteristic History and Clinical Indications . . . 59
3.3 Venous Thromboembolism . . . 60
3.4 GeneXpert Dx Framework . . . 60
3.4.1 Xpert® FII and FV . . . 61
3.5 Reagents . . . 61
3.5.1 Reagents Handling . . . 61
3.5.2 Reagents Storage . . . 61
3.6 Specimen Collection and Handling . . . 61
3.7 Assay Procedure . . . 62
3.8 Results Analysis . . . 62

4 Results and Discussion **64**

5 Conclusion and Future Work **71**

Bibliography **74**

List of Figures

4.1 Number of Male and Female with Respect to their Age 64
4.2 %age of Male and Female with Respect to their Age 65
4.3 % Age of FV and FII Mutation and Heterogeneous Homogenous with Mutation 66
4.4 %Family History of Patient with mutation 67
4.5 %Family History of Patient with Mutation 68
4.6 Positive percentage among all the sample 69

Abbreviations

APC	Activated protein C
DVT	Deep Venous Thromboembolism
EPL	Early pregnancy loss
FGR	Fatal growth restriction
MTHFR	5,10-Methylenetetrahydrofolate reductase
PE	Pulmonary embolism
ROS	Responsive oxygen species
SERMs	Selective estrogen receptor modulators
VTE	Venous Thromboembolism

Chapter 1

Introduction

The major medical problem is (VTE) Venous Thromboembolism and (DVT) Deep Venous Thrombosis or pulmonary embolism), one of 1000 people in a year are affected. In causing multicausal VTE disease there is a most wide range of genetic interactions also some elements are genetically engineered and acquired. Common thrombosis in patients leading to serious thrombophilic complications can be seen. From the genetic predisposition to the development of VTE is called hereditary thrombophilia which has occurred more than once. The Lack of antithrombin, the protein S, C protein which are passed from the patients with the several venous throbophilic uncommon and collectively accounts for 11% of patients with venous thrombosis. In 1994, Dahlbck et al., explore that the people with negative responses to the anticoagulant effect of APC in people with inherited and loved thrombosis. [1] The consequence from the single-point transformation expressed in the Elements V model were obtained by the fullness of the APC-resistant phenotype [2]. The most common VTE-based risk Element was identified as Elements V Leiden in a study involving 50% of family-based thrombophilia and 25% of patients with VTE.In recent times Elements V leiden has been considered the most widely tested test among others.[3, 4]

Negative anticoagulant response to APC in many genetic disorders considers that the Elements V Leiden is major cause. The inactivation of the Element V leiden procoagulant lead to a reduction in APC-induced thrombin generation known as an anticoagulant-response protein [5, 6].

APC with the help of cleavage is inactive Elements Va, in amino acids from three different sources: 305 amino acids R (arginine), 505 R and 680 R are purifiers. Elements V Leiden occurs after the incorporation of nucleotide into 1691 in the form of Elements V, a specific guanine to adenine, which predicts the separation of APC in the 506 region of Argenine from glutamine. Elements Va was found to be resistant to APC and the inactivity rate was 10 times slower than normal, resulting in an increase in thrombin generation all of which is due to the previous production of APC using the single amino acid of Elements VIIIa Element V, In a 506 clicking site with protein S, Elements V acts as a coElement. Thrombin formation is initiated by Elements V effect due to the lack of anticoagulant response. From the raised levels of D-dimer, prothrombin part F1+2 and the other category of coagulation marker are indicated a slight increase in clump condition. [7–9].

It is just because of the Dutch investigation of the city of Leiden were the first to report this change so mutant V Element is called Factor V Leiden [2].

1.1 Prevalence

Elements V Leiden is responsible for 40%-50% per cent of cases of common genetics inherited from thrombophilia. That varies with population growth.Element V leiden heterozygosity exists in 34%-9% of the European and US population. The highest prevalence of heterozygozity is observed in Europe; genetic abnormalities are uncommon in Asians, Africans, and Indigenous Australians. The rate at which development is found in Europe is from to 12%-16% in southern of Sweden and Greece to 1%-4% in Spain and Italy [10].Genetic transformation rates are seen in 3.8% of the France population, however the normal is from 1.3% in the southwestern locales to 7.1% percent in France northeastern. [9].The worldwide conveyance of this change addresses in the population of the United States [11].

In white people, around 1 out of 5000 homozygosity recurrence of V Element leiden was found. It was found in the hereditary investigation of Elements V by Haplotype that emphatically demonstrates that hereditary transformation was a solitary occasion that happened 20,000 to 35,000 years prior after the characteristic partition of Africans and Asians from whites[12]. Polymorphism related with a

heterozygous state-related one-of-a-kind types of endurance acquire demonstrated by the dissemination of Elements VI Leiden among whites. Given the change, a little improvement in the state of the cluster will diminish mortality from baby blues drain or injury before. Certain specialists have estimated on this reality [5][12]. In a few examinations, it has been discovered that almost no blood misfortune during labor, labor, and cardiovascular medical procedure by Elements VI Leiden heterozygotes [13–15].

Other proof proposes that it is likewise in accordance with this view, further verifying the way that the heterozygous hemophiliacs found in heterozygous Elements VI Leiden have extremely low pulse and decrease the utilization of thickening element concentrate use. [16, 17]. However, the endurance advantage of Elements V Leiden has not been demonstrated developmental.

1.2 Risk for a first VTE

In people suffering from Element VI Leiden as heterozygote carriers from the related chance for VTE is enhanced by 2%-7%. However, sometime the chance for being prone is less in heterozygote carriers as seen by data taken of different population [18, 19]. The formation of clump risk is enhanced by 8 to 10fold in homozygotes [20, 21].The danger for essential are higher extremity thrombosis (not identified with harm or a venous catheter) is expanded from 2 to 8% V Element Leiden heterozygotes [22, 23].

The probable V Leiden (FVL) and prothrombin quality changes are seen as the most generally perceived obtained thrombophilic wrecks during pregnancy [24]. FVL is actually the most notable changed sort of Element V, and it energizes thrombophilia. [25].FII G20210A change occurs after FVL change in Female with thromboembolism related with pregnancy [26]. FII G20210A happens in light of the substitution of guanine to adenine at position 20,210 of the prothrombin quality.[27] event assessments have affirmed that Female with FVL and FII G20210A changes have an extended threat for pregnancy traps, for instance, PE

[28, 29] in any case, the outcomes of specific examinations don't maintain this finding. [30–32].

Just now, a prothrombin quality change that shapes the danger of venous vein breakage was found by Poort et al., in an evaluation in the Netherlands of subjects with a family establishment of venous circulatory difficulty, depicted as archived venous vein breakage in at any rate two relatives and the proband [33]. The prothrombin quality on chromosome 11 include 22 kb, with 15 exons, 14 introns, a 5'UTR, and a 3'UTR [33, 34].The change revealed by Poort et al., is a solitary nucleotide G—▷A progress at position 21 210 in the movement of the 3'UTR. No particular breaking point has been depicted for this 3'UTR, however some impact on transcriptional rule was evaluated. The change was found in 3% of the Dutch public, in 7% of subjects with a first scene of critical venous vein breakage, and in 19% of subjects with an individual and family establishment of venous thrombosis [35].

The danger of venous thromboembolism is on different events as high among pregnant ladies as among nonpregnant ladies of comparative age [36–38].

1-3 Estimates of the time of pregnancy-related venous thromboembolism move from 1 of every 1000 to 2 out of 2000 deliveries [39].

Thromboembolic bothers, including pneumonic coagulum, are critical purposes behind death among Female during pregnancy and the postpartum period. [40].

Along these time periods, venous thromboembolism is a remarkable yet driving reason for grimness and mortality among ladies during this period. In blood coagulation and fibrinolysis change in typical pregnancy the plasma fixations and exercises of a few proteins included. These progressions may advance coagulation, decline anticoagulation, and repress fibrinolysis and accordingly may expand the danger of thromboembolic occasions, particularly among pregnant ladies who have obtained or hereditary danger Elements for apoplexy [2] [40–44].

Among actually picked acquired changes, Gene encoding Element V Iat nucleotide 1692 (G1691A, proposed as Element VI Leiden change, it is the most extensively seen acquired change in patients with thromboembolic disease, happening in 21% of patients with a first scene of venous circulatory difficulty and up to 60 percent

of those with sporadic venous thrombosis [2]. A guanine-to-adenine change in the prothrombin quality, G20211A, related with raised plasma prothrombin fixations and an all-inclusive danger of venous vein breakage, has been identified [33]. Moreover, the homozygosity for a typical cytosine-to-thymidine change in the quality encoding 10,15-methylenetetrahydrofolate reductase (MTHFR), C677T, is associated with high plasma homocysteine focuses and venous vein breakage, yet this coalition has been tended to by some investigators [45].

Causes variable maternal and fetal issues in the placenta originated by preeclampsia as a typical pregnancy issue. Both mother and infant endurance might be compromised in the most pessimistic scenarios. Preeclampsia ,multiple disorder, is a typical pregnancy-related hypertension condition that represents a significant danger of mortality and dismalness on both the lady and fetus [46]. It is depicted by over again hypertension (systolic heartbeat higher than 145 mm Hg and furthermore diastolic circulatory strain higher than 95 mm Hg) just as proteinuria (more than 305 mg/25 h) that happens following 20 weeks of advancement in pregnancies, and is went with multiorgan wrecks, which bargains the prosperity of both the mothers and the successors severely [47].

Preeclampsia, regularly described by raised pulse and proteinuria following 25 weeks of pregnancy. In industrialized nations, the rate of preeclampsia is roughly 5–7 for each 200 births. Most industrialized nations have encountered a decrease in the rate of preeclampsia over the previous decade, albeit secluded examinations report a fleeting expansion in recurrence. Preeclampsia is a genuine obstetric condition; in the United States, complexities of preeclampsia represent up to 32% of maternal passing during conveyance hospitalization. Two unique conditions preeclampsia has been progressively perceived with: late-beginning illness happening at least 35 weeks of gestation early-beginning preeclampsia happening at under 35 weeks of incubation. Beginning stage and late-beginning sickness have various ramifications for the hatchling and child, with an around 10-overlap higher danger of perinatal demise saw among moms with beginning stage illness, and a twofold expanded danger obvious among moms with late-beginning infection (contrasted and moms without preeclampsia). Be that as it may, the outcomes of beginning

stage contrasted and late-beginning preeclampsia on maternal wellbeing have not been enough measured through populace-based investigations

For reason for discovering pathophysiology of preeclampsia numerous examinations have been directed. Albeit the reason for preeclampsia isn't yet completely comprehended, it has been demonstrated that numerous variables, for example, inherited components, irritation, immunological unevenness and oxidative pressure, might be behind the reason for preeclampsia [47] [48].

It has been valued for right around forty years that it has a familial premise, albeit the specific method of legacy stays hazy [49].

Most industrialized nations have encountered a decrease in the occurrence of toxemia over the previous decade, albeit confined examinations report a transient expansion in recurrence language [50].

The pathophysiology of toxemia reflects inescapable brokenness of the maternal vascular endothelium, and vascular illnesses, for example, diabetes, fundamental hypertension, and antiphospholipid condition incline pregnant ladies to preeclampsia [51]. Inadequate maternal, fetal and placental course cause by the relationship of toxemia with vascular endothelium harm and intervillous and variations from the norm of coagulation.

It has been estimated that changes slanting patients to circulatory trouble may be huge threat Elements for pre-eclampsia and its complexities relavent to inadequate maternal–fetal course. The carriers of a point change R506Q in C ActaObstetGynecolScand 81 (2004) Element V(Leiden change), which prompts started C protein (APC) check, are at extended peril of development of cinch [1–4]. Elements V Leiden is seen as potentially the principal wellsprings of genetic thrombophilia, and its mean transcendence in Caucasian peoples is 5–6% [5][6]. G20210A muatation cause change in the Element leading to inborn thrombophilic issue. The change prompts higher prothrombin creation and to raised threat of circulatory trouble; its regularity in everybody is 1.5%. [52].

Element V Leiden and Mutation II G20210A toxemia and the conceivable pathogenic job of ApC obstruction have been examined in past investigations. The outcomes,

be that as it may, are as yet opposing. we have chosen to make our commitment to the examination, this was the explanation, and Element V Leiden and Element II G20210A predominance assessment in a radioelement measured gathering of ordinary pregnant ladies and subjects with toxemia, chosen by exacting and all-around characterized standards from city [52].

1.3 Aims and Objectives

- To find out the relationship of prothrombin G20211A and Elements V Leiden genetic variation in Pregnant Female Sample taken from Islamabad.
- To find out the relation of Factor V and Factor II mutation with homozygous and heterozygous mutation..
- The relation of Prothrombin Gene Mutation and Factor V Leiden with family history.
- To find out the relation of Prothrombin Gene Mutation and Factor V Leiden with age group among different gender
- Distribution of mutation in both gender..

Chapter 2

Literature Review

2.1 High Prothrombin Activity Association with G20210a Mutation Carriers

Poort S.R. what's more, his partners in 1996 with his associates initially depicted Prothrombin Mutation of G20210 A [33]. also the in 3-untranslated district of the quality nucleotide substitution of guanine (G) with adenine (A) makes 1.5–2 relative the typical reach an expansion in the prothrombin level in blood plasma (20211) [20] [33] [53] [54].

Antecedent of thrombin in the impact of enacted Elements X coagulation, transforms thrombin into Prothrombin, or forerunner of thrombin known to be Element II, nutrient K-subordinate glycoprotein zymogen known to be a. relies upon with identity prothrombin G20210A hereditary variety's predominance lies between 0.7 to 6.7% [55–57].

The relationship of GA genotype with the danger of apoplexies is upheld by a solid proof as by research [58–60]occurring because of an expansion in both movement of prothrombin in blood plasma and level [33][61, 62]. The risk of promoting pregnancy complications relation with prothrombin G20210A genetic variations still objectionable. The risk of pregnancy complications association with mutation is obvious and proven been shown by the multiple systematic reviews and also the

meta-analysiswere used. The risk of preterm placental abruption and early miscarriage (EPL) by 2.6–2.8, PE by 2.4–7.2, FGR by 2.51–4.14 by 3.9–7.9 heterozygous GA variant could be the association [63–65]. However, the association of it being denied in other studies [24] [66].

2.2 Devastating Effect of Mutation in Pregnancy

A supported placental capacity and ordinary placental advancement is the thing that on which a fruitful result of pregnancy depends. A proformation of cluster condition may, offering ascend to pregnancy complexities like serious toxemia, abruptic placentae, fetal development limitation and fetal misfortune lead by strange placental vasculature and aggravations of hemosta may bargain the fetomaternal circulatory framework. Relationship among these transformations and there impacts in various pregnancy confusions been arisen by late years proof, despite the fact that remains generally obscure the etiology of these conditions.

Either the maternal or the fetal side of the placental interface1 prompting placental infarction2,3 proposed pathophysiological system is rehashed apoplexies. Multigenic problem are cause by Inherited and gained absconds i.e. Albeit, first embroiled in pregnancy inconveniences was thrombophilia for the most part antiphospholipid disorder, with acquired conditions which was obtained thrombophilias comparative expanding group of confirmation has been found. Thrombophilia was limited to the inadequacies of the anti-thrombin-3, C protein and also the S the new examination of acquired thrombophilia (rare in everybody).

In investigation about the anti-coagulant response to established C protein an acquired cutoff was represented in 1993. Impacted family was found with Venous circulatory troubles with history not explaining absences of C protein, protein S or anti-thrombin III deficiencies explanation [1].

A point change has been perceived on the quality coding for Element V as the wellspring of the hereditary established C protein resistance (APC-r), Element V molecule that isn't true to form inactivated by C protein been fuse in a result, on

account of substitution of arginine from glycine at amino destructive circumstance of 506 [2]. In the Dutch town of Leiden, the work to recognize change was finished, this change has gotten known as 'Element V Leiden.

Autosomal prevalent plan this defect being obtained, for Element V Leiden the two heterozygotes and homozygotes are affected. This blemish is exceptionally fundamental in Caucasians (3–7%) [10] [66] [67] and for 40–45% of the overall large number of cases of familial thrombophilia and is obligated for 21–25% of the huge number of cases of limited course of action of pack events. In 3.5$ untranslated region of the nature of the prothrombin, Poort et al in 1995 the G20210A polymorphism new polymorphism has been depicted. [33].

High prothrombin is connected with change in the plasma of these patients. The G20210A polymorphism is normal in everybody (0.7–4.0%)([57]. G20210A polymorphism is connected with an extended risk for venous thromboembolism (6.2% of the large number of occasions of blood vessel breakages), cerebral vein circulatory troubles and myocardial restricted corruption. With the new portrayal of another Element V genetic assortment related with security from advancement of bundle events (Element V Cambridge, Arg 306 Thr) and impelled C protein the overview of known thrombophilic changes is still increasing [68].

Previous accumulated data suggested the association among these mutations and pregnancy complications, but further research needed for their precise effect on complications related to pregnancy and outcomes. To date there are no reliable predictors other than delivery for PE, specific preventive measures, or treatments [69–71]. Apart from many reasearch findings which have been done carried on similar topic but there isn't any clear underlying mechanism of PE, it has been demonstrated that in the pathogenesis of PE Elements including hereditary impacts, aggravation, the unevenness of resistant framework and the oxidative worry of which the most crucial job is being played by oxidative stressOxidative pressure is described as an awkwardness between responsive oxygen species (ROS) and cell reinforcement powers for ROS, which can trigger maternal endothelium brokenness through downstream flagging pathways, in the end prompting clinical impacts of PE during pregnancy [47].

2.3 Effect of Mutation in Preeclampsia and HELLP Syndrome

Since 1994, investigation was done to find out the existence of any likely pathogenic job of transformation in toxemia when most regular hereditary reason for protection from APC and of genetic thrombophilia been recognized as a Element V Leiden mutation.

In 1996, Dekker et al[72] APC hindrance for instance 16% rate found of 50 Dutch ladies with an establishment set apart by veritable beginning stage blood harming. The higher greatness of the both APC obstruction and also V leiden figure preeclamptic subjects than in controls coming about to discovering relationship between the hemostatic irregularities and the genuineness of the disorder[73].Lindoff et al. [74],for a condition-controlled assessment found in a preeclamptic patients a 10% rate in controls for example of a group of Swedish the higher allele rehash of consider VI Leiden Northern Europeans has been reflected by this high pervasiveness [75].

Kupferminc et al.[76] first found (chances proportion: 5.3; 95% CI: 1.8–15.6) affirmed the outcomes on a bigger populace in the wake of discovering ladies with serious toxemia at high pervasive than in controls [77]; in any case, the researchers consolidated subjects with HELLP condition and serious toxemia without recognizing the two types of the illness.

It has been addressed in evaluations toxemia may give quality combinations by that of ordinary Elements and stretched out shortcoming to preeclampsia. [78]. Prothrombin G20210A change evidently was linked with the hypercoagulable state. Prothrombin G20210A allele was seen as a danger Element for venous and vein circulatory difficulty and transport of prothrombin G20210A change isn't identical to individuals to another. It is high as 9.8% in Polish revealed as low as 0.01 % in Sudanese patients with blood harming. The relationship of Element II (prothrombin) changes with blood harming have been appeared by some past appraisal information [79].

2.4 Genetic Susceptibility to to Venous Thromboembolism in Pregnancy

Assessments vacillate of the event of pregnancy-related venous thromboembolism range lies between 1 out of 1000 to 1 in 2000. [80]. A state in which increase in coagulation Elements I, VII, VIII, and X a reducing in protein S, and a deterrent of fibrinolys pregnancy proformation of group state. During this period risk of venous circulatory trouble extended on various occasions and it is likely going to be contributed by these phenomena[81, 82]. For Female, with hugely extended threat of venous thromboembolism who have a procured inadequacy of a typically happening anticoagulant (antithrombin, C protein, or protein S) has been represented that pregnancy and postnatal depression period are connected in the Female [83]. Substitution at nucleotide position 1691 of guanine with adenine achieves an assurance from ordered C protein which is an autosomal winning quality it is a change in coagulation Element V gene [2]. Glutamine at 2 of the Element VIcleavage objections for started C protein results in a change subsequent to superseding of arginine development 506 with a glutamine.[2]. This change accepts a central part in causing significant venous circulatory trouble and named as Elements V Leiden [84]. Moreover, actually in case of significant venous blood vessel breakage in an obstetric masses work has furthermore been represented this mutation [43] [85].In the 3'- untranslated locale of the prothrombin quality customary inherited assortment (a guanine to adenine progress at position 20210) related with an extended event of venous thrombosis [33]. The individuals with this mutationn levels than non-carriers found higher prothrombin. There is late evidence of the relationship among blood vessel breakage and acquired homocystinuria, Element VI Leiden, On the other hand the overall risk of circulatory trouble related with the G20210A allele has been evaluated to be 2.7.9 paying little regard to sex and age, In the quality coding for 5,10-methylenetetrahydrofolate reductase (MTHFR) purpose behind moderate hyper homocysteinemia is a by and large progressive change. Element's occasion of venous circulatory trouble, for instance, Element V Leiden or antiphospholipid antibodies have been found to affect the effect of this nuclear variety.

2.5 Severe Preeclampsia and High Frequency of Genetic Thrombophilic Mutations

Hereditarily decided inclinations toward thromboembolism are acquired thrombophilias., change in Element VIis related with expanded danger for thromboembolism, brought about by a guanine to adenine replacement at nucleotide position 1691 (G1691A; Element V Leiden), [2] [84] [86] homozygosity for the guanine 20210 adenine transformation in the prothrombingenecytosine and 677 thymine (C677T) change in methylenetetrahydrofolatereductase (MTHFR) [87] In everyone seemed to have high predominance of a few changes in thrombophilic protein [33] [88] [89].

Protection from the Element V Leiden transformation and actuated C protein C,[72–74] [90] Preeclampsia is with raised degrees of homocysteine[72, 73] [91] and homozygosity for the MTHFR change are thromophilias [92, 93] In a past report we found from a sum of 110 ladies with serious obstetric difficulties a 64% rate of thrombophilias in 34 ladies with extreme preeclampsia [76]. Absence of a few danger Elements for example control gathering, improper coordinating, modest number of study gatherings, and the choice and assessment of a couple of uncommon known thrombophilias cause this examination to be reprimanded.

2.6 Association between the Factor V Leiden Mutation and also Pregnancy Outcomes of Mother and Baby

Pregnancy-related venous thromboembolism in the United Kingdom is the critical reason for maternal horribleness and basic reason for maternal death[94, 95]. Elements V Leiden (FVL) change inclines to apoplexy and is most ordinarily known hereditary Element [2] [96]. Review considers have detailed an expanded danger of venous thromboembolism among the pregnant ladies for example heterozygous for the FVL transformation has (10 – 25%)[43] [45] [97–99].

Be that as it may, without a background marked by earlier venous thromboembolism the danger of venous thromboembolism in gravid FVL change transporters restricted information exist to characterize it. In the moms or embryos with a gained or hereditary inclination that may show clinically as unfriendly pregnancy results it has been additionally estimated localized necrosis and unusual apoplexy of the uteroplacental dissemination can be available, that incorporates fetal development limitation, pregnancy misfortune, toxemia and placental unexpectedness. However, Contradiction been found in cross-sectional and review studies [37] [52] [63–68].

Because increasing number of individuals who have been treated and tested with anticoagulation make it more important to have accurate information regarding adverse pregnancy outcome and risks for thrombosis[76][100]. Anticoagulation which is costly Significant morbidity can be cause by Anticoagulation as well [101–103].

2.7 Some of the Risk Elements for Preeclampsia

Maternal impermanence, premature birth, intrauterine growth retardation, and perinatal impermanence can be contributed by hypertensive disorder known as Preeclampsia. In case of preventing its development low-dose aspirin has been found to be effective [104–107].

However, during pregnancy the use of aspirin may not be without risk [108]. Hence, it is important to identify them early in pregnancy Female prone to high risk for developing so that they can benefit from intervention. The preeclampsia has been called a "disease of theories", however the risk Elements for and causes of preeclampsia remain unclear. Universally agreed with few other risk Elements having a previous history of preeclampsia in multíparaswith the exception of nulliparity (approximately 80% of Female with preeclampsia are nulliparous).[109, 110] Furthermore, although it has been recommended that the causes of and risk Elements for preeclampsia in multíparas and nulliparas may be different few have examined these differences [111–113]. Some researchers have predicted that

preeclampsia is a disease of all social classes, others more recently believe it is a disease of the impoverished and still others think the upper class are at equal risk [114, 115].

Since most studies have not separated out the contributions of socioeconomic status-relevant variables such as race, employment status, and nutritional status it has been difficult to determine the exact role of socioeconomic status. Nor have these studies, such as essential hypertension, cardiovascular disease, and diabetes, and that may be more prevalent in groups with lower socioeconomic status selected this kind of controlled group or excluded Female with preexisting diseases that may be related to preeclampsia. Greater risk for developing preeclampsia have been observed in the Black Female. Chesley et al caution that higher prevalence of preexisting hypertension in black Female could be the reason for this increased risk of preeclampsia [111]. Nevertheless, a higher incidence of both preeclampsia and eclampsia in black Female has been found in the collaborative Perinatal Project compared with white Female whether or not they had preexisting hypertensive disease [116].

2.7.1 Age

The effect of age may be confounded by other Elements; however, extremes of age are also postulated as risks for preeclampsia [117]. For example, older Female are more prone to have essential hypertension and younger Female are more likely to be primigrávidas [109].

2.7.2 Body Habitus

For almost 200 years the relationship of preeclampsia and body habitus has bee debated. Some authors have concluded that heavy set of Female are more susceptible, whereas others claimed frail Female are more vulnerable [118–120]. Again, Chesley recommends that the association with heavy weight is an artifact of including Female in studies of preeclampsia with essential hypertension [109]. Nevertheless, the WHO Study Group concludes that a woman's risk for preeclampsia

has been increased by the high prepregnancy body mass [121]. From developing preeclampsia there are some attributes seem to protect Female. For example, cigarette smoking has been consistently demonstrated to protect Female against preeclampsia. [91, 92]. Its effect independent of body mass is dose related [122]. Also, a previously terminated pregnancy, may provide some protection against preeclampsia in a subsequent pregnancy if it ends later in gestation [123]. As noted by some authors, was doubtful of the increased susceptibility for preeclampsia of heaviest Female, and of black Female and, if was found, probably due to including Female with essential hypertension [109]. There is risk for being black in nulliparous Female remained strong and for high body mass.

2.7.3 Working During Pregnancy

The risk for preeclampsia gets doubled while working during pregnancy. However, socioeconomic status does not appear to be related with it. For example, professional/managerial job or employment in either a working-class increased Female's risk relative to unemployed Female.

Similarly, there is no variation in the proportion of partners of control patients case patients and held working-class and professional/managerial jobs. However, Kaiser Permanente Medical Care Program being used for their health care, by Female from wide range of social classes the extremes of income are probably underrepresented [124]. In a variety of studies working during pregnancy has been implicated as a risk Element for preeclampsia.

For example, in a cohort study of Female exposed to organic solvents similar finding was observed [125].In that study those Female were most at risk those who were working longer into their pregnancy (with solvents). Klebanoff et.al., reported that the risk of preeclampsia, 79% of whom worked during pregnancy was higher in a group of female residents (100% employed) than in a control group consisting of spouses of male residents [126]. A study by Marcoux et.al., found that Female protected against preeclampsia has an increased leisure-time activity (of which working Female presumably have less) [127]. Female who work have

different levels of physical activity than nonworking Female and may be more stressed; however, to determine the exact parameters of work that might increase risk further investigation is needed.

2.7.4 Cigarette Smoking and Alcohol Consumption

It was found that, on univariate analyses, alcohol consumption was protective. Cigarette smoking tended to protect against preeclampsia. The apparent smoking may be associated with protective effect of alcohol since in the multivariate models it was not found to be significant. In studies of light drinkers, cigarette smokers, and particularly Female, have been found to have lower blood pressures than abstainers' non-pregnant adults[128, 129]. Although, the well-known risk of both (tobacco and alcohol consumption may tend to protect against preeclampsia) of these agents to the fetus outweighs the slight benefit. Moreover, Duffus and MacGillivray et.al., found that among infants of smokers than of nonsmokers, perinatal death rate due preeclampsia was higher of smoker [130].

A risk Element for preeclampsia has been demonstrated with old or young age. On univariate analyses disappeared when parity was controlled for, as Chesley suggested, after slight increased risk of Female under 21 years old observed. Perhaps because Female with essential hypertension were excluded because the increased risk at older age was not evident in this sample. In addition, Lehmann did not show a clear increase in the incidence of preeclampsia until after Female reached the age of 45 years Lehman did not show any increase [117].

Patients with not above 41years of age re included in one study. Having a previous history in multiparous Female having a previous history of spontaneous abortion protected against preeclampsia. However, it does not have a previous therapeutic abortion did not protect against preeclampsia, in that having a previous pregnancy provides protection. MacGillivray et.al., suggested, pregnancy provided protection against preeclampsia especially the previous pregnancy that ended later [123]. In a recent study of Kaiser patients, on average, then therapeutic abortions (clinically recognized spontaneous abortions) occurred later in gestation [129].

The revert models' divine risk of preeclampsia were identical for nulliparous and multiparous lady except for being black and having a history of spontaneous abortion. Stringent criteria we used to define preeclamptic cases and controls may be related to the differential risk of these variables in the two group. For example, when applied the final multivariate model to the original sample of Female found that being black posed a significant increased risk in both nulliparous and multiparous Female, who received a discharge diagnosis of severe preeclampsia or eclampsia (n = 263) and the random sample of controls (n = 260),. Similarly, in both nulliparous and multiparous Female spontaneous abortion was significantly protective.

This finding suggests that used to define inclusion in this study by being black may be a risk in both nulliparous and multiparous Female with less severe forms of preeclampsia an on the other hand history of spontaneous abortion may be protective. The usefulness of low-dose aspirin therapy and other preventive measures depends on the Its on clinician's ability to identify Female who are at high risk for preeclampsia early in their pregnancy because of which low-dose aspirin therapy and other preventive measure's usefulness can be found. Therefore; included logistic model by the 20th week of gestation those potential risk Elements that can be known [129].

2.8 Recurrent VTE

Inside the ensuing 8 years Around 30% of people with an episode VTE create repetitive thrombosis [131]. There are conflicting information on the Elements VI Leiden heterozygosity related with the danger of intermittent VTE. The current proof recommends that after beginning treatment of a first VTE it has all things considered an unassuming impact on repeat hazard., Didn't locate an expanded danger for repeat in Elements VI Leiden heterozygotes a few forthcoming associate investigations of unselected people with a first VTE. [132, 133]. In the Leiden Thrombophilia concentrate likewise found no expansion in repeat danger in as of late revealed follow-up of participants. [134].

A meta-examination including 3104 people after a first occasion with a chances proportion of 1.4 with a first VTE presumed that altogether expanded danger for intermittent VTE is related with a heterozygous mutation [135].Comparative unassuming been found in the two ongoing methodical audits yet critical expansion in repeat hazard (pooled chances proportion 1.56 and 1.45, respectively). [136, 137].The decrease in danger during oral anticoagulation is comparable in people without and with the Element Leiden transformation has been appeared in a few studies. [136–138]. The peril for tedious VTE in Elements VI Leiden homozygotes isn't especially portrayed at this point dared to be higher than in heterozygotes. A 5-year all out recurrent speed of 13.5% in a touch of social affair of homozygotes not tolerating long stretch anticoagulation approaching improvement of the Leiden Thrombophilia study definite [132].A change have a 3 overlay higher threat than individuals heterozygous for Elements VI Leiden alone and a 5 to 15 cover higher peril for rehash than those with neither change. [136][139–141]. An adjustment regardless, when the assessment was kept to those with a first idiopathic VTE a change didn't have an extended threat for recurrence [142]. Twice fold heterozygotes associated with these examinations and unobtrusive number Danger checks were limiting the peril measures. Elements VI Leiden heterozygotes with hyper homocysteinemia have 5 to 6 overlay higher risk for irregular VTE than in individuals with a Elements VI Leiden allele alone [141].alternately, High Elements VIII levels of Elements VI Leiden heterozygotes didn't have a higher threat for monotonous [134].

2.9 Complication in Pregnancy

Available information demonstrate that Elements VI Leiden is related with an expanded danger of twofold to multiple times the danger of pregnancy and conceivably seizures, for instance, pre-eclampsia, intrauterine development restrictions and unexpected placental suddenness. Notwithstanding, the advancement of the Elements VI Leiden are totally viewed as one of the causal components that added to these negative impacts. Other hereditary and ecological Elements other than Element VI Leiden might be significant in improving pregnancy intricacies. By

and large, the odds of a productive pregnancy result are high, in any event, for homozygous ladies. [143].

Pregnancy

Many case-control techniques have found evident levels of Elements Leiden heterozygosity in Female irregular conceives, commensurate to 1-20% of controls, proposing a 1-to 5-fold higher prone to risk [11, 76] [144–146]. In an appropriate report, Elements VI Leiden heterozygotes with a foundation set apart by preterm births had an essentially lower rate of birth which is 38% and the woman with the same history of right now of her pregnancies without changes rate 70% [147]. Regardless, different tests didn't discover a relationship with the terrible pregnancy and proposed that the change had no impact on the result of the ensuing pregnancy after the primary unsuccessful labor [148–150].

A few meta-tests have found a strong association with fetal loss [151–154]. Other proof proposes that ladies have a higher danger of growing late pregnancy than the main trimester misfortune [152–157].

Meta-breaks down found that heterozygous transformations uncovered an expanded danger of 2 unusual unnatural birth cycle and a higher danger of 4 premature deliveries in the following trimester contrasted and the principal trimester [151]. Elements VI Leiden heterozygosity was related with an expanded danger of 4-wrinkle unexplained birth deserts and a 11-overlap expanded danger of birth-related placenta localized necrosis [158].

Another report found that homozygous females had a 5 times higher danger of past premature delivery (following 12 weeks of improvement) than heterozygous females and 11-wrinkle more than non-feverish females. Strangely, the repeat of unnatural birth cycle in the correct time (first trimester) analyzed the mix of every one of the three connections, proposing that the change has a relationship dependent on late pregnancy misfortune [143].

It is conceivable to determine that the unnatural birth cycle of a late pregnancy demonstrates the shortcoming of the placenta, instead of the mishap of the trimester, which is a typical event for an assortment of causes. Moreover, some

proof recommends that Elements V Leiden expands the danger of first trimester misfortune [151, 152] [159].

Other Birth Abandons

Beside the way that pre-eclampsia, stomach development, and placental suddenness can likewise influence placental unexpectedness, their relationship with Elements V Leiden is dubious. The aftereffects of the contention introduced in the different preliminaries may demonstrate a stamped increment in the articulation and assurance strategies, the convergence of the different races, and the modest number of cases included. Elements V heterozygosity will be found in ladies with unexplained genuine or periodic serious pregnancy impacts[160].

Blood poisoning is a confounding boost in the cerebrum, and it is far-fetched that segregated thrombophilic loss of motion assumes a significant part. Various investigations including a couple meta-tests have discovered an expanded danger of blood poisoning in ladies with Elements VI Leiden. [151][161–163]. Other tests didn't discover an association [148] [164–166].

The opposing consequences of this investigation propose that Elements VI Leiden heterozygosity all variables are viewed as a negative effect on the danger of pre-eclampsia. Elements VI Leiden has a more settled relationship with more extreme and early pre-eclampsia than moderate to serious types of the sickness [157] [167]. Heterozygous ladies are having higher risk of inward preeclampsia in her pregnancy accordingly. [168]. They may likewise have a higher danger of genuine maternal implantation and antagonistic birth results than young ladies without thrombophilia. [161] [168].

The subtleties on the danger of intrauterine turn of events and placental suddenness are seriously restricted and opposing. Numerous examinations have been assessed and enabled to locate a bigger association [160]. A few meta-analyzes have found an increased risk of 3-to-5-overlap lowering a child's developmental limit with a more consistent relationship with critical developmental constraints [153, 157, 169]. Interestingly, multiple case management, co-operation and close investigations did not find the organization[170] [148] [163] [164].

2.10 Clinical Expression of Factor V Leiden

The clinical verbalization of Elements V Leiden has been affected by genetic associations and the acknowledgment of thrombophilic issues and risk Elements. The mix of Elements V Leiden heterozygosity and different thrombophilic wrecks basically influence thrombotic peril.

2.10.1 Existing Thrombophilic Disorders

There is an expansion in Elements V Leiden among patients with inadequate side effects of C protein, Protein S, and antithrombin and proteinrombin 202011 > A Conversion [171]. People with two imperfections have a higher danger of apoplexy than relatives with one. highlight. In a joined investigation of eight case-control contemplates, people with one Elements VI Leiden or prothrombin 20211G > Allele had a 6 to 5-overlay increment in thrombotic hazard, individually. Conversely, double the heterozygous people in the two changes had a 21-overlay increment in danger, demonstrating the impact of the repeat of these two transformations in thrombotic hazard [172].

Prothrombin 20211G> Allele was 5 multiple times more normal in Elements VI Leiden homozygotes with VTE than in non-thrombotic controls [173]. Recent examinations have discovered that individuals with Elements V Leiden change who had-The main relative with a background marked by apoplexy had multiple times more danger of VTE than the Elements VI Leiden network with a helpless family ancestry. The danger has been expanded multiple times for those with at least two tainted family members. Family ancestry had an extra incentive in anticipating hazard other than the Elements VI sort, which recommends the presence of obscure variables in hereditary danger Elements [174].

Elements V Leiden heterozygotes with more critical degrees of Elements VIII (150% standard) have a couple of times more VTE cases than those with heterozygous change alone. [175]. The peril of circulatory trouble is similarly extended to the patients with Elements VI. In the Physicians' Health Study, people with

Elements VI Leiden allele or hyperhomocysteinemia had a three-to four-cover extended threat of idiopathic VTE diverged from those without abnormalities. The risk of thrombotic relative is on different occasions extended in people with the two irregularities. [176]. It isn't yet clear the sum Elements VI Leiden fabricates the thrombotic peril related with mortality. An enormous case-control study drove by individuals establish that Elements VI Leiden heterozygotes with a high-risk ailment had twofold the peril of VTE than threat patients without replacement and a 12 times higher risk than non-crack danger [177]. People with harm and heterozygosity of Elements VI Leiden or prothrombin 20211G > Genetic changes had a 25-overlay extended peril of making circulatory trouble more than non-prothrombotic infection patients [177]. Change of Elements VI Leiden may likewise add to venous-related catheter-related channels in malignant growth patients [178]. Interestingly, Elements VI heterozygosity didn't expand the danger of VTE during adjuvant chemotherapy in bosom or intestinal treatment [179].

2.10.2 Risk Elements for Certain Situations

Other VTE results incorporate intravenous antonyms use, pregnancy, estrogen pregnancy, HRT, SERMs, versatility, injury, age, condition, and operation. Elements VI Leiden teams up with these common dangers to make a VTE hazard. Regardless 55% of the thrombotic scenes in individuals with Elements VI Leiden are invigorated by different energizers [180]. For the bigger homozygotes' accomplice of Elements VI Leiden, fundamental VTE was related with dangerous conditions in 85% of ladies and 30% of men. Preventative strategies and contraceptives have been the most famous medicines for pregnant ladies. Thirteen percent of key treatment strategies are humiliated by VTE, which proposes around 25 expansions in danger. [173].

2.10.3 Intermediate Toxic Catheters

Elements VI Leiden heterozygotes contain 3-to-5-fold expanded danger of venous-related catheter-incited apoplexy [181]. The transformation makes a catheter-related circulatory trouble danger in patients at the edge or chest of the metastatic

with threatening development and those going through allogeneic bone marrow transplantation [182, 183].

2.10.4 Pregnancy

More than 20 - 46% of ladies with VTE-related pregnancy are determined to have Elements VI Leiden. [45]. A 10-to-50 fold excess expansion in thrombotic hazard during pregnancy and puerperium have a changing relationship, then in non-pregnant young ladies without thrombophilia [151, 184].

The overall danger is higher for ladies with touchy or hazard Elements, for instance, weight and development of maternal age. [185]. 51 Ladies with unmistakable or homozygous thrombophilic absconds have a high VTE hazard related with pregnancy. The danger is expanded by 20 to 40 ladies wearing the homozygous Elements V Leiden [151][186, 187].

In 1 examination, VTE pregnancy-related threat was extended by 9-fold in Elements VI Leiden heterozygotes, 16-overlay in prothrombin 20211G > A heterozygotes, and more than 150-cover in two heterozygotes, portraying the saw development in high peril when thrombophic changes included [45].

In an examination of thrombophilic families, VTE recalled 5% of pregnancies for heterozygous Female of Elements VI Leiden and prothrombin 20211G > Transmission and 19% of pregnancies in Hactzygotes of Elements VI Leiden, stood out from 1.5% of these species unaffected [187, 188].

In the continuation of randomized homozygous females, the commonness of VTE-related pregnancy was 9%. [189] [190]. In spite of the fact that during pregnancy and the pueperium Factor V Leiden increases the risk for VTE, the outright danger in asymptomatic heterozygotes isn't yet studied. [75][164] [18][45][151][186][187].

2.10.5 Oral Contraceptives

The peril for VTE in Female heterozygous for Elements V Leiden use increases with use of oral contraceptives fundamentally. 20 – 60% of Female found with

heterozygous change with oral safeguard use [191, 192]. In the Leiden Thrombophilia study, in oral prophylactic customers the peril for VTE was extended 4folds and in Female who were heterozygous for Elements V Leiden was extended 7-cover. Regardless, in antonyms Female who used oral contraceptives the peril was extended 30-overlay, exhibiting a multiplicative rather than added substance sway on as a rule thrombotic risk [193].

In various examinations and a meta-assessment with chances extents going from 11 to 41 for the blend of both threat Elements the supraadditive effect of a Elements V Leiden allele and oral contraceptives was confirmed[194–197]. A 60-overlay higher risk for cerebral vein circulatory trouble than nonusers without the change found in heterozygous Female who use oral contraceptives [198].

The peril for VTE is extended more than 100 percent in those Female homozygous for Elements V Leiden who use oral contraceptives. [193]. The individuals who are doubly heterozygous for Elements V Leiden and the prothrombin 20211G ¿A mutation with oral impediment client's hazard is found also especially increased [199].

Thrombotic disorders filled sooner in ladies with acquired thrombophilic issues, for example, Elements V Leiden, with a lot higher danger for circulatory difficulty during the significant year of oral prophylactic use [200]. A 2-overlay higher risk for VTE than second time courses of action have been found in oral contraceptives customers containing the third-age progestagendesogestrel, and the threat is especially high in Elements VI Leiden heterozygotes. Who used third generation courses of action the risk was extended 55 folds in Elements V Leiden heterozygotes, differentiated and Female without the change who were not using oral contraceptives [197]. The through and through event of VTE may regardless be low despite the stepped qincrease in relative peril, because of the low measure risk in young sound Female. For example, an additional 30 VTE events for each 10,000 Female every year Is surveyed to be found in Female with the blend of Elements V Leiden and oral contraceptives use [193].

Ladies suffered from Factor V Leiden, the risk of VTI was 2% each season of oral prophylactic use found in an approaching accessory examination of asymptomatic

Female [100]. Without thrombotic challenges has been represented in long stretch oral prophylactic use, underscoring the multiElemential etiology of VTE [201].

2.10.6 Hormone Replacement Therapy

In current customers of HRT differentiated and nonusers the relative risk for VTE is extended 5-to 10-fold [202, 203].

The HRT was connected with a 3-wrinkle extended risk for VTE found by the achievement Ladies' Wellbeing Activity randomized fundamental of estrogen and progesterone HRT versus counterfeit treatment in postmenopausal lady [203].A 7-to 15-overlay extended threat for VTE found in lady with Elements V Leiden who use HRT differentiated and nonusers without the mutation. [197] [204–206].

The peril of VTE was 3% each season of HRT use found in an approaching accomplice examination of asymptomatic Female with Elements VI Leiden. [100].The 1-to 4-overlay increase in thrombotic risk with oral contraceptives resembles the threat saw with HRT[205, 206].

A lower formation of clump risk than the oral route in postmenopausal women associated with transdermal estrogen [207**?** , 208]. A 4-overlay higher peril for VTE found among Female with Elements VI Leiden, the use of oral estrogen than transdermal estrogen [209].

2.10.7 Selective Estrogen Receptor Modulators

A 2-to 3-crease expanded danger of VTE, like the danger of HRT discovered to be related with SERMs, for example, tamoxifen and raloxifene. Females with Elements V Leiden they use SERMs the danger for VTE in ladies isn't very much characterized yet likely higher than that related with SERM utilize alone, considering the connection of the change with HRT. Danger of VTE related with tamoxifen in two case-control investigations of high-hazard solid ladies selected bosom malignant growth counteraction preliminaries Elements V Leiden had no critical impact on it. [210, 211]. For beginning phase bosom malignant growth was around 5-overlay higher in Elements V Leiden heterozygotes, the danger for

thromboembolic confusions during adjuvant tamoxifen, than in ladies without the transformation accepting a similar treatment.Estimated V Leiden heterozygosity in ladies who created thromboembolism was found in 19% of contrasted and 5% of ladies without these complications[212].

Name	**Statement**
Travel	Risk is bigger in people with Elements V Leiden mutation those who use to travel alot it counts as a risk Element for VTE. 14- to 16-fold higher occurrence risk for VTE is linked with both of thrombophilia (including Elements V Leiden) and air travel. (201,220)
Age	Expanded frequency and danger of VTE according to age. Danger increments as the years pass by in a freak variation of Elements VI Leiden changes, showing that apoplexy includes hereditary variables that have been foreordained. (221) A clinical report led showed that the pace of men with an immune system occasion was 33% of those more than 60 years old. In a populace-based examination, among Elements V Leiden heterozygotes the danger of VTE was altogether higher in individuals matured 60 years (mean danger 3.6). (18) Other forthcoming examinations incorporate some danger Elements that expansion Elements V Leiden as age increments for example individuals with weight file (BMI), and smoking. Studies have shown that the 10-year danger of creating VTE among heterozygotes was $< 1\%$ higher in non-smokers and those younger than 40 and who were fat, then again contrasted with 10% found in single smokers and their age was over 60 years with a BMI¿ 30 kg/m $\hat{2}$. Outside and with these danger Elements were 51% and 3%, separately they were a 10-year thrombotic apoplexy with the event of Elements V Leiden homozygotes. (19)
Minor injury	Upon minor leg injuries it has been found that VTE occurrence risk increased by 5-fold and it has been found in a large population-based study.

	A 50-fold higher thrombotic danger of occurrence was found in individuals than individuals without these danger Elements in a Elements V Leiden mutation carriers with a minor leg injury (222)
Obesity	In Elements V Leiden heterozygotes obesity increases the risk of VTE. The doubled risk of 2.5 VTE was found to be associated with obesity (BMI> 30 kg / m2). People had 6 fold in overweight (BMI> = 25 and 30 kg / m2) and 8 fold in obese Elements V Leiden obese people. (223)
Surgery	Elements V Leiden plays a role in creating a major thrombotic risk associated with surgery that needs to be studied as it is not yet clear. Surgery was the norm for VTE to predict relatives with mutations found in a randomized controlled trial with Elements V Leiden . (186) Numerous studies have suggested that after orthopedic surgery and other surgeries, a 5-fold increase in the prevalence of viral VTE is found to be associated with mutations. (224-226) Approximately 13 higher risk of high DVT in Elements V Leiden heterozygotes undergoing non-surgical control. On the other hand no links have been found in other studies. (227,228) 148,149 The increased risk of about 20 times VTE after surgery is found in the homozygotes of Elements V Leiden , especially the bone and urinary system. (179)

2.11 Thrombosis not Convincingly Related with Elements V Leiden

2.11.1 Thrombosis Arterial

With clashing outcomes from various examinations, the part of Elements V Leiden in blood vessel sickness is disputable. The accessible proof recommends that for blood vessel apoplexy Elements VI Leiden is certainly not a notable danger Element. Within the sight of set up cardiovascular danger Elements, for example, hypertension, hyperlipidemia, diabetes, and smoking, greater part of myocardial areas of dead tissue and strokes happen.

To these intricate infection's commitment of a solitary prothrombotic change is probably going to be little. Nonetheless, to advance blood vessel apoplexy it is conceivable that element V Leiden may associate with other hereditary and natural danger Elements. Discovered no relationship between and an expanded danger for myocardial localized necrosis or stroke and Elements V Leiden in many investigations of unselected grown-up populaces [222–224].

Conversely, a Elements VI Leiden allele gave a decently expanded danger for coronary sickness and myocardial localized necrosis found in huge meta-analysis. [225]. There is additionally information proposing hazard for blood vessel thrombotic occasions in explicit subgroups of people might be contributed by transformation. The danger (as not many were remembered for the accessible examinations) for blood vessel apoplexy in Elements V Leiden homozygotes is obscure.

2.11.2 Myocardial Infarction

Dead substance tissue in extremely youngsters and those with other normal cardiovascular danger variables can be given by Elements V Leiden . One investigation found an expanded danger of myocardial restricted rot in young ladies with other cardiovascular danger Elements, particularly smoking. Elements V Leiden heterozygotes smokers had a 30-wrinkle expanded danger of myocardial confined rot

contrasted and non-smokers. [226].In another new investigation, Elements V Leiden 's transformation was related with a twofold amplified danger of unexpectedly dead body tissue (before 40 years). The blend of hypercholesterolemia with the Elements V Leiden allele has expanded the danger of around fourfold [227]. Other examinations have correspondingly discovered a mix of Elements V Leiden and at any rate one halted cardiovascular danger Elements fundamentally expanded the danger of inside myocardial corruption. The mix of thrombophilic transformations and smoking gave the main danger, with the pronounced rates going from 6 to 18. [228, 229].

2.12 Stroke

Most considers of unselected adult populations didnt find a significant association between factor V leiden and ishchemic stroke [222] [230].The prevalence of factor V leiden was similar in unselected individuals with authentic carotid atherosclerosis and healthy controls[231][232, 233].

The interaction of factor v leiden with other cardio vacsular hazard fcators may increase the risk of ischemic stroke . young women with a factor V leiden allele who use oral contraceptives have a 9 to 13fold increased hazard for stroke compared with women without either threat factor. [234, 235].

Women younger than 60years with factor V leiden who smoked had a approximately 9 fold higher danger of stroke than non smoker without the mutation[230].

In these assessments, Factor V Leiden increased the danger of stroke only in women with these other peril factors. The combination of a factor V leiden allele and one or more traditional cardiovascular threat factor was associated with a approximately 11fold increase in stroke risk [232].

Another report found that were from an overall perspective bound to have wide atherosclerotic vascular infection and particular quiet areas of dead tissue of Elements V Leiden heterozygotes with a first ischemic stroke than stroke patients without the mutation [236].

A change was found in patients with a cryptogeneic stroke and a patent foramen ovale (PFO), for example high ordinariness of Elements V Leiden or the prothrombin 20211G >A proposing the chance of astonishing embolism [237].

Change had an around 2-cover broadened danger for PFO-related stroke separated and both control and non-PFO-related stroke patients found in a meta-assessment of people with a Elements V Leiden or prothrombin 20211G >A [238].

2.13 Genotype-Phenotype Correlations

People have a higher danger of circulatory trouble than heterozygotes found in their homozygous individuals of Elements V Leiden . Notwithstanding, if there ought to be a development in the clinical course of huge homozygotes of thrombotic status it isn't more touchy or unaffected by anticoagulation than heterozygotes. Homozygotes thrombotic hazard is imperceptible and isn't a danger Element for an absence of homozygous C protein or S. Twofold heterozygous individuals of Elements V Leiden and Elements V non-freak Element V Leiden and element V needed "Pseudohomozygous" Elements V Leiden happen. Around 1: 1000 heterozygous individuals for Element V Leiden co inheritance of a Elements V allele happens. As opposed to diminishing the effect of the Elements VI Leiden allele, the imbalance of the Elements V upgrades Elements V upgrades it, making a safer coordination of the APC, described by a much lower APC restraint rate, which isn't reflected in that solitary change [239].

The combination of heterozygous Elements V Leiden change, low-plasma Elements V level of action in addition (approximately half the normal), and a low degree of APC inhibition on normal access to homozygous conversion to the findings of pseudohomozygous Elements V Leiden is based. there seems to be an increased risk of thrombotic and clinical complications such as those of Elements V Leiden homozygotes appear to contain pseudohomozygotes of Elements V Leiden [240].

Humans have doubled the heterozygous of Elements V Leiden and Elements V Cambride expressed against the Pseudohomozygous APC [241]. In a rare case, on the same chromosomes in the cis structure both abnormal allele changes with

Elements V Leiden occur. For these individuals, the subsequent lack of Elements V values protects the specificity of the Elements V Leiden mutation [242].

2.13.1 HR2 Haplotype

Haplotype quality Elementlot V (HR2) is in a state of complete degradation of Elements V leiden (defined by R2 polymorphism (4070A> G)) and can bring about mild resistance to APC. [6]. Submitting a very strong APC rating on the conversion of Elements V leiden [243, 244].

Inherited HR2 haplotype increased VTE risk associated with Elements V Leiden by almost three times [245].

There is no doubt that the HR2 haplotype is associated with increased thrombotic risk without Elements V Leiden [243] [246–248].

2.13.2 Genetically Related (Allelic) Disorders

Two unique minor departure from the Arg306 APC cleavage site in Elements vare recorded, one of which is identified with the APC contraindication. The G-to-C adjustment point, which predicts the substitution of Arg and Thr 306 (Elements V Cambridge), was received from a British man with a foundation set apart by circulatory trouble resistance to APC without the transformation of Elements V Leiden . In any case, the change was not found in a couple of setups for individuals with VTE or sound controls, which proposes that it is a surprising variation of Elements V [68] [249].

Another adjustment in a similar codon standing by to supplant Argto-Gly was uncovered to two Chinese individuals with a circulatory trouble composed source. The Arg306Gly (Elements V hong Kong) change was not identified with APC obstruction in one individual tried for coagulation testing [250].

The clinical meaning of the Arg306Gly adjustment is uncertain because of its similar degree of Hong Kong Chinese blood beneElements (4.5%) and individuals with circulatory trouble stamped foundation (4.7%).[250, 251].

The difference in missense to Elements V, Ile359Thr (Elements V Liverpool) has been appeared in a couple of family members with transient apoplexy [252].

Elements V Liverpool exhibited assurance by the APC and obstructed the development of the APC coElement like that of Elements V Leiden [253].

But the available evidence suggests that the varieties Arg306Thr, Arg306Gly, and Ile359Thr are not the most hazardous substances in circulatory difficulty, they can give when gotten together with various assets or secure dangerous substances. There are meandering aimlessly reports of the two heterozygosity of Elements V Leiden and Elements V Cambridge [241].

2.14 Pen-etrance

Elements V leiden heterozygotes secluded by generally populace testing have a base total VTE speed of around different occasions VTE/1000 people/year and a full scale VTE speed of 6.5% over 65 years. The quick repeat for homozygotes is at the speed of 15 VTE times/1000 people/year [18] [19].

The risk of vein breakage is higher in the assessment of asymptomatic Elements V Leiden heterozygotes from thrombophilic families than randomized individuals isolated from human investigations. A couple of clever examinations of family members of the unselected Elements V marker and asymptomatic Elements Leiden heterozygotes have been found to constantly cut down thrombotic peril, in any, among high-risk conditions, for example, the clinical connection of pregnancy and insufficiency. The undeniable event of VTE is from 0.19%/year to 0.49%/year, appeared differently in relation to 0.05%/year to 0.10%/year in non-progress individuals [180] [254–256].

VTE occurred in 7-12% of family members with Elements V leiden heterozygosity, differentiated and 2-3% of family members without change, which can be foreseen by discrete tests that the presence peril of vein breakage is generally 10%. A couple of dear friend tests found low VTE repeat in asymptomatic Elements V Leiden heterozygotes, range 0.1%/year - 0.67%/year. Notwithstanding, thrombotic scenes were connected with other threat Elements. [100] [257, 258].

The total risk of VTE is generally significant in family members with homozygous Elements V Leiden (1.30%/year) and those with Elements V leiden in mix with other thrombophilic (0.62%/year - 1.54%/year) [256].

2.15 Difference Tests

The conclusion of the VTE variation includes some of the more frequent thrombophilic contamination. Since these problems are not clinically understandable, a clinical trial examination is needed to diagnose each condition.

2.15.1 Inheritance Disorder

- Prothrombin 20211G ¿ Changes to 3untranslated quality encoding prothrombin available to 2% of everyone, 6% of people providing initial VTE, up to 18% of individuals with individual and family thrombosis backgrounds [33]. Duplicate heterozygosity of Elements V Leiden andprotrombin20211G > Changes occur in approximately 1 in 1000 people per person and in 1-5% of people with VTE[139],[172].

- Acquired inadequacy or contrariness of the regular proteins of anticoagulant C, Protein S, and antilogarithm is very nearly multiple times more normal than Elements V Leiden , with a consolidated grouping of 1%. Damaged Anticoagulant protein is found in 1-3% of individuals with early VTE. ..

- Elevated levels of lipoprotein(a) are connected with inauspicious atherosclerosis and may moreover be a peril Element for venous circulatory trouble.

- Dysfibrinogenemias are normal and conversely cause thrombophilia and circulatory trouble.

- Change of specific focuses to the nature of MTHFR (677C > T) coding methylenetetrahydrofolatereductase brings about thermolabile variances with diminished homocysteine reuptake activity. The homozygosity of the 677C

> T transformation happens in 10 - 20% of everyone and is inclined to gentle hyperhomocysteinemia, regularly at ill-advised setting. Regardless, the MTHFR 677C > T change isn't identified with the expanded danger of free VTE plasma homocysteine levels. [259].

2.15.2 Disruption Detected

- APC opposition: Notwithstanding the way that Elements V leiden addresses 95% of APC boycott guidelines, 5% of cases happen outside of Elements V leiden allele. Contingent upon the exploratory tests utilized, APC recognition can be welcomed on by significant degrees of Elements VIII, pregnancy, utilization of oral contraceptives, or the accessibility of antibacterolipid antibodies.

  APC boycott without Elements V Leiden is additionally risky for VTE. [260, 261] [183, 184].In uncommon cases, some acquired resources could make a safe APC aggregate. [68].

- The Antiphospholipid antibodie Include a different body composition of autoantibodies targeted to phospholipid-binding proteins. Examples of antiphospholipid vaccine formulations include the following:

  In the past full of blood vessel or VTE OR at least one unexplained worm infestation (10 weeks of growth) or at least three failed antibodies AND continuous anticardiolipin OR antibody2-glycoprotein 1 antibodies or lupus any event two test events Separated 3 months. Prescribed lupus inhibitors, high-dose anti-titer IgGanticardiolipin, and antibeta2 glycoprotein 1 antibodies are closely linked to the blood vessel and VTE [262].

- The obvious degree of homocysteine happens in 10% of individuals with early VTE and is related with a 2-to-3-wrinkle increment in some danger. The plasma level of homocysteine reflects hereditary and ecological Elements and is straightforwardly connected to thrombotic hazard instead of nuclear legacy of MTHFR quality.

- Higher thickness levels: Elevated Elements VIII level¿ 150% ordinary is related with a 4-to-cover increment in VTE hazard and further makes a repeat hazard [263–265]. The irrefutable levels of Elements IX and Elements XI are related with an expanded danger of 2-fold VTE [266, 267].Suggested degrees for both Elements VIII and Elements IX offer an all-inclusive 8-overlay danger of VTE inclusion.(273) High prothrombin level> 110-115% standard is related with 2 expanded VTE broadened hazard without prothrombin 20211G >Heterozygosity. (33,200)[33][194].

2.16 Management

How would we assess after starting tests uncovers that an individual has acquired comparable qualities from both parents,after discovering those qualities convey the issue for unusual blood coagulating. At that point it ought to likewise be tried for other attire Elements that occasionally exist normally.

Tests ought to be done to survey the danger of cluttered coagulating face to face's body. Thickening issue causing Elements here and there exist alongside other aquired a lot hereditary issues. Prescribed lupus inhibitors, high-dose anti-titer IgGanticardiolipin, and antibeta2 glycoprotein 1 antibodies are closely linked to the blood vessel and VTE.

Testing ought to incorporate the accompanying: We ought to do the examine for assessment of high gambled patients for instance individuals who in the past had profound vein coagulating and pneumonic embolism in particular in the event that they had it at youthful age. Or then again it runs in family.They should experience tests of the accompanying

- Protein C activity.
- Antithrombin activity.
- Free Protein S antigen or Protein S movement.

Despite the fact that intermittent appraisal of Elements VIII levels isn't required, yet performing tests in specific cases can end up being useeful. Despite the fact that we actually couldn't say whether we incorporate coagulating fector levels in thrombophilia evaluation [268][269].

Treatment of indications The association of people with Elements V Leiden relies on the clinical conditions. The fundamental exceptional VTE ought to be treated by standard standards with a course of low atomic weight heparin (LMWH) or intravenous unfractionated heparin. Warfarin is begun simultaneously with LMWH (other than during pregnancy) and checked with the by and large standardized degree (INR). [270]. An objective INR of 2.5 (restorative reach: 2.0 – 3.0) gives persuading anticoagulation, even in people with homozygous Elements V leiden [271]. LMWH and warfarin ought to be covered for in any event 5 days and until the INR has been inside the recuperating reach on two consistent evaluations more than 2 days.

Decisions with respect to the term of anticoagulation should be established on assessing the threat of rehash of VTE and anticoagulant-related destruction. About 30% of people with a VTE scene make discontinuous vein breakage inside 10 years. [272].

People with unhindered VTE and who don't have energizers that require a course of anticoagulation treatment. Anticoagulation of any event for an extremely significant time-frame is recommended for people with VTE related with an ephemeral (changed) peril Element [270]. The suitable anticoagulation name for Elements V leiden heterozygotes is discussed. Figure V Leiden heterozygosity size is certainly not a sign of longterm anticoagulation without various results [270].For these individuals at high peril of rehash, the ordinary points of interest from extended length warfarin may surpass the threats of withdrawal Preventing basic manifestation

With the exception of circulatory difficulty stepped territory, long stretch antulocagulation isn't proposed for asymptomatic Elements V leiden heterozygotes, in light of the way that the risk of 1-3%/year of basic ingestion from warfarin is out and out higher than the 1%/yearly vein breakage attempted peril. Since VTE-based Elements V leiden heterozygotes occur in relationship with other peril

Elements with unforeseen conditions, the course of prophylactic anticoagulation during clinical dangers, for example, activity, pregnancy, or concede delays may midway thwart these scenes.

Notwithstanding, there is no proof to affirm the useful prophylaxis impact of asymptomatic Elements V leiden heterozygotes. Choices in regards to prophylactic anticoagulation ought to be founded on danger/advantage appraisal taking all things together cases. Recommendations for prophylaxis throughout treatment and other high-hazard conditions are accessible in the agreement direct [273].

Pregnancy There is no concession to legitimate treatment of young ladies with Elements V leiden during pregnancy. Prophylactic anticoagulation isn't constantly suggested for asymptomatic heterozygous Female who have no involvement in blood vessel breakage.

These ladies ought to be cautioned of thrombotic confusions and be guided by the dangers and advantages of anticoagulation during pregnancy. They ought to likewise be given an anticoagulation concentrate after 4 to 4 to about a month and a half after conveyance, as the best thrombotic hazard is in newborn children. [274].

Prophylactic anticoagulation ought to likewise be viewed as heterozygous ladies with estrogenxy-related pre-estrogenxy (identified with oral preventative use or pregnancy) that doesn't have an expanded danger of repeat. It might likewise be appropriate for homozygotes or non-heterozygous copies of twofold heterozygous Elements V leiden and prothrombin 20211G > Conversion or other joined thrombophilic deserts, particularly those with hazard Elements with existing conditions. [274–277].Prevention of pregnancy confusions The aftereffects of a randomized controlled preliminary and two randomized controlled preliminaries recommend that prophylaxis and LMWH may improve results for pregnancy in ladies with thrombophilia and the foundation uncovered by undiscovered fruitless or late pregnancies [278–280]. then again, separate preliminaries didn't discover LMWH advantage in pregnancy result [281, 282].

There are no impromptu future activities including an uncertain standing gathering affirming the advantages of LMWH in forestalling unsuccessful labor in ladies

with gained thrombophilia. The American College of Chest Physicians 2008 and continuous maternity arrangement controls and proper testing don't generally recommend antithrombotic treatment for ladies with Elements V leiden and premature delivery because of an absence of adequate proof to affirm.

[160, 274, 277]. Antithrombotic prophylaxis might be considered for chosen ladies with Elements V leiden and an unexplained birthing assistance or pregnancy inconvenience after an educated conversation about danger and limited data that raises benefits. Assessment of maternal thrombotic hazard during pregnancy ought to be remembered for the decision with respect to prophylaxis.

There is right now no proof that antithrombotic treatment lessens the danger of blood poisoning or other complex pregnancies in ladies with thrombophilia including Elements V Leiden . LMWH isn't constantly suggested for thrombophilic ladies with a foundation set apart by pre-eclampsia or other threatening pregnancy results [274, 276, 277].

2.17 Genetic Directing

Considering the high predominance of Calculate V leiden all inclusive community, the innate status of the two gatekeepers just as the conceptive assistant of an ought to be settled before information as for potential perils to family or any kind of family down the line can be given.

2.17.1 Proband Heterozygous for Element V Leiden

The Heterozygosity of Elements V leiden and the related VTE danger are identified in a standard autosomal way. On the off chance that one parent is heterozygous, every family is in danger of turning into a heterozygous Elements V Leiden allele. In the event that one parent is homozygous, every family has a 100% possibility of encountering a heterozygous change. With two heterozygous watchmen, each proband family has a 25% possibility of being homozygous, a half possibility of

being heterozygous, and a 25% possibility of getting ordinary Elements V levels. Every individual after Elements V leiden heterozygote has a large portion of the opportunity to accomplish change. In the event that the regenerative assistant of the heterozygous proband, each ensuing one has a 25% possibility of being homozygous, a large portion of an opportunity of being heterozygous, and a 25 % possibility of security from both Elements V alleles.

2.17.2 Proband Homozygous for Element V Leiden

The homozygosity of Elements V Leiden and the exceptionally great danger Element acquired by a particular self-guideline. On the off chance that the two gatekeepers are heterozygotes, On the off chance that the other parent has a homozygous and the other is a heterozygous parent, every family having a half opportunity to be a homozygous Elements V Leiden and a large portion of a half to be heterozygous. Devotees of the Elements V Leiden homozygote have a 100% possibility of getting one Elements V Leiden . In the event that the test aide hypertension is heterozygous, each resulting one has a large portion of a homozygous possibility and a half possibility of encountering a heterozygous change.

2.17.3 Examination of High-Rate Family Members

The condition got as asmptomatic in weak relatives can be set utilizing sub-nuclear testing; it doesn't make any difference, the papers finished for the family assessment are problematic. Since the heterozygosity of Elements V Leiden presents somewhat an expanded danger of circulatory trouble, routine trial of hazardous relatives are not suggested. Notwithstanding the affirmation that early testing of Elements V Leiden decreases uneasiness or passing, choices about testing ought to be made in one spot. The explicitness of the Elements V Leiden allele condition can be found in ladies thinking and moreover a solid history of intermittent circulatory trouble with a solid age. Relatives in danger regularly request a predetermination test to be viewed as a danger or to be interested about their condition. Fearless family members who are more grounded than 18 years old don't ordinarily attempt to consider how circulatory trouble happens every once in a

while in adulthood, even in homozygotes. People focusing on Elements V Leiden tests and those viewed as heterozygotes or homozygotes ought to be energized for signs and manifestations of VTE that require brief clinical idea, just as an expected prerequisite for prophylactic anticoagulation in high-hazard circumstances. They ought to be instructed that disregarding the way that Elements V Leiden , which is a danger Element, doesn't show that one makes certain to perceive how the clinical course is adaptable and inside a similar family [283].

2.18 Risk of Intermittent Venous Thromboembolism among Heterozygous Carriers of Element V Leiden or Prothrombin G20210A Mutation

After the revelation of Element V Leiden (FVL) and prothrombin G20210A change (PTM) in the basic piece of the 1990s, different contextual analyses, case arrangement, and family tests gave persuading affirmation that the heterozygosity of that transformation was connected totally expanded danger of venous thromboembolism (VTE) This danger is exceptionally high in homozygous carriers and in twofold heterozygosity. Despite the fact that it is broadly believed that these changes present an expanded danger of circulatory trouble, it is dicey that patients who are heterozygous transfers or who create thrombotic status have a higher danger of complex occasions in screening with non-transporters [284–286].

After all, it is not yet known whether the disclosure of this malpractice, which is particularly prevalent in western countries, could see a small group of patients who could benefit from the determination of independent anti-inflammatory techniques following the first thrombotic episode [287].

Available nominations for this issue include systematic reviews and audits. By definition, scheduled tests are based on the rescue process, as they incorporate a first-line practice approach, and provide adequate documentation of outcomes events and free trial of targeted tests and clinical outcomes. [288].

As needed, their choice may be more reliable. Recently, various partner planning trials and random clinical trial initiatives have shown which report of long-term outbreaks occurring in VTE patients with FVL or PTM or without postoperative anticoagulation.

2.18.1 Heterozygous Flow of FVL and Risk of VTE Recurrence

Ten trials (seven partner studies close to three scheduled bases) reviewing the threat of dreary VTE in delivering heterozygous FVL completed reinforcement measures [289–291].

Joined into the exploratory outcomes utilizing the Rack Haenszel model, the RR results for VTE introduced by the FVL heterozygous truck after the primary VTE occasion. The DerSimonian and Laird results model introduced a similar broadened hazard check (RR, 1.45; 95% CI, 1.13 to 1.85). In the 4 preliminaries that met the standards of the principal estimations just that Palareti accomplished a measurably huge RR development of VTE extraordinary for FVL heterozygous transporters (RR 2.69; 95% CI, 1.58 to 4.58). [291]. The channel's presentation plan even contrasted with typical activity was balanced), which recommends that there is no significant appropriation pattern.

All tests brought about a connection among FVL and VTE repeat. Higher RRs acquired: (I) in the assessment of segregated accomplices and amateurs of randomized clinical preliminaries; (ii) preliminaries that solitary objective patients with detached DVT and the individuals who incline toward more patients with PE; (iii) preliminaries covering all secluded VTE and those including idiopathic scenes; (iv) in tests with the most confined pre-treatment measurement anticoagulant was recognized and that is from an all-encompassing reach; and (v) in enrolled preliminaries of patients with an antiphospholipid immunization or disappointment of standard anticoagulants isolated from those that forestall these patients [289][291–293]

The general level of threat of VTE rehabilitation provided by the FVL heterozygous cartilage, determined based on the combined sensitivity combined RR of

rehabilitation resulting from experiments that selected patients for the first condition for VTE complexity and support.

2.18.2 Heterozygous Carriage of PTM and Danger of VTE Repeat

The RR of VTE go over gave by the heterozygous carriage of PTM was 1.20 (95% CI, range0.89-1.61) utilizing the MantelHaenszel fixed impacts model, and 1.36 (95% CI, range 1.02-1.82) by methodologies for the DerSimonian and Laird self-self-assured impacts technique.

No quantifiably enormous heterogeneity was distinguished among the assessments (p=0.53, I 2 =0%). None of the three assessments that fulfilled the first class gauges showed an extended threat for discontinuous VTE [132**?** , 133] [289–295] .

They fused an amount of 3,208 patients with a first scene of VTE, of whom 212 (6.6%, 95% domain CI, 5.8-7.5) were heterozygous carriers of PTM.

The ordinariness of PTM in patients with first unwarranted VTE was 7.1% (95% CI, range 5.3-9.3), and 6.9% (95% CI, range 6.0-8.0) among patients with strange and assistant VTE.

The length of follow-up went from 0.75 to 8.3 years. Irregular thromboembolism was fit by 38 out of the 212 heterozygous carriers of PTM (17.9%), and by 428 of the 2,996 non-carriers (14.3

The RR of VTE rehash gave by the heterozygous carriage of PTM was 1.20 (95% CI, range 0.89-1.61) using the MantelHaenszel fixed effects model, and 1.36 (95% CI, range 1.02-1.82) by strategies for the Der Simonian and Laird self-assertive effects method.

A funnel plot of effect size versus standard error was completely adjusted suggesting no critical circulation inclination. Affectability examinations considering some significant features of the included assessments are represented.

Beside the evaluations considering the three assessments that satisfied the amazing guidelines, and those enlisting patients with antiphospholipid safe response condition or insufficiencies of brand name anticoagulants, the wide extent of various

assessments incited a relationship among PTM and VTE go over (RR ¿1). Higher RRs were gotten in (I) companion thinks about separated and randomized clinical essentials; (ii) in assessments enlisting just patients with DVT; (iii) in those that excused patients with antiphospholipid safe response condition and insufficiencies of commonplace anticoagulants; (iv) in more settled assessments differentiated and later examinations; (v) in examinations with more restricted length of beginning anticoagulant treatment stood out and those from a more broadened term; and (v) in examinations with a more drawn out range of follow-up stood out and those from a more restricted range.

The danger degree for irregular VTE of patients with essentially heterozygous carriage of PTM and no other particularly saw thrombophilic conditions (i.e., FVL, antithrombin, C protein or S surrenders, and antiphospholipid killing expert issue) showed up distinctively corresponding to patients with no thrombophilia by the DerSimonian and Laird erratic impacts model, considering 1016 patients of the solitary four assessments included which gave the crucial data [289] [291–293].

Everybody inferable hazard level of VTE repeat presented by the heterozygous carriage of PTM, chose subject to the pooled commonness of the polymorphism FVL and the pooled RR for repeat (and its 95% CI), coming to fruition by virtue of the assessments that selected patients with silly and partner first VTE scene was 1.4% (95% CI, range 0-4.0%).

2.19 Maternal Morbidity

Early phase blood poisoning on a very basic level extended the peril of genuine maternal bleakness, particularly the risk of respiratory and cardiovascular frightfulness and renal dissatisfaction. The maternal passing rate among Female with beginning stage pre-eclampsia was also basically raised, but this measure relied upon a singular destruction. Speeds of genuine maternal bleakness were lower among Female with late-starting sickness differentiated and early phase pre-eclampsia. Regardless, express maternal dismalness rates were by and large raised among Female with late-starting disease differentiated and Female without late-starting

ailment, especially speeds of cardiomyopathy and exceptional renal disillusionment. A lower repeat of obstetric injury was seen among Female with early phase and late-starting blood poisoning, and this was ordinary since Female with pre-eclampsia had liberally higher speeds of cesarean transport and subsequently lower speeds of high vaginal cuts and extraordinary perineal injury. The speed of pre-eclampsia in Washington State extended some place in the scope of 2000 and 2008, with the transient addition more set apart as to early phase disease. Yet various examinations have assessed the effects of blood poisoning on neonatal outcomes, maternal mortality and grimness rates related with early phase and late-starting pre-eclampsia have not been sufficient inspected. The speeds of genuine maternal bleakness related with pre-eclampsia in our assessment resembled or fairly lower than those uncovered from crisis facility based examinations [296–298].

The lower rates saw in our examination are normal, as emergency clinic based investigations ordinarily incorporate tertiary clinics with a lopsided portrayal of ladies with extreme toxemia. What's more, our investigation populace just included singleton pregnancies that are ordinarily less confounded than multifetal pregnancies.

Writing show higher dangers of serious maternal bleakness related with beginning stage disease [299]. Pre-eclampsia occurring at early hatching gives clinicians the trial of hoping to change the risk of perinatal passing and extraordinary neonatal dismalness after transport at early development with the threat of falling apart the maternal condition related with excited administration [300**?** , 301].

Several little randomized primers have broke down confident organization and brief early transport among Female with early phase pre-eclampsia (24–34 weeks of hatching) and meta-examinations show that excited organization is connected with a lower recurrence of some neonatal terribleness (checking intraventricular channel and hyaline layer sickness), without basic differentiations in maternal results [297] [302–305]. Another starter furthermore fail to show any differentiations in neonatal and maternal outcomes after enthusiastic organization differentiated and early conveyance [297]. Regardless, these fundamentals were not controlled to perceive contrasts in extraordinary maternal inauspiciousness. It is possible that confident organization at early brooding may have added to our finding of

a common development in disagreeable maternal outcomes among Female with early phase blood poisoning. Standard changes in blood poisoning repeat may be ordinary as a result of transient changes in maternal characteristics and obstetric practice. Thusly late extensions in more prepared maternal age and prepregnancy weight may have added to transient developments in pre-eclampsia rates, however augments in early movement through work acknowledgment, cesarean transport, or both may have had the opposite effect. Our finding of a common extension in the recurrence of blood poisoning (predominantly early phase disease) shows up diversely comparable to transient models saw in most European countries that have nitty gritty a transitory decline in pre-eclampsia during the past ten years [306].

Regardless, tantamount extensions in blood poisoning rates have been found in Massachusetts, where pre-eclampsia rates extended by 23% from around 3.0 to 3.7 per 100 births some place in the scope of 1998 and 2007. One expected explanation for the discrepant momentary examples between the US and elsewhere relates to contrasts in pre-eclampsia coding [306].

Countries with a transient abatement in pre-eclampsia were those that gotten ICD-10 coding standards (eg, Sweden and Australia), while data from considers showing a brief rising in pre-eclampsia relied upon the ICD-9 coding structure (eg, Massachusetts and our examination). The momentary extension in early phase contamination is moreover unsurprising with the transient development in diligent hypertension among pregnant Female, which is all the more vehemently associated with early phase as opposed to late-starting infection [307].

The 20210 transformation in the prothrombin quality was found in 1996 by Poort et al after the prothrombin quality had been perceived as an up-and-comer quality for venous apoplexy in families with a foundation set apart by venous thromboembolism (VTE) [33].

The change is a result of a G to An advancement at base pair 20210 in the 39 untranslated area of the prothrombin quality. Haplotype assessment recommends that the transformation arose out of a singular coordinator 20 000 to 30 000 years back [55].

In Europe, the unavoidability of the G20210A change is 2.0% (95% affirmation length [CI], 1.4%–2.6%) all things considered, with a degree of 0.7% to 4.0%. The most indispensable amazing quality shows up, evidently, to be in southern European areas (by and large 3%), with negligible normality in the northern pieces of the domain (around 1.7%). In the US, the general routineness checks are some spot in the extent of 1% and 2%, yet this is especially obligated to race. The change is remarkable in African AmericansT (around 0.2%) and is also seldom found in Asians and close by Americans [308].

The constancy advantage gave by this polymorphism ought to be speculated at any rate plainly identifies with a diminished danger of death from channel during work or after horrible injury.

2.20 Pathophysiology

In a moderate exhibit of transformation, heterozygous transporters were found to have exceptionally high plasma prothrombin levels (1.32 U/mL; range, 0.95-1.78 U/mL) disconnected and in the past homozygous 20210 GG (wild sort) genotype (1.05) U/mL; width, 0.55-1.56 U/mL). Monster A/A homozygotes show movement levels of Element II of around 1.70 U/mL. As the magnitude (OR) level of VTE is increased by increasing levels of plasma prothrombin, hyperprothrombinemia has been found to be a major pathophysiologic component of thrombotic affinity. This hypothesis is maintained by another study4 of G20210A mutant families, in which a correlation between plasma prothrombin levels and G20210A mutations was shown[309]. In addition, various experiments have failed to find selected polymorphisms in the promotional and coding of prothrombin quality codes that may interact with offset and G20210A modification. [55].

One report shows that the G → A mutation causes an expansion limit due to the extended confirmation of the 39 end termination and the 39 end terminal expansion [310].

TThe result is a net communication of messenger RNA and an enlarged protein prothrombin. The idea of elevated prothrombin levels is important for the etiology

of VTE maintained by Butenas and its partners. [61]. Using an in vitro tissue model — which initiated blood pressure, it was shown that the increase in prothrombin levels to 150% normal (while maintaining 100% levels of any remaining procoagulant and anticoagulant) achieved conceptually normal extends the age of thrombin. Surprisingly, the same support for Elements V, VIII, IX, or X at a rate of 150% affected the age of thrombin. Also, Kyrle and colleagues found increased years of thrombin after the onset of coagulation in plasma of heterozygous and homozygous G20210A patients [54]. Some have suggested that high prothrombin levels may interfere with the inhibition of C protein-mediation of ElementVaVa, which will also reach the age of thrombin after the onset of coagulation [311].

2.21 Clinical Conditions

2.21.1 VTE Danger with Prothrombin G20210A Mutation

Different case-control looks at have practically dependably demonstrated a connection between the prothrombin G20210A change and VTE. Poort et al1 point by point that the 20210A allele grows the threat of VTE by practically 3-cover (OR, 2.8; 95% CI, 1.4–5.6) [33].

Since that time, a couple of other studies9 have surveyed a general risk of VTE some place in the scope of 2 and 12, with the bigger part in the 2 to 3 territory [312]. Up until now, there are simply limited data from approaching examinations insisting this alliance. In one of just a small bunch not many open, the US Specialists' Prosperity Study, a nonsignificant relationship of the An allele with VTE was found (OR, 1.7; 95% CI, 0.9–3.2) [313]. Despite this, generally verification to date recommends that the prothrombin transformation is a genuine, however by and large delicate, peril Element for VTE. Concerning this, homozygosity for the 20210A allele, though moreover associated with VTE, is undeniably not as tremendous a risk Element for apoplexy as is homozygosity for proteins C or S or apparently even the Element V Leiden transformation.(324) Regardless, more data are needed before legitimate closures can be drawn.

2.21.2 VTE Danger when Prothrombin 20210A Cosegregates with Different Types of Thrombophilia

Enormous thought has been paid to the possibility that yet the prothrombin 20210A allele isolated may be a by and large feeble threat Element for VTE, it may connect with other acknowledged risk Elements to on a very basic level update the peril of VTE. First among the associations that have been dissected is that with the Element V Leiden transformation. A couple of case-control considers have indicated that the prothrombin 20210A allele constructs the threat of apoplexy when coinherited with the Element V 506Q allele [172] [314] [315].

Fundamentally, coinheritance of these 2 transformations may similarly grow the risk of discontinuous VTE after a first event, giving a persuading inspiration to consider simultaneous testing for the two changes in interesting individuals.

Though the threat of apoplexy in subjects with the prothrombin 20210A allele is obviously extended by coinheritance of moderate hyperhomocyst(e)inemia or conceivably homozygosity for the C677T variety of the methylenetetrahydrofolatereductase (MTHFR) quality in specific examinations, various assessments have been not ready to certify this affiliation [314][316, 317, 317, 318].

The relationship among hyperhomocystinemia and VTE, which has been tended to by advancing unavoidable assessments, suggests that cosegregation of hyperhomocyst(e)inemia with prothrombin G20210A is likely not going to redesign the thrombotic inclination. At long last, regardless of whether coinheritance of prothrombin G20210A with heterozygous shortfall of antithrombin, C protein, or protein S prompts an updated danger of circulatory trouble, as is obviously the circumstance for Element V Leiden , is even more hard to contemplate considering the momentousness of these issues.

In any case, an improving impact of cosegregation has been addressed, different evaluations, for instance, in a goliath, especially portrayed C protein–lacking individual of French Canadian fall, have neglect to bear witness to a refreshed risk of circulatory trouble in people with the two changes [319] [320].

2.22 Reproductive Complications due to Prothrombin G20210A Mutation

In like way with the Element V Leiden change, the danger of VTE in ladies during pregnancy or oral impediment (OCP) treatment discharges an impression of being reached out inside seeing the prothrombin G20210A change [321].

Martinelli and associates clear that the general danger of critical vein circulatory trouble was broadened 16.3-cover (95% CI, 3.4–79.1) in ladies with prothrombin G20210A who utilized OCPs separated and noncarriers and nonusers [322].

TThis overall risk was typical for a multiplicative impact of the dangers related with OCPs and the prothrombin change. Strangely, a practically identical party revealed a 149-overlay expanded danger of cerebral vein circulatory trouble (95% CI, 31.0–711.0) in ladies with the prothrombin change taking OCPs [89].

The risk of VTE transmits an impression of being by and large critical during the fundamental 6 to a period of OCP treatment in these individuals [200].

Pregnancy and the puerperium are both related with an all-encompassing danger of VTE, with occasions that are around 8 and on various events, freely, the danger in nonpregnant ladies of the similar age [97].

The overall danger of pregnancy and puerperal VTE in ladies with the G20210A prothrombin change was 15.2 (95% CI, 4.2–52.6), and with both the 20210A allele and the 506Q Element V allele, the assessed OR stretched out to 107 [45].

Of late, there has been expansive interest in the work that normal and acquired thrombophilias may play in stillbirth and second-trimester pregnancy affliction, abruptioplacentae, intrauterine headway limitation, and toxemia [323].

These occasions are set out to be sequelae of traded off placental perfusion. Fundamentally totally passed on case control thinks about show as a relationship of at any rate one of these results with Element V Leiden similarly as the prothrombin 20210A allele. [76].

At last, postmenopausal compound substitution treatment (HRT) broadens the danger of VTE by 2-to 4-fold. [324–326].

It emits an impression of being likely that this danger is expanded further in ladies with the prothrombin G20210A change. This risk may counterbalance a touch of the obliging impact anticipated from HRT in ladies with atherosclerotic coronary conductor burden encountering this therapy.(208).

2.23 Prothrombin 20210A as a Potential Danger Elements for Blood Vessel Thrombotic Illness

Following break of an atherosclerotic plaque, extraordinary circulatory trouble results. Despite the fact that the coagulations in this site is by and large held to be platelet rich, the reasonableness of heparins and thrombin inhibitors in extraordinary coronary conditions shows that it is obviously additionally subject to authorizing of the plasma coagulation structure. Suitably, it is in all likelihood possible that, as different kinds of thrombophilia, the prothrombin G20210A change may acknowledge a part in vein thrombosis [327]. It very well may be colossal in under ideal atherosclerotic sickness, particularly when MI is the outcome [88] [328] [329] [330]. Notwithstanding, not all appraisals concur with this conclusion [331, 332]. An overall subject of those assessments with a positive association is a massive joint effort of the change with other danger Elements for atherosclerotic illness, for example, smoking and hypertension. [88, 333]. In postmenopausal Female, HRT will add to an increased risk of MI in the same way, precisely when the current condition occurs.(343,344).

2.24 Risk of Venous Thrombosis and Pregnancy Misfortune in Carriers

Elements V Leiden (FVL) develops the danger of venous circulatory trouble and pregnancy calamity in transporters. In a little while, this unobtrusively old change

is inevitable in Caucasion people groups, which could be clarified by sure affirmation pressure. Men with FVL have actually been found to have higher readiness (the time among marriage and first pregnancy).

Regardless of whether this is accomplished by broadened sperm recalls for men with FVL is dim. Of 37 FVL carriers and 921 non-carriers were perceived. FVL transporters had higher all out sperm tallies and complete motile sperm checks than non-transporters: 236 x 10(6) (95% CI 158-292 x 10(6)) versus 163 x 10(6) (95% CI 147-178 x 10(6)) and 81 x 10(6) (95% CI 54-105 x 10(6)) versus 52 x 10(6) (95% CI 48-57 x 10(6)), respectively [334].

A measure of 208 discretionary Greek men were explored, intertwining 108 unbeneficial men with idiopathic oligozoospermia, azoospermia, and oligozoospermia of different etiologies, comparatively as 100 prepared male controls. DNA eliminated from people's sperm or blood was dejected down for Element V Leiden and Element II G20210A changes. There were no essential separations in Element V and Element II genotypes between futile men and standard controls. A relationship of the two standard thrombophilia-related changes with male uselessness was not found in this focal study[335].

Human FVL transporters have a higher full scale sperm check than non-transporters, with a changed mean distinction of 31 $\times$ 106 (95%CI 0.2-61.7; P = 0.048). Mice with the FVL change don't have expanded spermatogenesis when veered from wildtype mice. None of the considered polymorphisms was in linkage disequilibrium, either in the public information bases or in a subgroup of FVL transporters with outstandingly high sperm tallies [336].

This report portrays an outline of neighborhood test disclosures that proposes making pointlessness in testing for FVL and PGM. Test requests for FVL and PGM were perused for another time of 2.5 years (starting from 2016 to end of June 2018) from an enormous tertiary-level pathology provider. From a proportion of more than 10,000 thrombophilia-related test requests throughout the evaluation time frame, 2,700 and 2,135 were, self-governingly, for FVL and PGM. The age levels of patients separated across the full future reach, yet the pinnacle evaluation age range for the entire extra was 30 to 39 years.

Assessments were fundamentally more consistently alluded to for females (¿70% of arrangements) than individuals, and the apex evaluation age range for females (30-39 years) was sooner than individuals (50-59 years). Notwithstanding, generally a more prominent number of individuals than females were identified with FVL (15.4 versus 6.6%) or PGM (10.4 versus 4.3%), uninhibitedly.

The age-related events of test referring to were furthermore seen as unflinchingly changed according to birth plans in females and vein breakage plans in individuals. There has been a manual for yearly lessening in revelation of FVL change from a zenith of more than 25% in 1996 to 10% in every time of the earlier decade, suggesting less regarded patient decision. Of test-alluding to signs, pregnancy/fetal seriousness was seen in 16.4% of all arrangements for females, and thromboembolism was seen in 21.4 and 18.0% of all referencing for females and individuals, exclusively.

As to evident evidence, a heterozygous model was seen in 4.2% of Female pursued for pregnancy/fetal premonition, yet 11.7 and 15.1% of females and individuals, autonomously, for thromboembolism. In assessment, the establishment speed of FVL attestation in everybody in our geological region is around 3 to 7%. Taking everything into account, better spun around merciful decision for testing of FVL and PGM occurred in the male partner subject to higher relative catch of thrombophilia changes than the female extra. Notwithstanding, calm decision was not ideal in either the male or female partners, since the got change rates were basically unimportantly higher than the average establishment people confirmation rate.

Likewise, the decline in relative ID of FVL from everything considered test requests as time goes on proposes rot of patient decision rehearses by suggesting topic specialists. Perceptibly, tests alluded to in the setting of thromboembolism gave a higher likelihood of FVL certification than pregnancy/fetal depressingness. These data suggest some contemporary worthlessness of inherited testing for FVL and PGM truly, and explicitly, in females for signs around pregnancy/fetal ghastliness, proposed to be related to powerless patient decision in many occurrences. [337].

Researchers played out a making review and meta-appraisal of proper normal affiliation considers (GAS) in pregnancy, to assess the innate peril of VTE in pregnancy. We used the without model strategy for summarized potential outcomes degree (Association) to examine quality to-disorder alliance and dissected the methodology for heritage using the degree of significance h list. Twelve case-control GAS considers gave the full genotype dispersals to at any rate one contender quality to diagram the gained danger.

FVL was related with a major threat of VTE in pregnancy (Association 7.28; 95% sureness range 5.53-9.58) and a general technique for heritage (h=0.76), that is the effect of heterozygous carriers will lie close to the homozygous beast genotype. Our evaluation gave impossible data on VTE in pregnancy, close with FVL and PT G20210A status and suggested that the genetic effects of heterozygous over homozygous carriers don't legitimize design of heterozygous as "lower hazard" over homozygous eccentricities. On clinical grounds this may affect decisions to particularly pardon heterozygous from anticoagulation prophylaxis.

PCR and single nucleotide foundation development reaction, followed by Synthetic Associated Immuno-Sorbent Analyze (ELISA) in 93 patients with venous thromboembolism, out of which: 56 patients were resolved to have unmerited, fundamental thromboembolism attested by target mulls over and 37 patients were resolved to have dull thromboembolism. As shown by verifiable examination of the results, pace of FVL change in the social event of patients with discontinuous apoplexy was inside and out higher diverged from patients with fundamental apoplexy – independently 0.21 and 0.44 (p=0.0164¡0.05).

It should in like manner be referred to that homozygous carriage of FVL transformation was certified particularly with patients having irregular apoplexy. Relative penchant was seen during examination of prothrombin quality; at any rate what is important was not really immense. Similar inclinations were not checked whether there ought to be an event of homozygous carriage of MTHFR quality C677T mutation. Twofold and triple heterozygous/homozygous carriage of pondered transformations (all out of 20 cases) was found in patients of the two social

occasions. Spread of these genotypes in the dreary apoplexy pack was higher appeared differently in relation to patients with fundamental apoplexy - exclusively 27% and 17.9%. Herewith, it should be referred to that the patients with fundamental apoplexy were significantly more young than those with irregular apoplexy and their age didn't outperform 50 years. According to the results got by us, it is possible to consider Leiden change, especially its homozygous construction and twofold/triple heterozygous/homozygous carriage of the considered transformations as a free risk Element of progress of irregular apoplexy in the Georgian people and postpone anticoagulation treatment in patients of equivalent genotype whatever amount as could sensibly be required to prevent dull apoplexy and related complications [286].

2.25 Factor V Leiden, PTH G20210A and MTHFR C677T Polymorphisms

Elements V Leiden , PTH G20210A and MTHFR C677T polymorphisms were found in 40 illness patients with VTE (pack 1) and 40 wickedness patients with no check of VTE (bunch 2) by PCR-based DNA appraisal. Elements V and MTHFR changes were higher in party 1 than in get-together 2 (Element V heterozygous change: 20 versus 7.5%, homozygous change: 10 versus 2.5%; MTHFR heterozygous change: 40 versus 25%, homozygous change 5 versus 0%, just) (P = 0.03). Demise rate was higher in party 1 (75%) than in get-together 2 (25%; P ¡ 0.001). No partition was found between those get-togethers concerning PTH change (P = 1). End rate was higher inside seeing homozygous and heterozygous Element V change (100 and 82%, uninhibitedly) veered from the wild sort (41%) (P = 0.0006). Having any of the three investigated quality changes annihilated the overall assurance (P = 0.0003). Cox fall away from the confidence showed that both circulatory difficulty and presence of Element V change are free figures influencing energy hazard patients (P ¡ 0.001 and P = 0.01, independently). Considering, there is a relationship between Element V and MTHFR changes and risk of VTE in Egyptian danger patients. Vein breakage and presence of Element V change are free thinks

about that impact dauntlessness those patients [338]. They saw 12 case-control and three associate considers. Female (0.48 to 0.7 versus 0.19 to 0.0), regardless with the reprimand that absolute threats were evaluated in relatives of thrombophilic patients with VTE (for instance with a positive family history). These results keep up incapacitating COC-use in Female with unprecedented hereditary thrombophilia. Then again, added substance VTE peril of smooth thrombophilia is unassuming. Exactly when no other peril Elements are free, (for instance family heritage) COCs can be offered to these Female when strong elective contraceptives are not tolerated [339].

A North Lebanese family has been assessed, from a record case, a 40-year-more settled individual, who had a foundation separate by venous circulatory issue with unexplained inconsistent surprising work. The outline case was found to be heterozygous for Element V Leiden G1691A, prothrombin G20210A, and C677T quality combinations. Her family members were heterozygous for in any occasion two of the three-point changes, and distinctive threat Elements related with thrombophilia were identified [340].

Chapter 3

Material and Methods

Thrombophilia is portrayed as a comprehensive risk or tendency to make blood groups because of slanting components that may be obtained or gotten. A coagulations may outline in either the venous or vein vascular plan. Venous thrombophilia is typically related to an inconsistency of the coagulation structure and may achieve basic venous vein breakage (DVT) or aspiratory embolism (PE).

Undeniably, research office examination for thrombophilia has contained basically of seeing inadequacies of Antithrombin, C protein and Protein S, and testing for dysfibrinogenemia and antiphospholid antibodies/lupus anticoagulants.

In the latest decade it has been shown that venous thromboembolism is an unusual pathology that is reliant upon the correspondence of both acquired and genetic parts. In such way, FII and FVI Leiden changes envision an essential part in the pathogenesis of DVT in blend in with got Elements, for instance, age.

The relationship of Elements II (G20210A) and Elements VI Leiden (G1691A) changes with a comprehensive danger for venous circulatory difficulty has been well documented.1, 2, 3, 4 The Elements II or Prothrombin (G20210A) change recommends the G to A change at nucleotide 20210 in the 3' untranslated zone of the quality and is related with widened plasma levels of prothrombin. Elements VI Leiden (G1691A) prescribes the G to A progress at nucleotide position 1691 of the Elements VIquality, achieving the substitution of the amino ruinous arginine by glutamine in the Elements VIprotein, making check cleavage by Initiated C

protein (APC).Elements II (G20210A) and Elements VI Leiden (G1691A) changes are open in 2% and 5% of everyone, independently

3.1 Determination

3.1.1 Testing

The affirmation of Elements VI Leiden requires the APC resistance investigate, a coagulation screening test, or DNA evaluation of F5, the quality encoding Component V, to perceive the Leiden change, a particular G-to-A replacement at nucleotide 1691 that predicts a solitary amino damaging substitution (R506Q). The APC resistance measure consolidates playing out an arranged fragmentary thromboplastin time (aPTT) on the person's plasma in the presence and nonattendance of a normalized extent of exogenous APC; the two outcomes are passed on as a degree (aPTT + APC/aPTT – APC).

This look at relies on the standard that when added to ordinary plasma, APC inactivates Components Va and VIIIa, which moves back coagulation and concedes the aPTT. The APC-safe supreme is depicted by an irrelevant prolongation of the aPTT in light of APC and a correspondingly low degree. Changed ("second time span") inspects audit predilution for Elements V-lacking plasma to normalize Elements that may influence the APC opposition degree (Protein S, other VitaminK-subordinate thickening Elements brought some place close to oral anticoagulation, etc) The changed test can be used to test plasma from patients suffering anticoagulation. This test has an affectability and expressness for Elements VI Leiden pushing toward 100%.[341]

Focused on change appraisal for Elements VI Leiden is performed by a get-together of in a general sense vague procedures using genomic DNA in periphery blood mononuclear cells.[342, 343]. Nuclear inherited tests are strong in individuals on warfarin or heparin anticoagulation and during ridiculous thrombotic scenes. Right when clinical thought requires testing for Elements VI Leiden , either direct DNA-based genotyping or a changed APC obstruction analyze is proposed.[342]

Fruitions authoritative work for testing There is a general arrangement that Elements VI Leiden testing may have utility in certain circumstances.[274, 277] [342–346]

Regardless, rules proceed onward the specific fruitions work area work for testing. The decision to test picked patients should be set up on the likelihood that the results are clearly going to impact treatment.[346]. Late strategy suggestions what's more proceed onward the fruitions work area work for screening Female with hostile pregnancy outcomes.[274, 277, 346]. Testing is fitting in picked people with the going with.

- A first strange VTE at whatever stage for the duration of regular day to day existence (particularly age 50 years).
- An establishment set apart by sporadic VTE.
- Venous circulatory trouble at uncommon complaints (e.g., cerebral, mesenteric, hepatic, and passageway veins
- Venous circulatory trouble at uncommon complaints (e.g., cerebral, mesenteric, hepatic, and passageway veins.
- Chose ladies with unexplained remarkable blood harming, placental surprising quality, or a lacking life form with certified intrauterine improvement limitation.
- A first VTE identified with the utilization of tamoxifen or other explicit estrogen receptor modulators (SERMs

3.2 Characteristic History and Clinical Indications

The clinical explanation of Elements VI Leiden thrombophilia is variable. Various individuals with a Elements VI Leiden allele never raise circulatory hell. However, most impacted individuals don't experience their first thrombotic event until

adulthood, some have inconsistent VTE before the age of 30 years. Elements VI Leiden homozygotes will no ifs, ands or buts develop their first VTE at a more young age. In a family study, 40% of homozygotes had a VTE by the age of 33 years, isolated and 20% of heterozygotes and 8% of unaffected individuals.[96] Populace considers propose normally 10% of Elements VI Leiden heterozygotes make VTE over their lifetime.The lifetime risk of VTE is higher (20-40%) in heterozygotes from thrombophilic families . [180, 348]. Heterozygosity for Elements V Leiden isn't related with an amplification in mortality or lessening in like way life expectancy.[349, 350].

3.3 Venous Thromboembolism

The foremost clinical sign of Elements VI Leiden is VTE. The change is found in 25% of patients with a first idiopathic VTE and up to 40 portion of those with drawn-out VTE or an estrogen-related circulatory difficulty. [215, 351]. An assessment of pooled information from a monstrous number of studies found that the routineness of a Consider VI Leiden allele people with withdrew pneumonic embolism was around a huge bit of the greatness in people with DVT[352]. The VI Leiden Elements were perceived from 10-20% of in people with farther point of DVT not identified with a focal venous catheter.[22, 23, 177]. Blood vessel breakage in uncommon zones also include the cerebral, ovarian, renal veins and hepatic are may additionally happen is less for the most important part. The risk of cerebral vein circulatory trouble are also vein circulatory risk in in stretched out of 3 to 5 cver in VIleidenElements heterozygotes.[198, 353][354].

3.4 GeneXpert Dx Framework

The GeneXpertDx Structure modernizes and consolidates test refinement, nucleic destructive increase, and revelation of the target course of action in whole blood using constant Polymerase PCR (Polymerase Chain Reaction) studies. An instrument, a PC, a handheld normalised label scanner, and preloaded programming for running tests and checking the results are all part of the setup.

The machine relies on single-use nonessential cartridges to carry PCR reagents and host the PCR cycle. Cross spoiling between experiments is possible because the cartridges are self-contained.

3.4.1 Xpert® FII and FV

Xpert® FII and FVIis a theoretical genotyping test for the rapid affirmation of Elements II (FII) and Elements VI(FV) alleles. Performed on the Cepheid GeneXpert Structure, the test is needed to give snappy outcomes to FII (G20210A) and FVI Leiden (G1691A) changes as a guide in the assessment of suspected thrombophilia.

The arrangements and tests in the Xpert Elements II and Elements VITest pick the genotype of the Elements II and Elements VIquality.

3.5 Reagents

3.5.1 Reagents Handling

The air bubbles was taken out if present in the reagent cartridge, with another implement stick. Then again permit the reagent to sit at the fitting stockpiling temperature to permit the air pockets to disseminate.

3.5.2 Reagents Storage

Reagents are stable at room temperature.

3.6 Specimen Collection and Handling

Whole Blood is the accepted sample. Sample should be heamolysis free. Pipette to dispense 50 μL sodium citrate or EDTA anti-coagulated blood with aerosol-resistant filter tips.

Blood ought to be handled inside 24 hours when put away at room temperature (22-28 °C). Tests will be put away at 2-8 °C whenever put away more than 24 hours. As Blood is steady as long as 15 days when put away at 2-8 °C.

The blood samples may also be stored at -20 °C or -80 °C for up to 3 months. Use of a freezer-compatible storage vial is recommended.

3.7 Assay Procedure

Cleaned the instrument externally. Switched on the Instrument .Turned the software ON. Then Prepared the Data Station as follows: To add the sample into the cartridge, removed catridge from the kit. It is not necessary to bring the cartridge to room temperature before use. Mixed sample by inverting the tube at least 5 times, until homogeneous. Turned on the instrument and afterward turn on the PC. The product will dispatch naturally. Sign on to the product utilizing your client name and secret word. In the window, clicked Create Test. The Create Test window showed up Scan standardized tag on cartridge. In the Sample ID box, test ID being composed and Made sure that it type the right example ID. Then again, examine the example standardized tag. The example ID is related with the test outcomes and appeared in the View Results window and all the reports. From the Select Assay drop-down menu, select the fitting measure to be run. Clicked Start Test. In the exchange box that shows up, type your secret word. Open the instrument module entryway with the flickering green light and burden the cartridge. Shut the entryway. The test began and the green light quit flickering. At the point when the test was done, the light being killed. Discard the pre-owned cartridges in the fitting example squander compartments, as indicated by foundation's standard practices.

3.8 Results Analysis

The Genxpert systems are fully automated systems and results e generated using standard callibration curves and internal control curves that determines the

efficacy of the process. The generated results are printed and reported through Medicube software. As it is a qualitative analysis the results will be given as: Not Detected, Detected (Homozygous or Heterozygous).

After completion of results, technologist correlated and uploaded the results in the software. Instrument printout be scanned with respective PIN number in the software. Whole blood will be stored for 7 days (fridge). All samples were capped before storage.

Chapter 4

Results and Discussion



FIGURE 4.1: Number of Male and Female with Respect to their Age

Figure 4.1 Random selection of patients with sample was made. The study cohort contains data of people of different age starting from minimum of 18 years to maximum of 52 years. Above chart shows the numbers of people with different age group included in study were divided on gender bases. From age group 18-22 female were 11 in number and male were 09 in number. 19 female and 13 Male were included in the age group from 23-27 years. 28-32 years age group was with 10 female and 04 male. The fourth age group i.e. 33-37 was with 11 male and

10 female. Number of female were 08 and 05 male were in age group of 38-42. Only 03 female in 43-47 age group and 04 male were included. Last age group of 48-52 were with 02 female and 03 male. Our study totally included people having symptoms of people with mutation has.

All included people were based on the recommendation of doctor for diagnostic testing of FV and FII and based on symptoms we have larger number of people with young age. This is both alarming and good. As we know this mutation usually occurs at old age of life so appearing symptoms in early age on large number is alarming. But early symptoms appearance could diagnose mutation earlier and prevent it from spreading into next generation.



FIGURE 4.2: %age of Male and Female with Respect to their Age

Figure 4.2 Above chart shows percentage of the inclusion of male and female in different age group out of total population. According to above chart Female of age group lies between 23-27 years were more in numbers with symptoms. Girls with this age group were either pregnant or preeclamptic all female of study has been choosen on symptoms and Preeclamptic bases. Graph is depicting that the number of people in studies were decreasing as the age goes on. Suggesting that mutation is somehow associated with age and Preeclampsia/pregnancy.



FIGURE 4.3: % Age of FV and FII Mutation and Heterogeneous Homogenous with Mutation

Figure 4.3 Above chart indicates the percentage of VIleiden Elements and mutations FII with the percentage of heterogeneous and homogeneous among total sample of 111.Elements VImutation was in 4.50% and also homozygous is 4.50% all of homozygous mutation was found with Elements VImutation. Elements II was in 0.90% and also of Heterozygous which has been found in the Elements II mutation.

This chart depicts the percentage of VIleiden Elements and mutations FII also percentage of heterogeneous and homogeneous among total sample of 111. Elements VImutation was in 4.50% and also homozygous is 4.50% all of homozygous mutation was found with Elements VImutation. Elements II was in 0.90% and also of Heterozygous which has been found in the Elements II mutation.

Result shows that the total of 111 people only 4.50% of people were found to be positive and all of those were found to be with homozygous mutation and also total of 4.50% of people included in our study were with homozygous mutation and all of people with homozygous mutation were present with Elements VImutation all other remainings were with heterozygous mutation amongst them only <1% were with mutation.

Previous studies also depicts that homozygous mutation increases chance of Elements VImutation by more than 100% percent.This finding suggests that people can inherit mutation from both homozygous or heterozygous parents only difference is the presence of percentage of risk which varies greatly.To prevent this sort of mutation prior diagnosis is important before getting married so that it could not be transmitted to the child.



FIGURE 4.4: %Family History of Patient with mutation

Figure 4.4 The chart indicates percentage of people was found with family history of people with positive mutation. Among total 5.4% positive mutation 4.50% were found to be 4.50% and 0.90% was without family history.

Family history plays a important role in depicting different Elements.In this study 4.5% samples were along with their family history and 0.9% samples were without family history. This graph again shows that the people i.e. 4.50% amongst total included were present with family history suggesting that their parents were present with mutation which our results have also suggested and all people with family history only one person was present with Elements II mutation having no family history that could be because of expressing the allele of parent that is carried by of spring by carrier parent.



FIGURE 4.5: %Family History of Patient with Mutation

Figure 4.5 Results depicts at what percentage mutation is present amongst age group of 23-27, 28-32, 38-42 and 48-52. Result Shows 7.14% out of 32 people in first age group, 7% out of 14 people, 7.69% out of 13 people and 20% out of 05 people was found to be present. Showing more positive percentage in the age group of 48-52 years.

Among the four age groups included in our study the highest percentage of people with genetic mutation was 20% in the age group of people aged 48-52 which is also similar to previously obtained data showing that VIleiden Elements mutation increases with age at a much higher rate than in non-men. this conversion. (199) The Female included in our study were also Female with preeclampsia and therefore approximately 50% of Female who had preeclampsia were approximately 50% found to have changes. This also suggests that there is a 50% chance of developing preeclapmsia if you have a Elements VImutation early to be found to help prevent Female from preeclampsia. In addition, the findings of the present study were conducted to consist explored by Dirula et al., who were found by the higher increase in VIleiden Elements mutations of Female with their preeclampsia alsi in the general control group to confirmed that there were significant relationship between VI Leiden Elements and PE mutations.[344].

The rate pace of venous thromboembolism in heterozygous male transporters is appeared in this expected information. It has been shown that in men more seasoned than 45 years old venous thromboembolism the rate among men with non-VI Leiden attributes was fundamentally more prominent when this was around the equivalent in men under 28 years old. For venous thromboembolism that was not related with malignant growth, medical procedure, or injury the training was clear. We found that the occurrence of venous thromboembolism expanded with an expansion of separate with VIleiden Elements in individuals with Element VIeiden transformation and this might be viewed as a hereditary inclination. It was proposed in past reports that in youthful years apoplexy in individuals with Element VI Leiden transformation normally happens. Rather than review and opposing investigations, which can be considered for randomized preliminaries, references, and treatment (all of which could prompt a misrepresented number of more youthful patients [341], the normal arrangement of Physics' Health Study guarantees that hereditary testing is performed freely if not in cases. 23 are prohibited, recently acquired human information propose that venous thromboembolism from any reason is uncommon in men of this age group.[342].



FIGURE 4.6: Positive percentage among all the sample

Figure 4.6 Above results on chart shows the percentage of people were found positive with Elements 5 and Elements 2 mutation. Amongst total 111 number of

symptomatic samples, 5.4% were found to be positive and remaining 94.6% were found negative. .

5.4% of the population among educated people were found to be positive of these individuals with certain risk Elements were at risk of the VI Leiden Elements and FII in all Homozygous, age group, preeclampsia found to be associated with Elements VImutations. All admissions were marked and had a doctor's recommendation for testing. Early diagnosis is very important in preventing future complications as our study suggests that many younger patients came with symptoms as most of them had homozygous mutations which thought that early diagnosis of FVIand FII mutations in their parents would prevent this mutation as 100% homozygous mutations. found to be present through the conversion of FV.

Worldwide there are many studies on the impact of inherited thrombophilia during pregnancy but this study is the first to be able to assess the frequency of FVIL and FII G20210A mutations among Pakistani Female with severe PE. It is steady with past investigations that decide any critical relationship between FVL changes and the presence of toxemia. Karimi et al.

Yet, there are some clashing subtleties in our discoveries. There is no critical relationship between FVL transformations, FII G20210A, and the recurrence of intense toxemia; for instance, Berks D, et al., directed an examination showing that changes in FVL, and FII G20210A were not related with PE. No huge connection among PE and FVL change uncovered by research. Driving LG et.al, led an investigation in a gathering of Native Americans with toxemia and showed that the improvement of extreme PE isn't related with the impacts of transformations in FVL and FII G20210A. The ebb and flow study is an in-clinic study which is the reason we cannot actually uncover everyone, along these lines, thrombophilia related with extreme PE proceeds in the field of continuous examination, so more patients and controls need to build clearness and lessen decision.

Chapter 5

Conclusion and Future Work

Normally acquired inconveniences of thrombophilic hereditary qualities during pregnancy are Elements VI Leiden (FVL) and hereditary alteration of prothrombin. The negative anticoagulant reaction to APC is viewed as Elements VI Leiden hereditary confusion. The most well-known sort of change VI is FVL, which helps thrombophilia. Also after the VI Leiden Elements transformation in the ladies with the thromboembolism related to the FII pregnancy of G20210-A happens. Because of the replacement of guanine rather than adenine 20,210 for the kind of prothrombin quality FII G20210A is conceivable. Ladies with the VI Leiden Element and FII G20210-A changes have an expanded danger of pregnancy difficulties emerging from late examinations, like PE be that as it may, the aftereffects of specific investigations don't coordinate these discoveries.

The most well-known type of innate thrombophilia acquired, is Elements VI Leiden represented 40-half of cases. The pervasiveness fluctuates from one individual to another. around 3-8% of Heterozygosity of Elements VI Leiden happens in Europe and the US all in all.

Spreading homozygosity is around 1 of every 5000 of Elements VI Leiden in white individuals. Hereditary change was one occasion that happened 20,000 to 30,000 years prior as proven by the Haplotype examination of the Elements VI sort, following the common partition of whites from Asians and Africans. The Oust study was performed on a Element V Iand consider 2 analysis male and female changes. To consider the connection between the VI Leiden Elements and the G20210-A

prothrombin changes in an example of pregnant ladies taken from Islamabad. All ladies had toxemia results showing a Elements VI transformation in homozygous transporters at 4.5% and a Elements II presence in a heterozygous transporter at 0.9

Adjustment of Elements VI Leiden is one of the numerous components that add to these results. Other hereditary and natural variables notwithstanding Elements VI Leiden might be expected to improve pregnancy difficulties. Generally speaking, the odds of an effective pregnancy result are high, in any event, for homozygous ladies.

Another reason for the investigation was to interface change with Age Element which showed that as age expands the danger of hereditary variety increments. These discoveries recommend that more seasoned patients are discovered to be more adaptable, more inclined to transformations than more youthful ones.

An expanded danger of profound venous apoplexy present in transporters of both VI Leiden and G20210A prothrombin transformation. The 3-to 8-related danger increments with VTE in the heterozygotes. In heterozygotes the okay dangers recognized in numerous investigations have been accounted for Heterozygous hemophiliacs serious Elements VI Leiden will in general decrease the utilization of thickening component concentrate use and less dying. Notwithstanding this article various investigations under which the components fundamental PE are as yet hazy, it has been shown that in the pathogenesis of PE particles, irritation, bacterial irregularity and oxidative pressure might be included, in addition to other things, oxidative pressure assumes a significant part in infection. PE This examination can go further by connecting different Elements and contrasting dangers and these Elements. Arrangement can prompt the investigation of variables identified with protein work, the action of catalysts. The succession will demonstrate if there are some other transformations or different components that lead to this adjustment and the related indications. It can empower us to recognize heterozygous and homozygous transporters and match its protein work. By knowing the science of protein and the enzymatic capacity of this succession one can gain proficiency with a portion of the issues related with manifestations. Factor V and

II mutation role in preeclampsia could be noticed and linked by finding out the effect of anticoagulant treatment on the outcomes of pregnancies by follow-up of the studied patients. Further follow-up could lead us to the information of child of patients being diagnosed with the homozygous and heterozygous mutation we could find out that what trend of positivity ratio lies amongst the children of parents both carrying homozygous mutation.

[294]

Bibliography

[1] B. Dahlbäck, M. Carlsson, and P. J. Svensson, "Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein c: prediction of a cofactor to activated protein c." *Proceedings of the National Academy of Sciences*, vol. 90, no. 3, pp. 1004–1008, 1993.

[2] R. M. Bertina, B. P. Koeleman, T. Koster, F. R. Rosendaal, R. J. Dirven, H. de Ronde, P. A. Van Der Velden, and P. H. Reitsma, "Mutation in blood coagulation factor v associated with resistance to activated protein c," *Nature*, vol. 369, no. 6475, pp. 64–67, 1994.

[3] P. M. Ridker, C. H. Hennekens, K. Lindpaintner, M. J. Stampfer, P. R. Eisenberg, and J. P. Miletich, "Mutation in the gene coding for coagulation factor v and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men," *New England journal of medicine*, vol. 332, no. 14, pp. 912–917, 1995.

[4] F. Rosendaal, T. Koster, J. Vandenbroucke, and P. Reitsma, "High risk of thrombosis in patients homozygous for factor v leiden (activated protein c resistance)[see comments]," 1995.

[5] B. Dahlbäck, "Advances in understanding pathogenic mechanisms of thrombophilic disorders," *Blood*, vol. 112, no. 1, pp. 19–27, 2008.

[6] K. Segers, B. Dahlback, and G. A. Nicolaes, "Coagulation factor v and thrombophilia: background and mechanisms," *Thrombosis and Haemostasis-Stuttgart-*, vol. 98, no. 3, p. 530, 2007.

[7] I. Martinelli, B. Bottasso, F. Duca, E. Faioni, and P. M. Mannucci, "Heightened thrombin generation in individuals with resistance to activated protein c," *Thrombosis and haemostasis*, vol. 75, no. 05, pp. 703–705, 1996.

[8] B. Zöller, J. Holm, P. Svensson, and B. Dahlbäck, "Elevated levels of prothrombin activation fragment 1+ 2 in plasma from patients with heterozygous arg506 to gin mutation in the factor v gene (apc-resistance) and/or inherited protein s deficiency," *Thrombosis and haemostasis*, vol. 75, no. 02, pp. 270–274, 1996.

[9] E. Mazoyer, L. Ripoll, R. Gueguen, L. Tiret, J.-P. Collet, C. B. dit Sollier, J. Roussi, L. Drouet, F. S. Group *et al.*, "Prevalence of factor v leiden and prothrombin g20210a mutation in a large french population selected for non-thrombotic history: geographical and age distribution," *Blood coagulation & fibrinolysis*, vol. 20, no. 7, pp. 503–510, 2009.

[10] D. C. Rees, M. Cox, and J. B. Clegg, "World distribution of factor v leiden." *Lancet (London, England)*, vol. 346, no. 8983, pp. 1133–1134, 1995.

[11] P. M. Ridker, J. P. Miletich, C. H. Hennekens, and J. E. Buring, "Ethnic distribution of factor v leiden in 4047 men and women: implications for venous thromboembolism screening," *Jama*, vol. 277, no. 16, pp. 1305–1307, 1997.

[12] A. Zivelin, J. H. Griffin, X. Xu, I. Pabinger, M. Samama, J. Conard, B. Brenner, A. Eldor, and U. Seligsohn, "A single genetic origin for a common caucasian risk factor for venous thrombosis," *Blood, The Journal of the American Society of Hematology*, vol. 89, no. 2, pp. 397–402, 1997.

[13] P. G. Lindqvist, B. Zöller, and B. Dahlbäck, "Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor v leiden–an evolutionary advantage?" *Thrombosis and haemostasis*, vol. 86, no. 10, pp. 1122–1123, 2001.

[14] P. G. Lindovist, P. J. Svensson, B. Dohlböck, and K. Morščill, "Foctor vq999 mutofion (activoited protein c resistonce) associoted with reduced intro-portum blood loss–ca possible evolutionory selection mechanism," *Thromb Haemost*, vol. 79, pp. 69–73, 1998.

[15] B. S. Donahue, D. Gailani, M. S. Higgins, D. C. Drinkwater, and A. L. George Jr, "Factor v leiden protects against blood loss and transfusion after cardiac surgery," *Circulation*, vol. 107, no. 7, pp. 1003–1008, 2003.

[16] W. C. Nichols, K. Amano, P. M. Cacheris, M. S. Figueiredo, K. Michaelides, R. Schwaab, L. Hoyer, R. J. Kaufman, and D. Ginsburg, "Moderation of hemophilia a phenotype by the factor v r506q mutation," 1996.

[17] D. Lee, I. Walker, J. Teitel, M.-C. Poon, B. Ritchie, J. Akabutu, G. Sinclair, M. Pai, J. Wu, S. Reddy *et al.*, "Effect of the factor v leiden mutation on the clinical expression of severe hemophilia a," *Thrombosis and haemostasis*, vol. 83, no. 03, pp. 387–391, 2000.

[18] J. A. Heit, J. Sobell, H. Li, and S. Sommer, "The incidence of venous thromboembolism among factor v leiden carriers: a community-based cohort study," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 2, pp. 305–311, 2005.

[19] K. Juul, A. Tybjærg-Hansen, P. Schnohr, and B. G. Nordestgaard, "Factor v leiden and the risk for venous thromboembolism in the adult danish population," *Annals of internal medicine*, vol. 140, no. 5, pp. 330–337, 2004.

[20] R. F. Franco and P. H. Reitsma, "Genetic risk factors of venous thrombosis," *Human genetics*, vol. 109, no. 4, pp. 369–384, 2001.

[21] R. Gohil, G. Peck, and P. Sharma, "The genetics of venous thromboembolism," *Thrombosis and haemostasis*, vol. 102, no. 08, pp. 360–370, 2009.

[22] B. Linnemann, F. Meister, J. Schwonberg, M. Schindewolf, D. Zgouras, and E. Lindhoff-Last, "Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis," *Thrombosis and haemostasis*, vol. 100, no. 09, pp. 440–446, 2008.

[23] I. Martinelli, T. Battaglioli, P. Bucciarelli, S. M. Passamonti, and P. M. Mannucci, "Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities," *Circulation*, vol. 110, no. 5, pp. 566–570, 2004.

[24] J. Lin and P. August, "Genetic thrombophilias and preeclampsia: a meta-analysis," *Obstetrics & Gynecology*, vol. 105, no. 1, pp. 182–192, 2005.

[25] V. Livrinova, M. H. Lega, A. H. Dimcheva, I. Samardziski, and R. Isjanovska, "Factor v leiden, prothrombin and mthfr mutation in patients with preeclamsia, intrauterine growth restriction and placental abruption," *Open access Macedonian journal of medical sciences*, vol. 3, no. 4, p. 590, 2015.

[26] R. Silver, "436: Prothrombin gene g20210a mutation and obstetric complications: A propsective cohort," *American Journal of Obstetrics & Gynecology*, vol. 199, no. 6, p. S131, 2008.

[27] F. Rosendaal and P. Reitsma, "Genetics of venous thrombosis," *Journal of Thrombosis and Haemostasis*, vol. 7, pp. 301–304, 2009.

[28] M. J. Paidas, D.-H. W. Ku, J. Langhoff-Roos, and Y. S. Arkel, "Inherited thrombophilias and adverse pregnancy outcome: screening and management," in *Seminars in perinatology*, vol. 29, no. 3. Elsevier, 2005, pp. 150–163.

[29] L. M. Hiltunen, H. Laivuori, A. Rautanen, R. Kaaja, J. Kere, T. Krusius, M. Paunio, and V. Rasi, "Blood group ab and factor v leiden as risk factors for pre-eclampsia: a population-based nested case-control study," *Thrombosis research*, vol. 124, no. 2, pp. 167–173, 2009.

[30] O. Salomon, U. Seligsohn, D. M. Steinberg, Y. Zalel, A. Lerner, N. Rosenberg, M. Pshithizki, M. Oren, B. Ravid, J. Davidson *et al.*, "The common prothrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction," *American journal of obstetrics and gynecology*, vol. 191, no. 6, pp. 2002–2009, 2004.

[31] C. A. Nath, C. V. Ananth, C. DeMarco, A. M. Vintzileos, N. J.-P. A. S. Investigators *et al.*, "Low birthweight in relation to placental abruption and maternal thrombophilia status," *American journal of obstetrics and gynecology*, vol. 198, no. 3, pp. 293–e1, 2008.

[32] H. O. Elzein, A. A. Saad, A. A. Yousif, E. Elamin, E. K. Abdalhabib, and S.-E. G. Elzaki, "Evaluation of factor v leiden and prothrombin g20210a mutations in sudanese women with severe preeclampsia," *Current research in translational medicine*, vol. 68, no. 2, pp. 77–80, 2020.

[33] S. R. Poort, F. R. Rosendaal, P. H. Reitsma, and R. M. Bertina, "A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis," 1996.

[34] S. J. F. Degen and E. W. Davie, "Nucleotide sequence of the gene for human prothrombin," *Biochemistry*, vol. 26, no. 19, pp. 6165–6177, 1987.

[35] R. K. Kapur, L. A. Mills, S. G. Spitzer, and M. B. Hultin, "A prothrombin gene mutation is significantly associated with venous thrombosis," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 17, no. 11, pp. 2875–2879, 1997.

[36] W. Kniffin, J. A. Baron, J. Barrett, J. D. Birkmeyer, and F. A. Anderson, "The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly," *Archives of internal medicine*, vol. 154, no. 8, pp. 861–866, 1994.

[37] A. Kierkegaard, "Incidence and diagnosis of deep vein thrombosis associated with pregnancy," *Acta obstetricia et gynecologica Scandinavica*, vol. 62, no. 3, pp. 239–243, 1983.

[38] P. Treffers, B. Huidekoper, G. Weenink, and G. Kloosterman, "Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women," *International Journal of Gynecology & Obstetrics*, vol. 21, no. 4, pp. 327–331, 1983.

[39] S. Rutherford, "Thromboembolic disease associated with pregnancy: an 11 year review," *Am J Obstet Gynecol*, vol. 164, p. 286, 1991.

[40] M. Hellgren, P. J. Svensson, and B. Dahlbäch, "Resistance to activated protein c as a basis for venous thromboembolism associated with pregnancy and oral contraceptives," *American journal of obstetrics and gynecology*, vol. 173, no. 1, pp. 210–213, 1995.

[41] A. Bloom, "The management of patients with inherited blood coagulation disorders," *Haemostasis and Thrombosis*, pp. 349–377, 1994.

[42] B. Dahlbäck and J. Stenflo, "A natural anticoagulant pathway: Proteins c," *S, C4b*, 1994.

[43] D. S. Dizon-Townson, L. M. Nelson, H. Jang, M. W. Varner, and K. Ward, "The incidence of the factor v leiden mutation in an obstetric population and its relationship to deep vein thrombosis," *American journal of obstetrics and gynecology*, vol. 176, no. 4, pp. 883–886, 1997.

[44] M. Bokarewa, K. Bremme, and M. Blombäck, "Arg506–gln mutation in factor v and risk of thrombosis during pregnancy," *British journal of haematology*, vol. 92, no. 2, pp. 473–478, 1996.

[45] A. Gerhardt, R. E. Scharf, M. W. Beckmann, S. Struve, H. G. Bender, M. Pillny, W. Sandmann, and R. B. Zotz, "Prothrombin and factor v mutations in women with a history of thrombosis during pregnancy and the puerperium," *New England Journal of Medicine*, vol. 342, no. 6, pp. 374–380, 2000.

[46] F. B. Pipkin, "Fortnightly review: The hypertensive disorders of pregnancy," *Bmj*, vol. 311, no. 7005, pp. 609–613, 1995.

[47] J. Wang, Y. Lin, F. Lv, H. Hou, K. Chu, B. Jiang, J. Liu, S. Liu, and B. Hou, "Effects of klotho polymorphisms on preeclampsia risk in a case-control study," *Pregnancy hypertension*, vol. 13, pp. 95–99, 2018.

[48] Y. Gu, D. F. Lewis, and Y. Wang, "Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies," *The Journal of Clinical Endocrinology & Metabolism*, vol. 93, no. 1, pp. 260–266, 2008.

[49] L. C. Chesley, J. E. Annitto, and R. A. Cosgrove, "The familial factor in toxemia of pregnancy," *Obstetrics & Gynecology*, vol. 32, no. 3, pp. 303–311, 1968.

[50] J. M. Roberts and C. A. Hubel, "The two stage model of preeclampsia: variations on the theme," *Placenta*, vol. 30, pp. 32–37, 2009.

[51] K. M. O'Shaughnessy, B. Fu, F. Ferraro, I. Lewis, S. Downing, and N. H. Morris, "Factor v leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an east anglian preeclampsia cohort," *Hypertension*, vol. 33, no. 6, pp. 1338–1341, 1999.

[52] ——, "Factor v leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an east anglian preeclampsia cohort," *Hypertension*, vol. 33, no. 6, pp. 1338–1341, 1999.

[53]

[54] P. A. Kyrle, C. Mannhalter, S. Beguin, A. Stumpflen, M. Hirschl, A. Weltermann, M. Stain, B. Brenner, W. Speiser, I. Pabinger *et al.*, "Clinical studies and thrombin generation in patients homozygous or heterozygous for the g20210a mutation in the prothrombin gene," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 18, no. 8, pp. 1287–1291, 1998.

[55] A. Zivelin, N. Rosenberg, S. Faier, N. Kornbrot, H. Peretz, C. Mannhalter, M. H. Horellou, and U. Seligsohn, "A single genetic origin for the common prothrombotic g20210a polymorphism in the prothrombin gene," *Blood, The Journal of the American Society of Hematology*, vol. 92, no. 4, pp. 1119–1124, 1998.

[56] U. Nowak-Goottl, R. Junker, W. Kreuz, A. von Eckardstein, A. Kosch, N. Nohe, R. Schobess, and S. Ehrenforth, "Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors," *Blood, The Journal of the American Society of Hematology*, vol. 97, no. 4, pp. 858–862, 2001.

[57] F. Rosendaal, C. J. M. Doggen, A. Zivelin, V. Arruda, M. Aiach, D. Siscovick, A. Hillarp, H. Watzke, F. Bernardi, A. Cumming *et al.*, "Geographic distribution of the 20210 g to a prothrombin variant," *Thrombosis and haemostasis*, vol. 79, no. 04, pp. 706–708, 1998.

[58] J. Emmerich, F. R. Rosendaal, M. Cattaneo, M. Margaglione, V. De Stefano, T. Cumming, V. Arruda, A. Hillarp, J.-L. Reny *et al.*, "Combined effect of factor v leiden and prothrombin 20210a on the risk of venous thromboembolism," *Thromb Haemost*, vol. 86, no. 3, pp. 809–816, 2001.

[59] S. M. Bates, I. A. Greer, S. Middeldorp, D. L. Veenstra, A.-M. Prabulos, and P. O. Vandvik, "Vte, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines," *Chest*, vol. 141, no. 2, pp. e691S–e736S, 2012.

[60] A. Thomsen and I. Greer, "Thromboembolic disease in pregnancy and the puerperium: acute management (green-top guideline no. 37b)," *Royal College of Obstetricians and Gynaecologists*, vol. 1, pp. 1–32, 2015.

[61] S. Butenas, C. van't Veer, and K. G. Mann, ""normal" thrombin generation: Presented in part at the xvith congress of the international society on thrombosis and haemostasis, june 6-12, 1997, florence, italy (abstr ps-1653), at the 15th international congress on thrombosis, october 16-21, 1998, antalya, turkey (abstr 234), and at the 40th annual meeting of the american society of hematology, december 4-8, 1998, miami beach, fl (abstr 151)." *Blood, The Journal of the American Society of Hematology*, vol. 94, no. 7, pp. 2169–2178, 1999.

[62] A. Momot, M. Nikolaeva, N. Yasafova, M. Zainulina, K. Momot, and I. Taranenko, "Clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age," *Journal of blood medicine*, vol. 10, p. 255, 2019.

[63] M. Nikolaeva, A. P. Momot, M. S. Zainulina, N. N. Yasafova, and I. A. Taranenko, "Great obstetrical syndromes in g20210a mutation carriers associated with high prothrombin activity," 2020.

[64] O. Wu, L. Robertson, S. Twaddle, G. Lowe, P. Clark, M. Greaves, I. Walker, P. Langhorne, I. Brenkel, L. Regan *et al.*, "Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. the thrombosis: Risk and economic assessment of thrombophilia screening (treats) study." *Health technology assessment (Winchester, England)*, vol. 10, no. 11, pp. 1–110, 2006.

[65] H. Gao and F.-b. Tao, "Prothrombin g20210a mutation is associated with recurrent pregnancy loss: a systematic review and meta-analysis update," *Thrombosis research*, vol. 135, no. 2, pp. 339–346, 2015.

[66] M. Rodger and N. Langlois, "Is thrombophilia associated with placenta-mediated pregnancy complications? a prospective cohort study: reply," *Journal of Thrombosis and Haemostasis*, vol. 12, no. 8, pp. 1378–1379, 2014.

[67] A. Lambropoulos, Z. Foka, M. Makris, M. Daly, A. Kotsis, and P. Makris, "Factor v leiden in greek thrombophilic patients: relationship with activated protein c resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1+ 2." *Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis*, vol. 8, no. 8, pp. 485–489, 1997.

[68] D. Williamson, K. Brown, R. Luddington, C. Baglin, and T. Baglin, "Factor v cambridge: a new mutation (arg306 thr) associated with resistance to activated protein c," *Blood, The Journal of the American Society of Hematology*, vol. 91, no. 4, pp. 1140–1144, 1998.

[69] A. I. Qureshi, M. R. Frankel, J. R. Ottenlips, and B. J. Stern, "Cerebral hemodynamics in preeclampsia and eclampsia," *Archives of neurology*, vol. 53, no. 12, pp. 1226–1231, 1996.

[70] J. P. Souza, A. M. Gülmezoglu, J. Vogel, G. Carroli, P. Lumbiganon, Z. Qureshi, M. J. Costa, B. Fawole, Y. Mugerwa, I. Nafiou *et al.*, "Moving beyond essential interventions for reduction of maternal mortality (the who multicountry survey on maternal and newborn health): a cross-sectional study," *The Lancet*, vol. 381, no. 9879, pp. 1747–1755, 2013.

[71] E. A. Steegers, P. Von Dadelszen, J. J. Duvekot, and R. Pijnenborg, "Preeclampsia," *The Lancet*, vol. 376, no. 9741, pp. 631–644, 2010.

[72] G. Dekker, J. De Vries, P. Doelitzsch, P. Huijgens, B. Von Blomberg, C. Jakobs, and H. Van Geijn, "Underlying disorders associated with severe early-onset preeclampsia," *American journal of obstetrics and gynecology*, vol. 173, no. 4, pp. 1042–1048, 1995.

[73] M. G. van Pampus, G. A. Dekker, H. Wolf, P. C. Huijgens, M. M. Koopman, B. M. E. von Blomberg, and H. R. Büller, "High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia," *American journal of obstetrics and gynecology*, vol. 180, no. 5, pp. 1146–1150, 1999.

[74] C. Lindoff, I. Ingemarsson, G. Martinsson, M. Segelmark, H. Thysell, and B. Åstedt, "Preeclampsia is associated with a reduced response to activated protein c," *American journal of obstetrics and gynecology*, vol. 176, no. 2, pp. 457–460, 1997.

[75] P. G. Lindqvist, P. J. Svensson, K. Maršál, L. Grennert, M. Luterkort, and B. Dahlbäck, "Activated protein c resistance (fv: Q506) and pregnancy," *Thrombosis and haemostasis*, vol. 81, no. 04, pp. 532–537, 1999.

[76] M. J. Kupferminc, A. Eldor, N. Steinman, A. Many, A. Bar-Am, A. Jaffa, G. Fait, and J. B. Lessing, "Increased frequency of genetic thrombophilia in women with complications of pregnancy," *New England Journal of Medicine*, vol. 340, no. 1, pp. 9–13, 1999.

[77] M. Kupferminc, G. Fait, A. Many, D. Gordon, A. Eldor, and J. Lessing, "Severe preeclampsia and high frequency of genetic thrombophilic mutations," *Obstetrics & Gynecology*, vol. 96, no. 1, pp. 45–49, 2000.

[78] N. Xu and W. Zhang, "Ptx3 gene 3'utr polymorphism and its interaction with environmental factors are correlated with the risk of preeclampsia in a chinese han population," *Medicine*, vol. 99, no. 3, 2020.

[79] N. A. Ahmed, H. Z. Hamdan, A. H. Kamis, and I. Adam, "The association of the prothrombin g20210a single-nucleotide polymorphism and the risk of preeclampsia: Systematic review and meta-analysis," *European Journal of Obstetrics & Gynecology and Reproductive Biology*, vol. 253, pp. 162–169, 2020.

[80] ——, "The association of the prothrombin g20210a single-nucleotide polymorphism and the risk of preeclampsia: Systematic review and meta-analysis," *European Journal of Obstetrics & Gynecology and Reproductive Biology*, vol. 253, pp. 162–169, 2020.

[81] M. D. McColl, J. E. Ramsay, R. Tait, I. D. Walker, F. McCall, J. Conkie, M. Carty, and I. Greer, "Risk factors for pregnancy associated venous thromboembolism," *Thrombosis and haemostasis*, vol. 78, no. 10, pp. 1183–1188, 1997.

[82] M. Hellgren and M. Blombäck, "Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium," *Gynecologic and obstetric investigation*, vol. 12, no. 3, pp. 141–154, 1981.

[83] J. Conard, M. Horellou, P. Van Dreden, T. Lecompte, and M. Samama, "Thrombosis and pregnancy in congenital deficiencies in at iii, protein c or protein s: study of 78 women," *Thrombosis and haemostasis*, vol. 63, no. 02, pp. 319–320, 1990.

[84] P. J. Svensson and B. Dahlback, "Resistance to activated protein c as a basis for venous thrombosis," *New England Journal of Medicine*, vol. 330, no. 8, pp. 517–522, 1994.

[85] M. Hallak, J. Senderowicz, A. Cassel, C. Shapira, E. Aghai, R. Auslender, and H. Abramovici, "Activated protein c resistance (factor v leiden) associated with thrombosis in pregnancy," *American journal of obstetrics and gynecology*, vol. 176, no. 4, pp. 889–893, 1997.

[86] B. Dahlbäck, "Inherited resistance to activated protein c, a major cause of venous thrombosis, is due to a mutation in the factor v gene," *Pathophysiology of Haemostasis and Thrombosis*, vol. 24, no. 2, pp. 139–151, 1994.

[87] L. Kluijtmans, L. Van den Heuvel, G. Boers, P. Frosst, E. Stevens, B. A. van Oost, M. den Heijer, F. Trijbels, R. Rozen, and H. J. Blom, "Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease." *American journal of human genetics*, vol. 58, no. 1, p. 35, 1996.

[88] F. Rosendaal, D. Siscovick, S. Schwartz, B. Psaty, T. Raghunathan, and H. Vos, "A common prothrombin variant (20210 g to a) increases the risk of myocardial infarction in young women," *Blood, The Journal of the American Society of Hematology*, vol. 90, no. 5, pp. 1747–1750, 1997.

[89] I. Martinelli, E. Sacchi, G. Landi, E. Taioli, F. Duca, and P. M. Mannucci, "High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives," *New England Journal of Medicine*, vol. 338, no. 25, pp. 1793–1797, 1998.

[90] D. S. Dizon-Townson, L. M. Nelson, K. Easton, and K. Ward, "The factor v leiden mutation may predispose women to severe preeclampsia," *American journal of obstetrics and gynecology*, vol. 175, no. 4, pp. 902–905, 1996.

[91] A. Rajkovic, P. M. Catalano, and M. R. Malinow, "Elevated homocyst (e) ine levels with preeclampsia," *Obstetrics & Gynecology*, vol. 90, no. 2, pp. 168–171, 1997.

[92] E. Grandone, M. Margaglione, D. Colaizzo, G. Cappucci, D. Paladini, P. Martinelli, S. Montanaro, G. Pavone, and G. Di Minno, "Factor v leiden, c¿ t mthfr polymorphism and genetic susceptibility to preeclampsia," *Thrombosis and haemostasis*, vol. 77, no. 06, pp. 1052–1054, 1997.

[93] S. Sohda, T. Arinami, H. Hamada, N. Yamada, H. Hamaguchi, and T. Kubo, "Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia." *Journal of medical genetics*, vol. 34, no. 6, pp. 525–526, 1997.

[94] C. J. Berg, J. Chang, W. M. Callaghan, and S. J. Whitehead, "Pregnancy-related mortality in the united states, 1991–1997," *Obstetrics & Gynecology*, vol. 101, no. 2, pp. 289–296, 2003.

[95] S. L. Clark, J. A. Meyers, D. K. Frye, and J. A. Perlin, "Patient safety in obstetrics–the hospital corporation of america experience," *American journal of obstetrics and gynecology*, vol. 204, no. 4, pp. 283–287, 2011.

[96] B. Zöller, P. J. Svensson, X. He, B. Dahlbäck *et al.*, "Identification of the same factor v gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein c." *The Journal of clinical investigation*, vol. 94, no. 6, pp. 2521–2524, 1994.

[97] M. D. McColl, J. E. Ramsay, R. Tait, I. D. Walker, F. McCall, J. Conkie, M. Carty, and I. Greer, "Risk factors for pregnancy associated venous thromboembolism," *Thrombosis and haemostasis*, vol. 78, no. 10, pp. 1183–1188, 1997.

[98] E. Grandone, M. Margaglione, D. Colaizzo, G. D'Andrea, G. Cappucci, V. Brancaccio, and G. Di Minno, "Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor v leiden, prothrombin g20210a, and methylenetetrahydrofolate reductase c677t mutations," *American journal of obstetrics and gynecology*, vol. 179, no. 5, pp. 1324–1328, 1998.

[99] D. Tormene, P. Simioni, P. Prandoni, S. Luni, P. Zerbinati, D. Sartor, F. Franz, and A. Girolami, "Factor v leiden mutation and the risk of venous thromboembolism in pregnant women," *Haematologica*, vol. 86, no. 12, pp. 1305–1309, 2001.

[100] S. Middeldorp, J. R. Meinardi, M. M. Koopman, E. C. van Pampus, K. Hamulyák, J. van der Meer, M. H. Prins, and H. R. Büller, "A prospective study of asymptomatic carriers of the factor v leiden mutation to determine the incidence of venous thromboembolism," *Annals of Internal Medicine*, vol. 135, no. 5, pp. 322–327, 2001.

[101] D. J. Rouse, R. L. Goldenberg, and K. D. Wenstrom, "Antenatal screening for factor v leiden mutation: a critical appraisal," *Obstetrics & Gynecology*, vol. 90, no. 5, pp. 848–851, 1997.

[102] J. P. Vandenbroucke, F. J. Van Der Meer, F. M. Helmerhorst, and F. R. Rosendaal, "Factor v leiden: should we screen oral contraceptive users and pregnant women?" *Bmj*, vol. 313, no. 7065, pp. 1127–1130, 1996.

[103] B. M. Sibai, "Thrombophilias and adverse outcomes of pregnancy—what should a clinician do?" 1999.

[104] M. Beaufils, R. Donsimoni, S. Uzan, and J. Colau, "Prevention of pre-eclampsia by early antiplatelet therapy," *The Lancet*, vol. 325, no. 8433, pp. 840–842, 1985.

[105] H. Wallenburg, J. Makovitz, G. Dekker, and P. Rotmans, "Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae," *The Lancet*, vol. 327, no. 8471, pp. 1–3, 1986.

[106] E. Schiff, E. Peleg, M. Goldenberg, T. Rosenthal, E. Ruppin, M. Tamarkin, G. Barkai, G. Ben-Baruch, I. Yahal, J. Blankstein *et al.*, "The use of aspirin to prevent ppregnancy-induced hypertension and lower the ratio of thromboxane a2 to prostcyclin in relatively high risk pregnancies," *New England Journal of Medicine*, vol. 321, no. 6, pp. 351–356, 1989.

[107] A. Benigni, G. Gregorini, T. Frusca, C. Chiabrando, S. Ballerini, A. Valcamonico, S. Orisio, A. Piccinelli, V. Pinciroli, R. Fanelli *et al.*, "Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for ppregnancy-induced hypertension," *New England Journal of Medicine*, vol. 321, no. 6, pp. 357–362, 1989.

[108] I. Hertz-Picciotto, C. Hopenhayn-rich, M. Golub, and K. Hooper, "The risks and benefits of taking aspirin during pregnancy," *Epidemiologic reviews*, vol. 12, no. 1, pp. 108–148, 1990.

[109] L. C. Chesley, "History and epidemiology of preeclampsia-eclampsia," *Clinical obstetrics and gynecology*, vol. 27, no. 4, pp. 801–820, 1984.

[110] B. M. Sibai, A. El-Nazer, and A. Gonzalez-Ruiz, "Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis," *American journal of obstetrics and gynecology*, vol. 155, no. 5, pp. 1011–1016, 1986.

[111] L. C. Chesley, J. E. Annitto, and R. A. Cosgrove, "The remote prognosis of eclamptic women: sixth periodic report," *American journal of obstetrics and gynecology*, vol. 124, no. 5, pp. 446–459, 1976.

[112] N. Gleicher, L. R. Boler Jr, M. Norusis, and A. Del Granado, "Hypertensive diseases of pregnancy and parity," *American journal of obstetrics and gynecology*, vol. 154, no. 5, pp. 1044–1049, 1986.

[113] B. M. Sibai, "Pitfalls in diagnosis and management of preeclampsia," *American journal of obstetrics and gynecology*, vol. 159, no. 1, pp. 1–5, 1988.

[114] G. FitzGibbon, "The relationship of eclampsia to the other toxæmias of pregnancy. 1," *BJOG: An International Journal of Obstetrics & Gynaecology*, vol. 29, no. 3, pp. 402–415, 1922.

[115] A. Davies *et al.*, "Toxemia of pregnancy in jerusalem. i. epidemiological studies of a total community." *Israel journal of medical sciences*, vol. 6, no. 2, pp. 253–66, 1970.

[116] K. R. Niswander, "The collaborative perinatal study of the national institute of neurological diseases and stroke," *The Woman and Their Pregnancies*, 1972.

[117] K. Lehmann, *Eklampsien i Danmark i aarene 1918-1927.* Nyt Nordisk Forlag-Arnold Busck, 1933.

[118] T. Denman, *An introduction to the practice of midwifery.* E. Bliss and E. White, 1825.

[119] D. Baird *et al.*, "Social factors in obstetrics." *Lancet*, pp. 1079–83, 1949.

[120] S. Barron, "The epidemiology of human pregnancy," *Proceedings of the Royal Society of Medicine*, vol. 61, no. 11P2, pp. 1200–1206, 1968.

[121] W. S. G. on the Hypertensive Disorders of Pregnancy, *The Hypertensive Disorders of Pregnancy: Report of a WHO Study Group.* World Health Organization, 1987, no. 758.

[122] S. Marcoux, J. Brisson, and J. Fabia, "The effect of cigarette smoking on the risk of preeclampsia and gestational hypertension," *American journal of epidemiology*, vol. 130, no. 5, pp. 950–957, 1989.

[123] D. M. Campbell and T. Macgillivray, "The effect of a low calorie diet or a thiazide diuretic on the incidence of pre-eclampsia and on birth weight," *BJOG: An International Journal of Obstetrics & Gynaecology*, vol. 82, no. 7, pp. 572–577, 1975.

[124] R. A. Hiatt and G. D. Friedman, "The frequency of kidney and urinary tract diseases in a defined population," *Kidney international*, vol. 22, no. 1, pp. 63–68, 1982.

[125] B. Eskenazi, M. B. Bracken, T. R. Holford, and J. Grady, "Exposure to organic solvents and hypertensive disorders of pregnancy," *American journal of industrial medicine*, vol. 14, no. 2, pp. 177–188, 1988.

[126] M. A. Klebanoff, P. H. Shiono, and G. G. Rhoads, "Outcomes of pregnancy in a national sample of resident physicians," *New England Journal of Medicine*, vol. 323, no. 15, pp. 1040–1045, 1990.

[127] S. Marcoux, J. Brisson, and J. Fabia, "The effect of leisure time physical activity on the risk of pre-eclampsia and gestational hypertension." *Journal of Epidemiology & Community Health*, vol. 43, no. 2, pp. 147–152, 1989.

[128] A. L. Klatsky, M. A. Armstrong, and G. D. Friedman, "Coffee, tea, and mortality," *Annals of epidemiology*, vol. 3, no. 4, pp. 375–381, 1993.

[129] B. Eskenazi, L. Fenster, and S. Sidney, "A multivariate analysis of risk factors for preeclampsia," *Jama*, vol. 266, no. 2, pp. 237–241, 1991.

[130] G. Duffus and I. Macgillivray, "The incidence of pre-eclamptic toxaemia in smokers and non-smokers," *The Lancet*, vol. 291, no. 7550, pp. 994–995, 1968.

[131] P. Prandoni, A. W. Lensing, A. Cogo, S. Cuppini, S. Villalta, M. Carta, A. M. Cattelan, P. Polistena, E. Bernardi, and M. H. Prins, "The long-term clinical course of acute deep venous thrombosis," *Annals of internal medicine*, vol. 125, no. 1, pp. 1–7, 1996.

[132] S. C. Christiansen, S. C. Cannegieter, T. Koster, J. P. Vandenbroucke, and F. R. Rosendaal, "Thrombophilia, clinical factors, and recurrent venous thrombotic events," *Jama*, vol. 293, no. 19, pp. 2352–2361, 2005.

[133] T. Baglin, R. Luddington, K. Brown, and C. Baglin, "Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study," *The Lancet*, vol. 362, no. 9383, pp. 523–526, 2003.

[134] W. Lijfering, S. Christiansen, F. Rosendaal, and S. Cannegieter, "Contribution of high factor viii, ix and xi to the risk of recurrent venous thrombosis in factor v leiden carriers," *Journal of Thrombosis and Haemostasis*, vol. 7, no. 11, p. 1944, 2009.

[135] W. K. Ho, G. J. Hankey, D. J. Quinlan, and J. W. Eikelboom, "Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review," *Archives of internal medicine*, vol. 166, no. 7, pp. 729–736, 2006.

[136] J. B. Segal, D. J. Brotman, A. J. Necochea, A. Emadi, L. Samal, L. M. Wilson, M. T. Crim, and E. B. Bass, "Predictive value of factor v leiden and prothrombin g20210a in adults with venous thromboembolism and in family members of those with a mutation: a systematic review," *Jama*, vol. 301, no. 23, pp. 2472–2485, 2009.

[137] A. Marchiori, L. Mosena, M. H. Prins, and P. Prandoni, "The risk of recurrent venous thromboembolism among heterozygous carriers of factor v leiden or prothrombin g20210a mutation. a systematic review of prospective studies," *haematologica*, vol. 92, no. 8, pp. 1107–1114, 2007.

[138] C. Kearon, J. A. Julian, M. J. Kovacs, D. R. Anderson, P. Wells, B. MacKinnon, J. I. Weitz, M. A. Crowther, S. Dolan, A. G. Turpie *et al.*, "Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial," *Blood*, vol. 112, no. 12, pp. 4432–4436, 2008.

[139] V. De Stefano, I. Martinelli, P. M. Mannucci, K. Paciaroni, P. Chiusolo, I. Casorelli, E. Rossi, and G. Leone, "The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor v leiden and the g20210a prothrombin mutation," *New England Journal of Medicine*, vol. 341, no. 11, pp. 801–806, 1999.

[140] M. Margaglione, G. D'Andrea, D. Colaizzo, G. Cappucci, A. Del Popolo, V. Brancaccio, A. Ciampa, E. Grandone, and G. Di Minno, "Coexistence of factor v leiden and factor ii a20210 mutations and recurrent venous thromboembolism," *Thrombosis and haemostasis*, vol. 82, no. 12, pp. 1583–1587, 1999.

[141] J. R. Meinardi, S. Middeldorp, P. J. De Kam, M. M. Koopman, E. C. Van Pampus, K. Hamulyák, M. H. Prins, H. R. Büller, and J. Van Der Meer,

"The incidence of recurrent venous thromboembolism in carriers of factor v leiden is related to concomitant thrombophilic disorders," *British journal of haematology*, vol. 116, no. 3, pp. 625–631, 2002.

[142] D. D. Ribeiro, W. M. Lijfering, S. M. Barreto, F. R. Rosendaal, and S. M. Rezende, "Epidemiology of recurrent venous thrombosis," *Brazilian journal of medical and biological research*, vol. 45, no. 1, pp. 1–7, 2012.

[143] C. Biron-Andréani, A. Bauters, V. Le Cam-Duchez, B. Delahousse, A. Lequerrec, F. Dutrillaux, C. Boinot, C. Saladin-Thiron, B. Polack, Y. Gruel *et al.*, "Factor v leiden homozygous genotype and pregnancy outcomes," *Obstetrics & Gynecology*, vol. 114, no. 6, pp. 1249–1253, 2009.

[144] B. Brenner, G. Sarig, Z. Wether, J. Founts, Z. Blumenfeld, and N. Lanir, "Thrombophilic polymorphisms are common in women with fetal loss without apparent cause," *Thrombosis and Haemostasis-Stuttgart-*, vol. 82, pp. 6–9, 1999.

[145] J.-C. Gris, I. Quéré, F. Monpeyrou, E. Mercier, S. Ripart-Neveu, M.-L. Tailland, M. Hoffet, J. Berlan, J.-P. Daurès, and P. Marès, "Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent," *Thrombosis and haemostasis*, vol. 81, no. 06, pp. 891–899, 1999.

[146] I. Martinelli, E. Taioli, I. Cetin, A. Marinoni, S. Gerosa, M. V. Villa, M. Bozzo, and P. M. Mannucci, "Mutations in coagulation factors in women with unexplained late fetal loss," *New England Journal of Medicine*, vol. 343, no. 14, pp. 1015–1018, 2000.

[147] R. Rai, M. Backos, S. Elgaddal, A. Shlebak, and L. Regan, "Factor v leiden and recurrent miscarriage—prospective outcome of untreated pregnancies," *Human reproduction*, vol. 17, no. 2, pp. 442–445, 2002.

[148] P. Clark, I. D. Walker, L. Govan, O. Wu, and I. A. Greer, "The goal study: a prospective examination of the impact of factor v leiden and abo (h) blood groups on haemorrhagic and thrombotic pregnancy outcomes," *British journal of haematology*, vol. 140, no. 2, pp. 236–240, 2008.

[149] S. Middeldorp, "New studies of low-molecular-weight heparin in pregnancy," *Thrombosis research*, vol. 135, pp. S26–S29, 2015.

[150] S. Jivraj, M. Makris, S. Saravelos, and T. Li, "Pregnancy outcome in women with factor v leiden and recurrent miscarriage," *BJOG: An International Journal of Obstetrics & Gynaecology*, vol. 116, no. 7, pp. 995–998, 2009.

[151] L. Robertson, O. Wu, P. Langhorne, S. Twaddle, P. Clark, G. Lowe, I. D. Walker, M. Greaves, I. Brenkel, L. Regan *et al.*, "Thrombophilia in pregnancy: a systematic review," *British journal of haematology*, vol. 132, no. 2, pp. 171–196, 2006.

[152] E. Rey, S. R. Kahn, M. David, and I. Shrier, "Thrombophilic disorders and fetal loss: a meta-analysis," *The Lancet*, vol. 361, no. 9361, pp. 901–908, 2003.

[153] T. E. Dudding and J. Attia, "The association between adverse pregnancy outcomes and maternal factor v leiden genotype: a meta-analysis," *Thrombosis and haemostasis*, vol. 91, no. 04, pp. 700–711, 2004.

[154] G. Kovalevsky, C. R. Gracia, J. A. Berlin, M. D. Sammel, and K. T. Barnhart, "Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis," *Archives of internal medicine*, vol. 164, no. 5, pp. 558–563, 2004.

[155] G. Lissalde-Lavigne, P. Fabbro-Peray, E. Cochery-Nouvellon, E. Mercier, S. Ripart-Neveu, J.-P. Balducchi, J.-P. Daures, T. Perneger, I. Quere, M. Dauzat *et al.*, "In focus: Factor v leiden and prothrombin g20210a polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case–control 'noha first'study," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 10, pp. 2178–2184, 2005.

[156] D. Tormene, P. Simioni, P. Prandoni, S. Luni, B. Innella, P. Sabbion, and A. Girolami, "The risk of fetal loss in family members of probands with factor v leiden mutation," *Thrombosis and haemostasis*, vol. 82, no. 10, pp. 1237–1239, 1999.

[157] W. J. Kist, N. G. Janssen, J. J. Kalk, W. M. Hague, G. A. Dekker, and J. De Vries, "Thrombophilias and adverse pregnancy outcome-a confounded problem!" *Thrombosis and haemostasis*, vol. 99, no. 1, pp. 77–85, 2008.

[158] L. M. Hiltunen, H. Laivuori, A. Rautanen, R. Kaaja, J. Kere, T. Krusius, M. Paunio, and V. Rasi, "Factor v leiden as risk factor for unexplained stillbirth–a population-based nested case-control study," *Thrombosis research*, vol. 125, no. 6, pp. 505–510, 2010.

[159] J. Tal, L. M. Schliamser, Z. Leibovitz, G. Ohel, and D. Attias, "A possible role for activated protein c resistance in patients with first and second trimester pregnancy failure," *Human Reproduction*, vol. 14, no. 6, pp. 1624–1627, 1999.

[160] M. A. Rodger, M. Paidas, M. Claire, S. Middeldorp, S. Kahn, I. Martinelli, W. Hague, K. R. Montella, and I. Greer, "Inherited thrombophilia and pregnancy complications revisited," *Obstetrics & Gynecology*, vol. 112, no. 2, pp. 320–324, 2008.

[161] G. Mello, E. Parretti, L. Marozio, C. Pizzi, A. Lojacono, T. Frusca, F. Facchinetti, and C. Benedetto, "Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study," *Hypertension*, vol. 46, no. 6, pp. 1270–1274, 2005.

[162] E. Grandone, M. Margaglione, D. Colaizzo, G. Cappucci, N. Sciannamé, S. Montanaro, D. Paladini, P. Martinelli, and G. Di Minno, "Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria," *Thrombosis and haemostasis*, vol. 81, no. 03, pp. 349–352, 1999.

[163] T. Dudding, J. Heron, A. Thakkinstian, E. Nurk, J. Golding, M. Pembrey, S. Ring, J. Attia, and R. Scott, "Factor v leiden is associated with preeclampsia but not with fetal growth restriction: a genetic association study and meta-analysis," *Journal of Thrombosis and Haemostasis*, vol. 6, no. 11, pp. 1868–1875, 2008.

[164] D. Dizon-Townson, C. Miller, B. Sibai, C. Y. Spong, E. Thom, G. Wendel Jr, K. Wenstrom, P. Samuels, M. A. Cotroneo, A. Moawad *et al.*, "The relationship of the factor v leiden mutation and pregnancy outcomes for mother and fetus," *Obstetrics & Gynecology*, vol. 106, no. 3, pp. 517–524, 2005.

[165] S. R. Kahn, R. Platt, H. McNamara, R. Rozen, M. F. Chen, J. Genest Jr, L. Goulet, J. Lydon, L. Seguin, C. Dassa *et al.*, "Inherited thrombophilia and preeclampsia within a multicenter cohort: the montreal preeclampsia study," *American journal of obstetrics and gynecology*, vol. 200, no. 2, pp. 151–e1, 2009.

[166] J. M. Said, J. R. Higgins, E. K. Moses, S. P. Walker, A. J. Borg, P. T. Monagle, and S. P. Brennecke, "Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women," *Obstetrics & Gynecology*, vol. 115, no. 1, pp. 5–13, 2010.

[167] E. Nurk, G. Tell, H. Refsum, P. Ueland, and S. Vollset, "Factor v leiden, pregnancy complications and adverse outcomes: the hordaland homocysteine study," *Journal of the Association of Physicians*, vol. 99, no. 5, pp. 289–298, 2006.

[168] F. Facchinetti, L. Marozio, T. Frusca, E. Grandone, P. Venturini, G. L. Tiscia, S. Zatti, and C. Benedetto, "Maternal thrombophilia and the risk of recurrence of preeclampsia," *American journal of obstetrics and gynecology*, vol. 200, no. 1, pp. 46–e1, 2009.

[169] H. E. Howley, M. Walker, and M. A. Rodger, "A systematic review of the association between factor v leiden or prothrombin gene variant and intrauterine growth restriction," *American journal of obstetrics and gynecology*, vol. 192, no. 3, pp. 694–708, 2005.

[170] C. Infante-Rivard, G.-E. Rivard, W. V. Yotov, E. Génin, M. Guiguet, C. Weinberg, R. Gauthier, and J. C. Feoli-Fonseca, "Absence of association of thrombophilia polymorphisms with intrauterine growth restriction," *New England Journal of Medicine*, vol. 347, no. 1, pp. 19–25, 2002.

[171] S. Mustafa, C. Mannhalter, C. Rintelen, P. Kyrle, P. Knöbl, K. Lechner, and I. Pabinger, "Clinical features of thrombophilia in families with gene defects in protein c or protein s combined with factor v leiden." *Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis*, vol. 9, no. 1, pp. 85–89, 1998.

[172] J. Emmerich, F. R. Rosendaal, M. Cattaneo, M. Margaglione, V. De Stefano, T. Cumming, V. Arruda, A. Hillarp, J.-L. Reny *et al.*, "Combined effect of factor v leiden and prothrombin 20210a on the risk of venous thromboembolism," *Thromb Haemost*, vol. 86, no. 3, pp. 809–816, 2001.

[173] S. Ehrenforth, L. Nemes, C. Mannhalter, F. Rosendaal, S. Koder, C. Zoghlami-Rintelen, I. Scharrer, and I. Pabinger, "Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor v: G1691a," *Journal of Thrombosis and Haemostasis*, vol. 2, no. 3, pp. 430–436, 2004.

[174] I. D. Bezemer, L. A. Bare, C. J. Doggen, A. R. Arellano, C. Tong, C. M. Rowland, J. Catanese, B. A. Young, P. H. Reitsma, J. J. Devlin *et al.*, "Gene variants associated with deep vein thrombosis," *Jama*, vol. 299, no. 11, pp. 1306–1314, 2008.

[175] R. Lensen, R. M. Bertina, J. P. Vandenbroucke, and F. R. Rosendaal, "High factor viii levels contribute to the thrombotic risk in families with factor v leiden," *British journal of haematology*, vol. 114, no. 2, pp. 380–386, 2001.

[176] P. M. Ridker, C. H. Hennekens, K. Lindpaintner, M. J. Stampfer, and J. P. Miletich, "Arterial and venous thrombosis is not associated with the 4g/5g polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of us men," *Circulation*, vol. 95, no. 1, pp. 59–62, 1997.

[177] F. Rosendaal, A. Van Hylckama Vlieg, and C. J. M. Doggen, "Venous thrombosis in the elderly," *Journal of thrombosis and haemostasis*, vol. 5, pp. 310–317, 2007.

[178] F. Dentali, M. Gianni, G. Agnelli, and W. Ageno, "Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis," *Journal of Thrombosis and Haemostasis*, vol. 6, no. 1, pp. 70–75, 2008.

[179] M. Mandala, S. Barni, M. Prins, R. Labianca, C. Tondini, L. Russo, A. Milesi, M. Cremonesi, M. Zaccanelli, C. Regonesi *et al.*, "Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial," *Annals of oncology*, vol. 21, no. 4, pp. 871–876, 2010.

[180] R. Lensen, R. Bertina, H. De Ronde, J. Vandenbroucke, and F. Rosendaal, "Venous thrombotic risk in family members of unselected individuals with factor v leiden," *Thrombosis and haemostasis*, vol. 83, no. 06, pp. 817–821, 2000.

[181] C. J. Van Rooden, F. R. Rosendaal, A. E. Meinders, J. A. Van Oostayen, F. Van Der Meer, and M. V. Huisman, "The contribution of factor v leiden and prothrombin g20210a mutation to the risk of central venous catheter-related thrombosis," *haematologica*, vol. 89, no. 2, pp. 201–206, 2004.

[182] R. Fijnheer, B. Paijmans, L. F. Verdonck, H. K. Nieuwenhuis, M. Roest, and A. W. Dekker, "Factor v leiden in central venous catheter-associated thrombosis," *British journal of haematology*, vol. 118, no. 1, pp. 267–270, 2002.

[183] M. Mandalà, G. Curigliano, P. Bucciarelli, G. Ferretti, P. Mannucci, M. Colleoni, A. Ventura, G. Peruzzotti, G. Severi, P. Pelicci *et al.*, "Factor v leiden and g20210a prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter," *Annals of oncology*, vol. 15, no. 4, pp. 590–593, 2004.

[184] E. Pomp, A. Lenselink, F. Rosendaal, and C. J. M. Doggen, "Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the mega study," *Journal of Thrombosis and Haemostasis*, vol. 6, no. 4, pp. 632–637, 2008.

[185] L. Hiltunen, A. Rautanen, V. Rasi, R. Kaaja, J. Kere, T. Krusius, E. Vahtera, and M. Paunio, "An unfavorable combination of factor v leiden with age, weight, and blood group causes high risk of pregnancy-associated venous thrombosis—a population-based nested case-control study," *Thrombosis research*, vol. 119, no. 4, pp. 423–432, 2007.

[186] A. Gerhardt, R. E. Scharf, and R. B. Zotz, "Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium," *Thrombosis and haemostasis*, vol. 90, no. 07, pp. 77–85, 2003.

[187] I. Martinelli, C. Legnani, P. Bucciarelli, E. Grandone, V. De Stefano, and P. M. Mannucci, "Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia," *Thrombosis and haemostasis*, vol. 86, no. 09, pp. 800–803, 2001.

[188] S. Middeldorp, E. J. Libourel, K. Hamulyák, J. Van Der Meer, and H. R. Büller, "The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor v leiden," *British journal of haematology*, vol. 113, no. 2, pp. 553–555, 2001.

[189] I. Martinelli, T. Battaglioli, V. De Stefano, D. Tormene, L. Valdre, E. Grandone, A. Tosetto, P. Mannucci, and G. G. I. TROMBOFILIA), "The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor v leiden and prothrombin g20210a," *Journal of Thrombosis and Haemostasis*, vol. 6, no. 3, pp. 494–498, 2008.

[190] I. Pabinger, L. Nemes, C. Rintelen, S. Koder, E. Lechler, R. Loreth, P. Kyrle, I. Scharrer, G. Sas, K. Lechner *et al.*, "Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor v leiden," *The Hematology Journal*, vol. 1, no. 1, pp. 37–41, 2000.

[191] D. R. Hirsch, K. M. Mikkola, P. W. Marks, E. A. Fox, D. M. Dorfman, B. M. Ewenstein, and S. Z. Goldhaber, "Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor v leiden," *American heart journal*, vol. 131, no. 6, pp. 1145–1148, 1996.

[192] C. Laczkovics, H. Grafenhofer, A. Kaider, P. Quehenberger, R. Simanek, C. Mannhalter, K. Lechner, and I. Pabinger, "Risk of recurrence after a first venous thromboembolic event in young women," *haematologica*, vol. 92, no. 9, pp. 1201–1207, 2007.

[193] J. P. Vandenbroucke, T. Koster, F. Rosendaal, E. Briët, P. Reitsma, and R. Bertina, "Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor v leiden mutation," *The Lancet*, vol. 344, no. 8935, pp. 1453–1457, 1994.

[194] C. Legnani, G. Palareti, G. Guazzaloca, B. Cosmi, B. Lunghi, F. Bernardi, and S. Coccheri, "Venous thromboembolism in young women. role of thrombophilic mutations and oral contraceptive use," *European heart journal*, vol. 23, no. 12, pp. 984–990, 2002.

[195] I. Martinelli, E. Taioli, T. Battaglioli, G. M. Podda, S. M. Passamonti, P. Pedotti, and P. M. Mannucci, "Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives," *Archives of internal medicine*, vol. 163, no. 22, pp. 2771–2774, 2003.

[196] S. Sidney, D. B. Petitti, G. A. Soff, D. L. Cundiff, K. K. Tolan, and C. P. Quesenberry Jr, "Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives," *Contraception*, vol. 70, no. 1, pp. 3–10, 2004.

[197] O. Wu, L. Robertson, P. Langhorne, S. Twaddle, G. D. Lowe, P. Clark, M. Greaves, I. D. Walker, I. Brenkel, L. Regan *et al.*, "Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review the thrombosis: Risk and economic assessment of thrombophilia screening (treats) study," *Thrombosis and haemostasis*, vol. 94, no. 1, pp. 17–25, 2005.

[198] I. Martinelli, T. Battaglioli, P. Pedotti, M. Cattaneo, and P. M. Mannucci, "Hyperhomocysteinemia in cerebral vein thrombosis," *Blood*, vol. 102, no. 4, pp. 1363–1366, 2003.

[199] A. P. Mohllajee, K. M. Curtis, S. L. Martins, and H. B. Peterson, "Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? a systematic review," *Contraception*, vol. 73, no. 2, pp. 166–178, 2006.

[200] K. W. Bloemenkamp, F. R. Rosendaal, F. M. Helmerhorst, and J. P. Vandenbroucke, "Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects," *Archives of internal medicine*, vol. 160, no. 1, pp. 49–52, 2000.

[201] A. Girolami, D. Tormene, S. Gavasso, C. Bertolo, and B. Girolami, "Long term use of oral contraceptives without thrombosis in patients with fv leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous)," *Journal of thrombosis and thrombolysis*, vol. 17, no. 2, pp. 145–149, 2004.

[202] D. Grady, N. K. Wenger, D. Herrington, S. Khan, C. Furberg, D. Hunninghake, E. Vittinghoff, and S. Hulley, "Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study," *Annals of internal medicine*, vol. 132, no. 9, pp. 689–696, 2000.

[203] J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson *et al.*, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial." *Jama*, vol. 288, no. 3, pp. 321–333, 2002.

[204] F. Rosendaal, M. Vessey, A. Rumley, E. Daly, M. Woodward, F. Helmerhorst, and G. Lowe, "Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis," *British journal of haematology*, vol. 116, no. 4, pp. 851–854, 2002.

[205] D. M. Herrington, E. Vittinghoff, T. D. Howard, D. A. Major, J. Owen, D. M. Reboussin, D. Bowden, V. Bittner, J. A. Simon, D. Grady *et al.*, "Factor v leiden, hormone replacement therapy, and risk of venous thromboembolic

events in women with coronary disease," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 22, no. 6, pp. 1012–1017, 2002.

[206] M. Cushman, L. H. Kuller, R. Prentice, R. J. Rodabough, B. M. Psaty, R. S. Stafford, S. Sidney, F. R. Rosendaal *et al.*, "Estrogen plus progestin and risk of venous thrombosis," *Jama*, vol. 292, no. 13, pp. 1573–1580, 2004.

[207] P.-Y. Scarabin, "Hormone therapy and venous thromboembolism among postmenopausal women," *Cardiovascular Issues in Endocrinology*, vol. 43, pp. 21–32, 2014.

[208] Y. Vinogradova, C. Coupland, and J. Hippisley-Cox, "Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the qresearch and cprd databases," *bmj*, vol. 364, 2019.

[209] C. Straczek, E. Oger, M. B. Yon de Jonage-Canonico, G. Plu-Bureau, J. Conard, G. Meyer, M. Alhenc-Gelas, H. Lévesque, N. Trillot, M.-T. Barrellier *et al.*, "Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration," *Circulation*, vol. 112, no. 22, pp. 3495–3500, 2005.

[210] C. Duggan, K. Marriott, R. Edwards, and J. Cuzick, "Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer," *Journal of clinical oncology*, vol. 21, no. 19, pp. 3588–3593, 2003.

[211] N. Abramson, J. P. Costantino, J. E. Garber, N. Berliner, D. L. Wickerham, and N. Wolmark, "Effect of factor v leiden and prothrombin g20210 a mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial," *Journal of the National Cancer Institute*, vol. 98, no. 13, pp. 904–910, 2006.

[212] J. E. Garber, S. Halabi, S. M. Tolaney, E. Kaplan, L. Archer, J. N. Atkins, S. Edge, C. L. Shapiro, L. Dressler, E. M. Paskett *et al.*, "Factor v leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer," *Journal of the National Cancer Institute*, vol. 102, no. 13, pp. 942–949, 2010.

[213] S. C. Cannegieter, C. J. Doggen, H. C. van Houwelingen, and F. R. Rosendaal, "Travel-related venous thrombosis: results from a large population-based case control study (mega study)," *PLoS Med*, vol. 3, no. 8, p. e307, 2006.

[214] P. M. Ridker, R. J. Glynn, J. P. Miletich, S. Z. Goldhaber, M. J. Stampfer, and C. H. Hennekens, "Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor v leiden mutation," *Annals of internal medicine*, vol. 126, no. 7, pp. 528–531, 1997.

[215] K. J. van Stralen, F. R. Rosendaal, and C. J. Doggen, "Minor injuries as a risk factor for venous thrombosis," *Archives of internal medicine*, vol. 168, no. 1, pp. 21–26, 2008.

[216] E. R. Pomp, S. Le Cessie, F. R. Rosendaal, and C. J. Doggen, "Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations," *British journal of haematology*, vol. 139, no. 2, pp. 289–296, 2007.

[217] M. T. DeSancho, T. Dorff, and J. H. Rand, "Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy," *Blood Coagulation & Fibrinolysis*, vol. 21, no. 6, pp. 534–538, 2010.

[218] T. L. Lindahl, T. H. Lundahl, L. Nilsson, and C. A. Andersson, "Apc-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee–a prospective study," *Thrombosis and haemostasis*, vol. 81, no. 01, pp. 18–21, 1999.

[219] M. Baba-Ahmed, G. Le Gal, F. Couturaud, K. Lacut, E. Oger, and C. Leroyer, "High frequency of factor v leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis," *Thrombosis and haemostasis*, vol. 97, no. 02, pp. 171–175, 2007.

[220] J. E. Joseph, J. Low, B. Courtenay, M. J. Neil, M. McGrath, and D. Ma, "A single-centre prospective study of clinical and haemostatic risk factors for

venous thromboembolism following lower limb arthroplasty," *British journal of haematology*, vol. 129, no. 1, pp. 87–92, 2005.

[221] D. H. Ryan, M. A. Crowther, J. S. Ginsberg, and C. W. Francis, "Relation of factor v leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery," *Annals of internal medicine*, vol. 128, no. 4, pp. 270–276, 1998.

[222] F. Rosendaal, "Factor v leiden is not a risk factor for arterial vascular disease in the elderly: results from the cardiovascular health study," 1998.

[223] B. Linnemann, M. Schindewolf, D. Zgouras, M. Erbe, M. Jarosch-Preusche, and E. Lindhoff-Last, "Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?" *Thrombosis research*, vol. 121, no. 6, pp. 743–750, 2008.

[224] R. J. Kim and R. C. Becker, "Association between factor v leiden, prothrombin g20210a, and methylenetetrahydrofolate reductase c677t mutations and events of the arterial circulatory system: a meta-analysis of published studies," *American heart journal*, vol. 146, no. 6, pp. 948–957, 2003.

[225] Z. Ye, E. H. Liu, J. P. Higgins, B. D. Keavney, G. D. Lowe, R. Collins, and J. Danesh, "Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls," *The Lancet*, vol. 367, no. 9511, pp. 651–658, 2006.

[226] F. Rosendaal, D. Siscovick, S. Schwartz, R. Beverly, B. Psaty, W. Longstreth Jr, T. Raghunathan, T. Koepsell, and P. Reitsma, "Factor v leiden (resistance to activated protein c) increases the risk of myocardial infarction in young women," *Blood, The Journal of the American Society of Hematology*, vol. 89, no. 8, pp. 2817–2821, 1997.

[227] M. Franchini and P. M. Mannucci, "Thrombogenicity and cardiovascular effects of ambient air pollution," *Blood*, vol. 118, no. 9, pp. 2405–2412, 2011.

[228] C. J. Doggen, V. M. Cats, R. M. Bertina, and F. R. Rosendaal, "Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor v leiden or prothrombin 20210a," *Circulation*, vol. 97, no. 11, pp. 1037–1041, 1998.

[229] A. Inbal, D. Freimark, B. Modan, A. Chetrit, S. Matetzky, N. Rosenberg, R. Dardik, Z. Baron, and U. Seligsohn, "Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males," *Blood, The Journal of the American Society of Hematology*, vol. 93, no. 7, pp. 2186–2190, 1999.

[230] W. Lalouschek, M. Schillinger, K. Hsieh, G. Endler, S. Tentschert, W. Lang, S. Cheng, and C. Mannhalter, "Matched case-control study on factor v leiden and the prothrombin g20210a mutation in patients with ischemic stroke/-transient ischemic attack up to the age of 60 years," *Stroke*, vol. 36, no. 7, pp. 1405–1409, 2005.

[231] R. Marcucci, F. Sofi, S. Fedi, B. Lari, I. Sestini, A. Cellai, R. Pulli, G. Pratesi, C. Pratesi, G. Gensini *et al.*, "Thrombophilic risk factors in patients with severe carotid atherosclerosis," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 3, pp. 502–507, 2005.

[232] M. Margaglione, G. D'Andrea, N. Giuliani, V. Brancaccio, D. De Lucia, E. Grandone, V. De Stefano, P. A. Tonali, and G. Di Minno, "Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor v leiden," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 19, no. 7, pp. 1751–1756, 1999.

[233] J. Aznar, Y. Mira, A. Vayá, D. Corella, F. Ferrando, P. Villa, and A. Estellés, "Factor v leiden and prothrombin g20210a mutations in young adults with cryptogenic ischemic stroke," *Thrombosis and haemostasis*, vol. 91, no. 05, pp. 1031–1034, 2004.

[234] A. Slooter, F. Rosendaal, B. Tanis, J. Kemmeren, Y. Van der Graaf, and A. Algra, "Prothrombotic conditions, oral contraceptives, and the risk of

ischemic stroke," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 6, pp. 1213–1217, 2005.

[235] I. Martinelli, T. Battaglioli, I. Burgo, S. Di Domenico, and P. M. Mannucci, "Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke," *Haematologica*, vol. 91, no. 6, pp. 844–847, 2006.

[236] E. Haapaniemi, J. Helenius, D. Jakovljeviâ, L. Soinne, M. Syrjälä, M. Kaste, R. Lassila, and T. Tatlisumak, "Ischaemic stroke patients with heterozygous factor v leiden present with multiple brain infarctions and widespread atherothrombotic disease," *Thrombosis and haemostasis*, vol. 101, no. 01, pp. 145–150, 2009.

[237] V. Karttunen, L. Hiltunen, V. Rasi, E. Vahtera, and M. Hillbom, "Factor v leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale," *Blood coagulation & fibrinolysis*, vol. 14, no. 3, pp. 261–268, 2003.

[238] A. Pezzini, M. Grassi, E. Zotto, A. Giossi, I. Volonghi, and P. Costa, "Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale?" *Thromb Haemost*, vol. 101, pp. 813–817, 2009.

[239] J. Brugge, P. Simioni, F. Bernardi, D. Tormene, B. Lunghi, G. Tans, A. Pagnan, J. Rosing, and E. Castoldi, "Expression of the normal factor v allele modulates the apc resistance phenotype in heterozygous carriers of the factor v leiden mutation," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 12, pp. 2695–2702, 2005.

[240] P. Simioni, E. Castoldi, B. Lunghi, D. Tormene, J. Rosing, and F. Bernardi, "An underestimated combination of opposites resulting in enhanced thrombotic tendency," *Blood*, vol. 106, no. 7, pp. 2363–2365, 2005.

[241] A. Santamaría, J. M. Soria, I. Tirado, J. Mateo, I. Coll, J. C. Souto, and J. Fontcuberta, "Double heterozygosity for factor v leiden and factor v cambridge mutations associated with low levels of activated protein c resistance

in a spanish thrombophilic family," *Thrombosis and haemostasis*, vol. 93, no. 06, pp. 1193–1195, 2005.

[242] Y. Dargaud, M. C. Trzeciak, S. Meunier, C. Angei, D. Pellechia, C. Négrier, and C. Vinciguerra, "Two novel factor v null mutations associated with activated protein c resistance phenotype/genotype discrepancy," *British journal of haematology*, vol. 123, no. 2, pp. 342–345, 2003.

[243] M. De Visser, J. F. Guasch, P. W. Kamphuisen, H. L. Vos, F. R. Rosendaal, R. M. Bertina *et al.*, "The hr2 haplotype of factor v-effects on factor v levels, normalized activated protein c sensitivity ratios and the risk of venous thrombosis," *Thrombosis and Haemostasis-Stuttgart-*, vol. 83, no. 4, pp. 577–582, 2000.

[244] F. Mingozzi, C. Legnani, B. Lunghi, D. Scanavini, E. Castoldi, G. Palareti, G. Marchetti, and F. Bernardi, "A fv multiallelic marker detects genetic components of apc resistance contributing to venous thromboembolism in fv leiden carriers," *Thrombosis and haemostasis*, vol. 89, no. 06, pp. 983–989, 2003.

[245] E. Faioni, F. Franchi, P. Bucciarelli, M. Margaglione, V. De Stefano, G. Castaman, G. Finazzi, and P. Mannucci, "Coinheritance of the hr2 haplotype in the factor v gene confers an increased risk of venous thromboembolism to carriers of factor v r506q (factor v leiden)," *Blood, The Journal of the American Society of Hematology*, vol. 94, no. 9, pp. 3062–3066, 1999.

[246] M. Jadaon and A.-R. DASHTI, "Hr2 haplotype in arab population and patients with venous thrombosis in kuwait," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 7, pp. 1467–1471, 2005.

[247] P. McColgan, G. E. Peck, R. M. Greenhalgh, and P. Sharma, "The genetics of abdominal aortic aneurysms: a comprehensive meta-analysis involving eight candidate genes in over 16,700 patients." *International surgery*, vol. 94, no. 4, pp. 350–358, 2009.

[248] R. Luddington, A. Jackson, S. Pannerselvam, K. Brown, and T. Baglin, "The factor v r2 allele: risk of venous thromboembolism, factor v levels

and resistance to activated protein c," *Thrombosis and haemostasis*, vol. 83, no. 02, pp. 204–208, 2000.

[249] V. Djordjevic, L. Rakicevic, D. Mikovic, M. Kovac, P. Miljic, D. Radojkovic, and A. Savic, "Prevalence of factor v leiden, factor v cambridge, factor ii g20210a and methylenetetrahydrofolate reductase c677t mutations in healthy and thrombophilic serbian populations," *Acta haematologica*, vol. 112, no. 4, pp. 227–229, 2004.

[250] W. Chan, C. Lee, Y. Kwong, C. Lam, and R. Liang, "A novel mutation of arg306 of factor v gene in hong kong chinese," *Blood, The Journal of the American Society of Hematology*, vol. 91, no. 4, pp. 1135–1139, 1998.

[251] R. Liang, C. Lee, M. Wat, Y. Kwong, C. Lam, and H. Liu, "Clinical significance of arg306 mutations of factor v gene," *Blood, The Journal of the American Society of Hematology*, vol. 92, no. 7, pp. 2599–2600, 1998.

[252] A. Mumford, J. McVey, C. Morse, K. Gomez, M. Steen, E. Norstrom, E. Tuddenham, B. Dahlback, and P. Bolton-Maggs, "Factor v i359t: a novel mutation associated with thrombosis and resistance to activated protein c," *British journal of haematology*, vol. 123, no. 3, pp. 496–501, 2003.

[253] M. Steen, E. A. Norstrøm, A.-L. Tholander, P. H. Bolton-Maggs, A. Mumford, J. H. McVey, E. G. Tuddenham, and B. Dahlbaack, "Functional characterization of factor v-ile359thr: a novel mutation associated with thrombosis," *Blood*, vol. 103, no. 9, pp. 3381–3387, 2004.

[254] S. Middeldorp, C. M. Henkens, M. M. Koopman, E. C. van Pampus, K. Hamulyak, J. van der Meer, M. H. Prins, and H. R. Buller, "The incidence of venous thromboembolism in family members of patients with factor v leiden mutation and venous thrombosis," *Annals of internal medicine*, vol. 128, no. 1, pp. 15–20, 1998.

[255] P. Simioni, B.-J. Sanson, P. Prandoni, D. Tormene, P. W. Friederich, B. Girolami, S. Gavasso, M. V. Huisman, H. R. Büller, J. W. ten Cate *et al.*, "Incidence of venous thromboembolism in families with inherited

thrombophilia," *Thrombosis and haemostasis*, vol. 81, no. 02, pp. 198–202, 1999.

[256] W. M. Lijfering, J.-L. P. Brouwer, N. J. Veeger, I. Bank, M. Coppens, S. Middeldorp, K. Hamulyák, M. H. Prins, H. R. Büller, and J. van der Meer, "Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives," *Blood*, vol. 113, no. 21, pp. 5314–5322, 2009.

[257] P. Simioni, D. Tormene, P. Prandoni, P. Zerbinati, S. Gavasso, P. Cefalo, and A. Girolami, "Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor v leiden: a prospective cohort study," *Blood, The Journal of the American Society of Hematology*, vol. 99, no. 6, pp. 1938–1942, 2002.

[258] C. Vossen, J. Conard, J. Fontcuberta, M. Makris, F. Van Der Meer, I. Pabinger, G. Palareti, F. Preston, I. Scharrer, J. Souto *et al.*, "Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. the european prospective cohort on thrombophilia (epcot)," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 3, pp. 459–464, 2005.

[259] I. D. Bezemer, C. J. Doggen, H. L. Vos, and F. R. Rosendaal, "No association between the common mthfr 677c t polymorphism and venous thrombosis: results from the mega study," *Archives of internal medicine*, vol. 167, no. 5, pp. 497–501, 2007.

[260] M. C. de Visser, F. R. Rosendaal, and R. M. Bertina, "A reduced sensitivity for activated protein c in the absence of factor v leiden increases the risk of venous thrombosis," *Blood, The Journal of the American Society of Hematology*, vol. 93, no. 4, pp. 1271–1276, 1999.

[261] F. Rodeghiero and A. Tosetto, "Activated protein c resistance and factor v leiden mutation are independent risk factors for venous thromboembolism," *Annals of internal medicine*, vol. 130, no. 8, pp. 643–650, 1999.

[262] M. Galli, D. Luciani, G. Bertolini, and T. Barbui, "Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature," *Blood*, vol. 101, no. 5, pp. 1827–1832, 2003.

[263] I. Bank, E. J. Libourel, S. Middeldorp, K. Hamulyák, E. C. Van Pampus, M. M. Koopman, M. H. Prins, J. Van Der Meer, and H. Büller, "Elevated levels of fviii: C within families are associated with an increased risk for venous and arterial thrombosis," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 1, pp. 79–84, 2005.

[264] T. Koster, J. Vandenbroucke, F. Rosendaal, E. Briët, and A. Blann, "Role of clotting factor viii in effect of von willebrand factor on occurrence of deep-vein thrombosis," *The Lancet*, vol. 345, no. 8943, pp. 152–155, 1995.

[265] P. A. Kyrle, E. Minar, M. Hirschl, C. Bialonczyk, M. Stain, B. Schneider, A. Weltermann, W. Speiser, K. Lechner, and S. Eichinger, "High plasma levels of factor viii and the risk of recurrent venous thromboembolism," *New England Journal of Medicine*, vol. 343, no. 7, pp. 457–462, 2000.

[266] A. v. H. Vlieg, I. K. van der Linden, R. M. Bertina, and F. R. Rosendaal, "High levels of factor ix increase the risk of venous thrombosis," *Blood, The Journal of the American Society of Hematology*, vol. 95, no. 12, pp. 3678–3682, 2000.

[267] M. Cushman, E. S. O'Meara, A. R. Folsom, and S. R. Heckbert, "Coagulation factors ix through xiii and the risk of future venous thrombosis: the longitudinal investigation of thromboembolism etiology," *Blood, The Journal of the American Society of Hematology*, vol. 114, no. 14, pp. 2878–2883, 2009.

[268] W. L. Chandler, G. M. Rodgers, J. T. Sprouse, and A. R. Thompson, "Elevated hemostatic factor levels as potential risk factors for thrombosis," *Archives of pathology & laboratory medicine*, vol. 126, no. 11, pp. 1405–1414, 2002.

[269] M. den Heijer, H. P. Willems, H. J. Blom, W. B. Gerrits, M. Cattaneo, S. Eichinger, F. R. Rosendaal, and G. M. Bos, "Homocysteine lowering by b vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial," *Blood*, vol. 109, no. 1, pp. 139–144, 2007.

[270] C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota, "Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines," *Chest*, vol. 133, no. 6, pp. 454S–545S, 2008.

[271] C. Baglin, K. Brown, R. Luddington, T. Baglin, and E. A. T. S. Group, "Risk of recurrent venous thromboembolism in patients with the factor v leiden (fvr506q) mutation: effect of warfarin and prediction by precipitating factors," *British journal of haematology*, vol. 100, no. 4, pp. 764–768, 1998.

[272] P. Prandoni, P. Simioni, and A. Girolami, "Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation," *Thrombosis and haemostasis*, vol. 75, no. 05, pp. 859–859, 1996.

[273] W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell, "Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines," *Chest*, vol. 133, no. 6, pp. 381S–453S, 2008.

[274] S. M. Bates, I. A. Greer, I. Pabinger, S. Sofaer, and J. Hirsh, "Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American college of chest physicians evidence-based clinical practice guidelines," *Chest*, vol. 133, no. 6, pp. 844S–886S, 2008.

[275] I. Pabinger, H. Grafenhofer, A. Kaider, P. Kyrle, P. Quehenberger, C. Mannhalter, and K. Lechner, "Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 5, pp. 949–954, 2005.

[276] V. D. Stefano, I. Martinelli, E. Rossi, T. Battaglioli, T. Za, P. Mannuccio Mannucci, and G. Leone, "The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis," *British journal of haematology*, vol. 135, no. 3, pp. 386–391, 2006.

[277] A. J. Duhl, M. J. Paidas, S. H. Ural, W. Branch, H. Casele, J. Cox-Gill, S. L. Hamersley, T. M. Hyers, V. Katz, R. Kuhlmann *et al.*, "Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes," *American journal of obstetrics and gynecology*, vol. 197, no. 5, pp. 457–e1, 2007.

[278] J.-C. Gris, E. Mercier, I. Quéré, G. Lavigne-Lissalde, E. Cochery-Nouvellon, M. Hoffet, S. Ripart-Neveu, M.-L. Tailland, M. Dauzat, and P. Mares, "Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder," *Blood*, vol. 103, no. 10, pp. 3695–3699, 2004.

[279] ——, "Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder," *Blood*, vol. 103, no. 10, pp. 3695–3699, 2004.

[280] B. Brenner, R. Hoffman, H. Carp, M. Dulitsky, J. Younis, and L.-E. Investigators, "Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the live-enox study," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 2, pp. 227–229, 2005.

[281] J. E. Warren, S. E. Simonsen, D. W. Branch, T. F. Porter, and R. M. Silver, "Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias," *American journal of obstetrics and gynecology*, vol. 200, no. 3, pp. 281–e1, 2009.

[282] C. A. Laskin, K. A. Spitzer, C. A. Clark, M. R. Crowther, J. S. Ginsberg, G. A. Hawker, J. Barrett, M. Gent *et al.*, "Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled hepasa trial," *The Journal of rheumatology*, vol. 36, no. 2, pp. 279–287, 2009.

[283] V. Factor, "Leiden thrombophilia. kujovich jl," *Genet Med*, vol. 13, pp. 1–16, 2011.

[284] K. A. Bauer, "The thrombophilias: well-defined risk factors with uncertain therapeutic implications," *Annals of internal medicine*, vol. 135, no. 5, pp. 367–373, 2001.

[285] M. A. Crowther and J. G. Kelton, "Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system," *Annals of internal medicine*, vol. 138, no. 2, pp. 128–134, 2003.

[286] N. Pirtskhelani, N. Kochiashvili, L. Makhaldiani, N. Pargalava, E. Gaprindashvili, and K. Kartvelishvili, "Impact of inherited thrombophilia on the risk of recurrent venous thromboembolism onset in georgian population." *Georgian medical news*, no. 227, pp. 93–97, 2014.

[287] A. Nicolaides, H. Breddin, P. Carpentier, S. Coccheri *et al.*, "International consensus statement: guidelines according to scientific evidence," *International angiology*, vol. 24, no. 1, p. 1, 2005.

[288] A. W. Lensing and M. H. Prins, "Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis?" *Thrombosis and haemostasis*, vol. 82, no. 12, pp. 1564–1566, 1999.

[289] P. Simioni, P. Prandoni, A. W. Lensing, D. Manfrin, D. Tormene, S. Gavasso, B. Girolami, C. Sardella, M. Prins, and A. Girolami, "Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor v gene mutation with a first episode of deep-vein thrombosis," *Blood, The Journal of the American Society of Hematology*, vol. 96, no. 10, pp. 3329–3333, 2000.

[290] J. S. Miles, J. P. Miletich, S. Z. Goldhaber, C. H. Hennekens, and P. M. Ridker, "G20210a mutation in the prothrombin gene and the risk of recurrent venous thromboembolism," *Journal of the American College of Cardiology*, vol. 37, no. 1, pp. 215–218, 2001.

[291] G. Palareti, C. Legnani, B. Cosmi, L. Valdré, B. Lunghi, F. Bernardi, and S. Coccheri, "Predictive value of d-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia," *Circulation*, vol. 108, no. 3, pp. 313–318, 2003.

[292] M. G. Santamaria, G. Agnelli, M. R. Taliani, P. Prandoni, M. Moia, M. Bazzan, G. Guazzaloca, W. Ageno, A. Bertoldi, M. Silingardi *et al.*, "Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment," *Thrombosis research*, vol. 116, no. 4, pp. 301–306, 2005.

[293] J. R. González-Porras, R. García-Sanz, I. Alberca, M. L. López, A. Balanzategui, O. Gutierrez, F. Lozano, and J. San Miguel, "Risk of recurrent venous thrombosis in patients with g20210a mutation in the prothrombin gene or factor v leiden mutation," *Blood coagulation & fibrinolysis*, vol. 17, no. 1, pp. 23–28, 2006.

[294] P. Lindmarker, S. Schulman, M. Sten-Linder, B. Wiman, N. Egberg, H. Johnsson, D. T. S. Group *et al.*, "The risk of recurrent venous thromboembolism in carriers and non-carriers of the g1691a allele in the coagulation factor v gene and the g20210a allele in the prothrombin gene," *Thrombosis and haemostasis*, vol. 81, no. 05, pp. 684–689, 1999.

[295] C. Kearon, M. Gent, J. Hirsh, J. Weitz, M. J. Kovacs, D. R. Anderson, A. G. Turpie, D. Green, J. S. Ginsberg, P. Wells *et al.*, "A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism," *New England Journal of Medicine*, vol. 340, no. 12, pp. 901–907, 1999.

[296] P. von Dadelszen, B. Payne, J. Li, J. M. Ansermino, F. B. Pipkin, A.-M. Côté, M. J. Douglas, A. Gruslin, J. A. Hutcheon, K. Joseph *et al.*, "Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullpiers model," *The Lancet*, vol. 377, no. 9761, pp. 219–227, 2011.

[297] P. Vigil-De Gracia, O. R. Tejada, A. C. Miñaca, G. Tellez, V. Y. Chon, E. Herrarte, A. Villar, and J. Ludmir, "Expectant management of severe preeclampsia remote from term: the mexpre latin study, a randomized, multicenter clinical trial," *American journal of obstetrics and gynecology*, vol. 209, no. 5, pp. 425–e1, 2013.

[298] A. E. Bombrys, J. R. Barton, E. A. Nowacki, M. Habli, L. Pinder, H. How, and B. M. Sibai, "Expectant management of severe preeclampsia at less than 27 weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management," *American journal of obstetrics and gynecology*, vol. 199, no. 3, pp. 247–e1, 2008.

[299] S. Lisonkova, Y. Sabr, C. Mayer, C. Young, A. Skoll, and K. Joseph, "Maternal morbidity associated with early-onset and late-onset preeclampsia," *Obstetrics & Gynecology*, vol. 124, no. 4, pp. 771–781, 2014.

[300] B. M. Sibai and J. R. Barton, "Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications," *American journal of obstetrics and gynecology*, vol. 196, no. 6, pp. 514–e1, 2007.

[301] B. M. Sibai, P. Committee, S. for Maternal-Fetal Medicine *et al.*, "Evaluation and management of severe preeclampsia before 34 weeks' gestation," *American journal of obstetrics and gynecology*, vol. 205, no. 3, pp. 191–198, 2011.

[302] L. Magee, P. Yong, V. Espinosa, A. Cote, I. Chen, and P. Von Dadelszen, "Expectant management of severe preeclampsia remote from term: a structured systematic review," *Hypertension in pregnancy*, vol. 28, no. 3, pp. 312–347, 2009.

[303] H. J. Odendaal and R. C. Pattinson, "Aggressive or expectant management for patients with severe preeclampsia between 28–," *Obstet Gynecol*, vol. 76, no. 1070, 1990.

[304] B. M. Sibai, B. M. Mercer, E. Schiff, and S. A. Friedman, "Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a

randomized controlled trial," *American journal of obstetrics and gynecology*, vol. 171, no. 3, pp. 818–822, 1994.

[305] D. Churchill, L. Duley, J. G. Thornton, M. Moussa, H. S. Ali, and K. F. Walker, "Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation," *Cochrane Database of Systematic Reviews*, no. 10, 2018.

[306] C. L. Roberts, J. B. Ford, C. S. Algert, S. Antonsen, J. Chalmers, S. Cnattingius, M. Gokhale, M. Kotelchuck, K. K. Melve, A. Langridge *et al.*, "Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study," *BMJ open*, vol. 1, no. 1, 2011.

[307] S. Lisonkova and K. Joseph, "Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease," *American journal of obstetrics and gynecology*, vol. 209, no. 6, pp. 544–e1, 2013.

[308] A. Dilley, H. Austin, W. C. Hooper, M. El-Jamil, C. Whitsett, N. K. Wenger, J. Benson, and B. Evatt, "Prevalence of the prothrombin 20210 g-to-a variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects," *Journal of Laboratory and Clinical Medicine*, vol. 132, no. 6, pp. 452–455, 1998.

[309] J. M. Soria, L. Almasy, J. C. Souto, I. Tirado, M. Borell, J. Mateo, S. Slifer, W. Stone, J. Blangero, and J. Fontcuberta, "Linkage analysis demonstrates that the prothrombin g20210a mutation jointly influences plasma prothrombin levels and risk of thrombosis," *Blood, The Journal of the American Society of Hematology*, vol. 95, no. 9, pp. 2780–2785, 2000.

[310] N. H. Gehring, U. Frede, G. Neu-Yilik, P. Hundsdoerfer, B. Vetter, M. W. Hentze, and A. E. Kulozik, "Increased efficiency of mrna 3 end formation: a new genetic mechanism contributing to hereditary thrombophilia," *Nature genetics*, vol. 28, no. 4, pp. 389–392, 2001.

[311] M. D. Smirnov, O. Safa, N. L. Esmon, and C. T. Esmon, "Inhibition of activated protein c anticoagulant activity by prothrombin," *Blood, The Journal of the American Society of Hematology*, vol. 94, no. 11, pp. 3839–3846, 1999.

[312] A. Girolami, P. Simioni, L. Scarano, and G. Carraro, "Prothrombin and the prothrombin 20210 g to a polymorphism: their relationship with hypercoagulability and thrombosis," *Blood reviews*, vol. 13, no. 4, pp. 205–210, 1999.

[313] P. M. Ridker, C. H. Hennekens, and J. P. Miletich, "G20210a mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of us men," *Circulation*, vol. 99, no. 8, pp. 999–1004, 1999.

[314] B. Zoller, P. J. Svensson, B. Dahlbaack, and A. Hillarp, "The a20210 allele of the prothrombin gene is frequently associated with the factor v arg 506 to gln mutation but not with protein s deficiency in thrombophilic families," *Blood, The Journal of the American Society of Hematology*, vol. 91, no. 6, pp. 2210–2211, 1998.

[315] O. Salomon, D. M. Steinberg, A. Zivelin, S. Gitel, R. Dardik, N. Rosenberg, S. Berliner, A. Inbal, A. Many, A. Lubetsky *et al.*, "Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 19, no. 3, pp. 511–518, 1999.

[316] V. De Stefano, B. Zappacosta, S. Persichilli, E. Rossi, I. Casorelli, K. Paciaroni, P. Chiusolo, A. M. Leone, B. Giardina, and G. Leone, "Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor v leiden and prothrombin g20210a) in italian patients with venous thromboembolic disease," *British journal of haematology*, vol. 106, no. 2, pp. 564–568, 1999.

[317] A. Tosetto, F. Rodeghiero, I. Martinelli, V. De Stefano, E. Missiaglia, P. Chiusolo, and P. M. Mannucci, "Additional genetic risk factors for venous thromboembolismin carriers of the factor v leiden mutation," *British journal of haematology*, vol. 103, no. 3, pp. 871–876, 1998.

[318] K. Brown, R. Luddington, and T. Baglin, "Effect of the mthfrc677t variant on risk of venous thromboembolism: interaction with factor v leiden and

prothrombin (f2g20210a) mutations," *British journal of haematology*, vol. 103, no. 1, pp. 42–44, 1998.

[319] M. Makris, F. Preston, N. Beauchamp, P. Cooper, M. Daly, K. Hampton, P. Bayliss, I. Peake, and G. Miller, "Co-inheritance of the 20210a allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia," *Thrombosis and haemostasis*, vol. 78, no. 12, pp. 1426–1429, 1997.

[320] E. G. Bovill, S. J. Hasstedt, P. W. Callas, J. E. Valliere, B. T. Scott, K. A. Bauer, and G. L. Long, "The g20210a prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein c deficient kindred," *Thrombosis and haemostasis*, vol. 83, no. 03, pp. 366–370, 2000.

[321] J. P. Vandenbroucke, J. Rosing, K. W. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal, "Oral contraceptives and the risk of venous thrombosis," *New England Journal of Medicine*, vol. 344, no. 20, pp. 1527–1535, 2001.

[322] I. Martinelli, E. Taioli, P. Bucciarelli, S. Akhavan, and P. M. Mannucci, "Interaction between the g20210a mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 19, no. 3, pp. 700–703, 1999.

[323] I. A. Greer, "Thrombosis in pregnancy: maternal and fetal issues," *The Lancet*, vol. 353, no. 9160, pp. 1258–1265, 1999.

[324] E. Daly, M. P. Vessey, M. M. Hawkins, J. L. Carson, P. Gough, and S. Marsh, "Risk of venous thromboembolism in users of hormone replacement therapy," *The Lancet*, vol. 348, no. 9033, pp. 977–980, 1996.

[325] H. Jick, S. S. Jick, M. W. Myers, and C. Vasilakis, "Third-generation oral contraceptives and venous thrombosis," *The Lancet*, vol. 349, no. 9053, pp. 731–732, 1997.

[326] F. Grodstein, M. J. Stampfer, S. Z. Goldhaber, J. E. Manson, G. A. Colditz, F. E. Speizer, W. C. Willett, and C. H. Hennekens, "Prospective study

of exogenous hormones and risk of pulmonary embolism in women," *The Lancet*, vol. 348, no. 9033, pp. 983–987, 1996.

[327] D. A. Lane, P. M. Mannucci, K. A. Bauer, R. M. Bertina, N. P. Bochkov, V. Boulyjenkov, M. Chandy, B. Dahlbäck, E. Ginter, J. P. Miletich *et al.*, "Inherited thrombophilia: part 1," *Thrombosis and haemostasis*, vol. 76, no. 5, pp. 651–662, 1996.

[328] A. Girolami, P. Simioni, B. Girolami, and L. Scarano, "State-of-the-art review: G to a 20210 prothrombin polymorphism and venous thrombosis: Simple association or causal relationship?" *Clinical and Applied Thrombosis/Hemostasis*, vol. 6, no. 3, pp. 135–138, 2000.

[329] R. Franco, M. Trip, H. Ten Cate, A. Van Den Ende, M. Prins, J. Kastelein, and P. Reitsma, "The 20210 g a mutation in the 3-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease," *British journal of haematology*, vol. 104, no. 1, pp. 50–54, 1999.

[330] J. Eikelboom, R. Baker, R. Parsons, R. Taylor, and F. Van Bockxmeer, "No association between the 20210 g/a prothrombin gene mutation and premature coronary artery disease," *Thrombosis and haemostasis*, vol. 80, no. 12, pp. 878–880, 1998.

[331] J. Corral, R. Gonzalez-Conejero, M. L. Lozano, J. Rivera, I. Heras, and V. Vicente, "The venous thrombosis risk factor 20210 a allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease," *British journal of haematology*, vol. 99, no. 2, pp. 304–307, 1997.

[332] P. Ferraresi, G. Marchetti, C. Legnani, E. Cavallari, E. Castoldi, F. Mascoli, D. Ardissino, G. Palareti, and F. Bernardi, "The heterozygous 20210 g/a prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 17, no. 11, pp. 2418–2422, 1997.

[333] B. M. Psaty, N. L. Smith, R. N. Lemaitre, H. L. Vos, S. R. Heckbert, A. Z. LaCroix, and F. R. Rosendaal, "Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women," *Jama*, vol. 285, no. 7, pp. 906–913, 2001.

[334] D. Cohn, S. Repping, H. Büller, J. Meijers, and S. Middeldorp, "Increased sperm count may account for high population frequency of factor v leiden," *Journal of Thrombosis and Haemostasis*, vol. 8, no. 3, pp. 513–516, 2010.

[335] C. Yapijakis, N. Pachis, S. Natsis, and C. Voumvourakis, "Is neurofibromatosis type 1–noonan syndrome a phenotypic result of combined genetic and epigenetic factors?" *in vivo*, vol. 30, no. 3, pp. 315–320, 2016.

[336] T. van Mens, U. Joensen, Z. Bochdanovits, A. Takizawa, J. Peter, N. Jørgensen, P. Szecsi, J. Meijers, H. Weiler, E. Rajpert-De Meyts *et al.*, "Factor v leiden is associated with increased sperm count," *Human Reproduction*, vol. 32, no. 11, pp. 2332–2339, 2017.

[337] P. D. Ziakas, M. Pavlou, and M. Voulgarelis, "Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis," *Obstetrics & Gynecology*, vol. 115, no. 6, pp. 1256–1262, 2010.

[338] M. A. Wahba, M. A. Ismail, A. A. Saad, D. M. Habashy, Z. M. A. Hafeez, and N. H. Boshnak, "Impact of thrombophilic genes mutations on thrombosis risk in egyptian nonmetastatic cancer patients," *Blood Coagulation & Fibrinolysis*, vol. 26, no. 3, pp. 309–315, 2015.

[339] E. F. van Vlijmen, S. Wiewel-Verschueren, T. B. Monster, and K. Meijer, "Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis," *Journal of Thrombosis and Haemostasis*, vol. 14, no. 7, pp. 1393–1403, 2016.

[340] S. Khalife and N. Bissar-Tadmouri, "Inherited thrombophilia in a lebanese family of four generations: A case report of recurrent miscarriage," *Vascular health and risk management*, vol. 16, p. 53, 2020.

[341] S. Kapiotis, P. Quehenberger, B. Jilma, S. Handler, I. Pabinger-Fasching, C. Mannhalter, and W. Speiser, "Improved characteristics of apc-resistance assay: Coatest apc resistance by predilution of samples with factor v deficient plasma," *American journal of clinical pathology*, vol. 106, no. 5, pp. 588–593, 1996.

[342] W. W. Grody, J. H. Griffin, A. K. Taylor, B. R. Korf, and J. A. Heit, "American college of medical genetics consensus statement on factor v leiden mutation testing," *Genetics in Medicine*, vol. 3, no. 2, pp. 139–148, 2001.

[343] E. B. Spector, W. W. Grody, C. J. Matteson, G. E. Palomaki, D. B. Bellissimo, D. J. Wolff, L. A. Bradley, T. W. Prior, G. Feldman, B. W. Popovich *et al.*, "Technical standards and guidelines: venous thromboembolism (factor v leiden and prothrombin 20210g¿ a testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories," *Genetics in Medicine*, vol. 7, no. 6, pp. 444–453, 2005.

[344] R. D. Press, K. A. Bauer, J. L. Kujovich, and J. A. Heit, "Clinical utility of factor v leiden (r506q) testing for the diagnosis and management of thromboembolic disorders," *Archives of pathology & laboratory medicine*, vol. 126, no. 11, pp. 1304–1318, 2002.

[345] M. J. Manco-Johnson, E. Grabowski, M. Hellgreen, A. Kemahli, M. Massicotte, W. Muntean, M. Peters, and U. Nowak-Göttl, "Laboratory testing for thrombophilia in pediatric patients," *Thrombosis and haemostasis*, vol. 88, no. 07, pp. 155–156, 2002.

[346] T. Baglin, E. Gray, M. Greaves, B. J. Hunt, D. Keeling, S. Machin, I. Mackie, M. Makris, T. Nokes, D. Perry *et al.*, "Clinical guidelines for testing for heritable thrombophilia," *British journal of haematology*, vol. 149, no. 2, pp. 209–220, 2010.

[347] M. Coppens, J. H. Reijnders, S. Middeldorp, C. J. Doggen, and F. R. Rosendaal, "Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis," *Journal of Thrombosis and Haemostasis*, vol. 6, no. 9, pp. 1474–1477, 2008.

[348] R. Lensen, F. Rosendaal, J. Vandenbroucke And, and R. Bertina, "Factor v leiden: the venous thrombotic risk in thrombophilic families," *British journal of haematology*, vol. 110, no. 4, pp. 939–945, 2000.

[349] E. T. Hille, R. G. Westendorp, J. P. Vandenbroucke, and F. R. Rosendaal, "Mortality and causes of death in families with the factor v leiden mutation (resistance to activated protein c)," *Blood, The Journal of the American Society of Hematology*, vol. 89, no. 6, pp. 1963–1967, 1997.

[350] B. T. Heijmans, R. G. Westendorp, D. L. Knook, C. Kluft, and E. P. Slagboom, "The risk of mortality and the factor v leiden mutation in a population-based cohort," *Thrombosis and haemostasis*, vol. 80, no. 10, pp. 607–609, 1998.

[351] S. Schulman, "Thrombophilia and location of venous thromboembolism," *Journal of Thrombosis and Haemostasis*, vol. 5, no. 10, pp. 2151–2152, 2007.

[352] P. De Moerloose, G. Reber, A. Perrier, T. Perneger, and H. Bounameaux, "Prevalence of factor v leiden and prothrombin g20210a mutations in unselected patients with venous thromboembolism," *British journal of haematology*, vol. 110, no. 1, pp. 125–129, 2000.

[353] F. Dentali, M. Crowther, and W. Ageno, "Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis," *Blood*, vol. 107, no. 7, pp. 2766–2773, 2006.

[354] I. Martinelli, M. Cattaneo, E. Taioli, V. De Stefano, P. Chiusolo, and P. M. Mannucci, "Genetic risk factors for superficial vein thrombosis," *Thrombosis and haemostasis*, vol. 82, no. 10, pp. 1215–1217, 1999.